



1. lékařská fakulta 
 
 
Studijní program: Biomedicína 









Hledání biologické role rodiny proteinů podobných Ddi1 














































Prohlašuji, že jsem závěrečnou práci zpracovala samostatně a že jsem řádně uvedla a 
citovala všechny použité prameny a literaturu. Současně prohlašuji, že práce nebyla využita 
k získání jiného nebo stejného titulu. 
Souhlasím s trvalým uložením elektronické verze mé práce v databázi systému 
meziuniverzitního projektu Theses.cz za účelem soustavné kontroly podobnosti 
kvalifikačních prací. 
 
V Praze, 1.3.2019    
                                                                                                                    …………………………… 





































SIVÁ, Monika. Hledání biologické role rodiny proteinů podobných Ddi1. [Deciphering the 
biological role of Ddi1 like protein family]. Praha, 2018. 169 stran, 3 přílohy. Disertační 
práce. Univerzita Karlova, 1. lékařská fakulta, Přírodovědecká fakulta, Ústav organické 




SIVÁ, Monika. Deciphering the biological role of Ddi1 like protein family. [Hledání 
biologické role rodiny proteinů podobných Ddi1]. Prague, 2018. 169 pages, 3 appendices. 
PhD Thesis. Charles University, First Faculty of Medicine, Faculty of Science, Institute of 

















Ddi1-like protein family has been recently raised into the spotlight by the scientific 
community due to its important roles in cellular homeostasis maintenance. It represents a 
specific group among shuttling proteins of the ubiquitin-proteasome system. When compared 
to other shuttles, Ddi1-like protein family members harbor a unique retroviral-protease like 
domain besides the conventional ubiquitin-like (UBL) domain and domains interacting with 
ubiquitin. In addition, a helical domain of Ddi (HDD) has been recently found in most of the 
orthologs.  
In this thesis, I focus on characterization of several members of Ddi1-like protein 
family, both on molecular level using NMR and in model mouse strains via a variety of 
biological methods.  
Solution structure of the UBL domain of Ddi1p of S. cerevisiae was solved and its 
characteristics were compared to those of the UBL domain of its human ortholog. 
Furthermore, we show that human DDI2 specifically binds to ubiquitin with its terminal 
domains, both the UBL and the UIM; however, with very low affinity in contrast to binding 
properties of its yeast counterpart. Our study also show that hDDI2 does not form a head-to-
tail homodimer. Based on our structural studies, we hypothesize that human DDI2 might have 
evolved a different function compared to its yeast ortholog. Next, we focused on Ddi1 protein 
analysis using model mouse strains. Our expression studies of the Ddi1 homolog contributed 
to proposition of relevance of DDI1 in clinical research of Angelman syndrome. Moreover, 
our two mouse models exhibit embryonal lethality in mid-late gestation period, which suggest 
an essential role of the mammalian Ddi2 proteins.  
Results acquired during this work shed light on possible functions of several Ddi1-
like family members and will pave the way towards understanding of their compact biological 
roles. 
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Představitelé rodiny proteinů podobných Ddi1 (z angl. DNA damage-inducible 
protein homolog 1) patří do skupiny tzv. „přenašečů“, které jsou v buňce zodpovědné za 
regulaci degradace proteinů v ubikvitin-proteasomálním systému. Proteiny podobné Ddi1 se 
od ostatních přenašečů liší specifickou doménou podobnou retrovirálním proteasam, která 
patří mezi aspartové proteasy. Nedávno byla v jejich struktuře taktéž objevena vysoce 
konservovaná helikální doména. V poslední době se objevují studie, které popisují nové 
funkce členů rodiny protein podobných Ddi1 a to v rámci udržování buněčné homeostázy v 
odpovědi na stresové podněty, např. v reakci na proteotoxické podmínky nebo v opravě 
poškozené DNA. 
Tato disertační práce se zabývá charakterizací vybraných členů rodiny proteinů 
podobných Ddi1 a to jak na molekulární úrovni, tak v biologických studiích na myších 
modelech. 
Byla vyřešena struktura domény podobné ubikvitinu (ubiquitin-like domain, UBL) 
v rámci kvasinkového proteinu Ddi1. Následně byly porovnány vazebné vlastnosti domén 
UBL kvasinkového proteinu Ddi1 a lidského proteinu DDI2. Doména UBL a motiv vázající 
ubikvitin (ubiquitin interacting motif, UIM) lidského homologu DDI2 sice specificky vážou 
ubikvitin, zároveň je však tato vazba velice slabá v porovnání s jinými ubikvitin vazebnými 
doménami. Naše studie taktéž vedly k objasnění celkové konformace homodimeru lidského 
DDI2. Na základě našich zjištění jsme formulovali hypotézu o odlišné funkci jednotlivých 
orthologů jinak vysoce konservovaných členů rodiny proteinů podobných Ddi1. Myší 
modely, ve kterých jsme inaktivovali expresi genu Ddi2, případně funkce proteasové 
domény, vykazují embryonální letalitu, což svědčí důležité biologické roli tohoto proteinu. 
Pomocí mapování exprese myšího genu Ddi1 jsme zároveň přispěly k objasnění relevance 
tohoto genu pro klinický výzkum Angelmanovho syndromu. Výsledky dosažené v této práci 
poukazují na některé vlastnosti a funkce členů rodiny proteinů podobných Ddi1, čímž 
představují pevný základ pro další studie, které by mohly vést k porozumění komplexní 
biologické role této proteinové rodiny. 
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AAA .................................... ATPases Associated with diverse cellular Activities 
AD ....................................... acidic domain 
ADP ..................................... adenosine diphosphate 
ADRM1 ............................... adhesion regulating molecule 1 
AIDS ................................... acquired immune deficiency syndrome 
AMP .................................... adenosine monophosphate 
AP ........................................ alkaline phosphatase 
AP-1 .................................... activator protein 1 
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BHT ..................................... butylated hydroxytoluene 
BiP ....................................... binding immunoglobulin protein 
BRCA .................................. breast cancer protein 
BSA ..................................... bovine serum albumin 
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bZIP ..................................... basic-leucine zipper 
CAS ..................................... Czech Academy of Science 
CCP ..................................... Czech Center for Phenogenomics 
cDNA .................................. complementary DNA 
CENT2 ................................ centrin 2 
CHOP .................................. CCAAT-enhancer-binding protein homologous protein 
CNC ..................................... cap-and-collar 
CSP ...................................... chemical shift perturbation 
CP ........................................ core particle 
CREBP ................................ cAMP response element binding protein 
Cul1 ..................................... cullin 1 
DDR .................................... DNA damage repair 
DEPC ................................... diethyl pyrocarbonate 
Derlin ................................... degradation in endoplasmic reticulum like protein 
DEUBAD ............................ deubiquitinase adaptor domain 
DIG ...................................... digoxigenin 
DMEM ................................ Dulbecco's modified Eagle's medium 
DMSO ................................. dimethylsulfoxide 
DNA .................................... deoxyribonucleic acid 
Doa10 .................................. degradation of alpha2-10 
DPC ..................................... DNA-protein crosslink 
DSB ..................................... double-strand break 
DSF ...................................... differential scanning fluorimetry 
DTT ..................................... dithiotreitol 
DUB..................................... deubiquitinase 
DVC-1 ................................. DNA Damage Protein Targeting VCP 1 
E........................................... embryonic day 
EDEM1 ................................ ER degradation enhancing alpha mannosidase-like protein 1 
EDTA .................................. ethylenediaminetetraacetic acid 
EGTA .................................. egtazic acid 
eIF2α .................................... eukaryotic translation initiation factor 2 subunit alpha 
dNTP ................................... deoxy-nucleotide triphosphate 
ER ........................................ endoplasmic reticulum 
ERAD .................................. endoplasmic reticulum associated degradation 
EUCOMM ........................... European Conditional Mouse Mutagenesis  
FBS ...................................... fetal bovine serum 
Fbw7 .................................... F-Box/WD repeat-containing protein 7 
FDA ..................................... Food and Drug Administration 
FPLC ................................... fast protein liquid chromatography 
GADD34 ............................. growth arrest and DNA damage-inducible protein 34 
GRP78 ................................. 78-kDa glucose-regulated protein 
GSH ..................................... glutathione 
H2afz ................................... H2A Histone Family Member Z 
HDD .................................... helical domain of Ddi 
hDDI1 .................................. human DNA damage-inducible protein 1 homolog 1 
hDDI2 .................................. human DNA damage-inducible protein 1 homolog 2 
HDR..................................... homology-directed repair 
HECT ................................... homologous to the E6AP carboxyl terminus 
Herpud1 ............................... homocysteine inducible ER protein with ubiquitin like domain 1 
HIV-1 ................................... human immunodeficiency virus 1 
HOIP .................................... HOIL-1-interacting protein 
HPLC ................................... high-performance liquid chromatography 
hPLIC2 ................................ human protein linking IAP with cytoskeleton 
HR ....................................... homologous recombination  
Hrd1 ..................................... β-hydroxy β-methylglutaryl-coenzyme A reductase degradation 1 
HSQC .................................. heteronuclear single quantum coherence 
IKK ...................................... IκB kinase 
IMDM .................................. Iscove's modified Dulbecco's medium 
IMG ..................................... Institute of Molecular Genetics 
IMPC ................................... International Mouse Phenotyping Consortium 
IOCB ................................... Institute of Organic Chemistry and Biochemistry  
IpGTT .................................. intra-peritoneal glucose tolerance test 
IPTG .................................... isopropyl β-D-1-thiogalactopyranoside 
IRE1..................................... inostiol requiring enzyme 1 
ISH....................................... in situ hybridization 
JAMM ................................. Jab1/Mov34/Mpr1 Pad1 N-terminal+ domain-containing protease 
Keap1 ................................... kelch like, erythroid cell-derived protein with cnc homology 
                                              associated protein 1 
KO ....................................... knockout 
LB ........................................ Luria-Bertani (lysogeny broth) 
 17 
LCR-F1 ............................... locus control region-factor 1 
LIG ...................................... DNA ligase 
Maf ...................................... avian musculoaponeurotic fibrosarcoma gene 
MAG ................................... 3-MethylAdenine DNA Glycosylase 
MAPK ................................. mitogen-activated protein kinase 
MAT .................................... mating type region 
mDdi1 .................................. murine DNA damage-inducible protein 1 
mDdi2 .................................. murine DNA damage-inducible protein 2 
MEF ..................................... mouse embryonic fibroblast 
MEM ................................... minimum essential medium 
MLH1 .................................. MutL homolog 1 
MMR ................................... mismatch repair  
MPN .................................... Mpr1 Pad1 N-terminal+ domain 
Mre11 .................................. meiotic recombination protein 11  
mRNA ................................. messenger ribonucleic acid 
mTORC1 ............................. mammalian target of rapamycin complex 1 
N/A ...................................... not available 
NADPH ............................... nicotinamide adenine dinucleotide phosphate (reduced) 
Neh (domain)....................... Nrf2- erythroid, cell-derived protein with cnc homology, 
                                               homology 2 domain 
NER ..................................... nucleotide excision repair 
NF-κB .................................. nuclear factor kappa B 
NFE2 ................................... nuclear factor, erythroid 2 
NFE2L ................................. nuclear factor, erythroid-derived 2-related factor  
NHB .................................... N-terminal homology box  
NHEJ ................................... non-homologous DNA end joining 
Ni-NTA ............................... nickel - nitrilotriacetic acid 
NMR .................................... nuclear magnetic resonance 
NOE ..................................... nuclear Overhauser effect 
NOESY ............................... nuclear Overhauser effect spectroscopy 
Npl4 ..................................... nuclear protein localization homolog 4 
Nrf1 ..................................... NF-E2-Related Factor 1 
Nrf1 A ................................. Nrf1 activated variant 
Nrf1 FL ................................ Nrf1 full-length variant 
NST ..................................... Asp/Ser/Thr-rich region 
NTD ..................................... N-terminal domain 
OS9 ...................................... osteosarcoma amplified protein 9 
PARP1 ................................. poly(ADP-ribose) polymerase 1 
PBS ...................................... phosphate buffered saline 
PCNA .................................. proliferating cell nuclear antigen 
PCR ..................................... polymerase chain reaction 
PD ........................................ protease defective 
PDB ..................................... Protein Data Bank 
PDS1 ................................... precocious dissociation of sisters 1 
PERK ................................... protein kinase A-like ER kinase 
PFA ..................................... paraformaldehyde 
PNGase ................................ peptide-N-glycanase 
PICS .................................... proteomic identification of protease cleavage sites 
Psm ...................................... proteasomal subunit mammalian 
PUB ..................................... PNGase/UBA domain 
RAD..................................... RADiation sensitive 
RBR ..................................... RING-betweenRING 
REDAC ............................... redundant dihedral angle constraints 
RFC ..................................... replication factor C 
RIN ...................................... RNA integrity number 
RING ................................... really interesting new gene 
RMSD .................................. root mean square deviaiton 
RNA..................................... ribonucleic acid 
Rngo .................................... rings lost 
ROS ..................................... reactive oxygen species 
RP ........................................ regulatory particle 
RPA ..................................... replication protein A 
Rpn ...................................... regulatory particle non-ATPase 
Rpt ....................................... regulatory particle triphosphatase 
RSC1A1 ............................... regulatory solute carrier protein A1 
RTF2 .................................... replication termination factor 2 
RUVBL ............................... RuvB like AAA ATPase 
RVP ..................................... retroviral protease (-like domain) 
qPCR ................................... quantitative polymerase chain reaction 
SATB ................................... special AT-rich sequence binding protein 
SAXS ................................... small-angle X-ray scattering 
SCF ...................................... Skp1-Cul1-F-box protein complex 
Sc UIM ................................ scrambled ubiquitin interacting motif 
SDS ...................................... sodium dodecyl sulfate 
SDSA ................................... synthesis-dependent strand annealing 
SDS-PAGE .......................... sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
Sel1L ................................... suppressor of lin-12-like protein 1 
Sem1 .................................... split hand/foot malformation (ectrodactyly) type 1 
siRNA .................................. small interfering ribonucleic acid 
Skn-1 ................................... skinhead-1 
Skp1 ..................................... S-phase kinase associated protein 1 
Snc2 ..................................... synaptobrevin homolog 2 
SNP ...................................... single nucleotide polymorphism 
SP1 and 2 ............................. site-1 and site-2 proteases 
SPRTN ................................. SprT-like N-terminal domain 
SREBP1 ............................... sterol regulatory element-binding protein 1 
Sso1B ................................... supressor of Sec 1-binding 
Sti1-like ............................... stress-inducible phosphoprotein 1-like 
TALEN ................................ Transcription Activator-Like Effector Nuclease  
Tbp....................................... TATA-Box binding protein 
TCF11 .................................. transcription factor 11 
TEMED ............................... tetramethylethylendiamine 
TEV ..................................... tobacco etch virus 
TFIIH ................................... transcription initiation factor IIH 
TLS ...................................... translesion synthesis 
TOCSY ................................ total correlated spectroscopy 
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TRAIP ................................. tumor necrosis factor receptor associated factor Interacting protein 
t-SNARE ............................. target soluble N-ethylmaleimide-sensitive factor attachment protein 
                                               receptor 
UBA .................................... ubiquitin-associated domain 
Ube3a .................................. ubiquitin protein ligase E3A 
UBL ..................................... ubiquitin-like domain 
Ubp6 .................................... ubiquitin-specific protease 6 
UBQ .................................... ubiquitin 
UBX .................................... ubiquitin regulatory X domain 
Uch37 .................................. ubiquitin C-terminal hydrolase 37 
UCHL5 ................................ ubiquitin C-terminal hydrolase L1 
Ufd` ..................................... ubiquitin fusion degradation 1 
UHMK1 ............................... U2AF homology motif kinase 1 
UIM ..................................... ubiquitin-interacting motif 
UPR ..................................... unfolded protein response 
UPS ..................................... ubiquitin-proteasome system 
Usp14 .................................. ubiquitin specific peptidase 14 
UV ....................................... ultraviolet 
UVB .................................... ultraviolet B 
UV-DDB ............................. UV radiation–DNA damage-binding protein 
VBM .................................... VCP binding motif 
VCP ..................................... valosin containing protein 
VIM ..................................... VCP-interacting motif 
VIMP ................................... VCP-interacting membrane protein 
Vsm-1 .................................. v-SNARE master protein 1 
v-SNARE ............................ vesicle soluble N-ethylmaleimide-sensitive factor attachment 
                                               protein receptor 
Wss1 .................................... weak suppresor of smt3 
WT ....................................... wild-type  
XBP1 ................................... X-box binding protein 1 
xCT ...................................... XAP5 cysteine/glutamate transporter 
XPA ..................................... xeroderma pigmentosum group A protein 
XPC ..................................... xeroderma pigmentosum group C protein 
XPD ..................................... xeroderma pigmentosum group D protein 
XTP3B ................................. HBV X-transactivated gene 3 protein-transactivated gene B protein 
yDdi1 ................................... yeast DNA damage-inducible protein homolog 1 







































































































1.1 THE CONCEPT OF HOMEOSTASIS – BRIEF HISTORY 
One of the first theories on constancy maintenance and its importance in a biological 
system (human body), humorism (from Greek χυμός – chymós, translates to juice), dates back 
to ancient Egyptian or Mesopotamian medicine (Sertima I. V., 1992, Sudhoff K. and Garrison 
F. H., 1985). Humorism presents health of human body as a state, when the four bodily fluids: 
black bile, yellow bile, blood and phlegm, are in balance. Balance distortion of bodily 
liquids - dyscrasia - causes disease (mental or physical condition) (Jackson W. A., 2001). 
Holistic basis of this medical system interconnects mental and physical health and so the four 
body fluids additionally correspond to human temperaments: a choleric, a melancholic, 
a sanguinic and a phlegmatic(Jackson W. A., 2001).  
The concept of internal balance of bodily fluids was not only used in ancient Egyptian 
or Mesopotamian medicine, however it most probably simultaneously set basis in Indian 
Ayurveda and traditional Chinese medical practices (Lutz P. L., 2002, Magner L. N., 2002, 
Sertima I. V., 1992, Sudhoff K. and Garrison F. H., 1985). Even though this theory had been 
used in ancient medicines previously, it was first described and systematized in ancient Greek 
collection of medical works called Hippocratic Corpus (from Latin: Corpus Hippocraticum) 
(Conrad L. I. N., Michael; Nutton, Vivian ;  Porter, Roy; Wear, Andrew 1995).  In spite of its 
name, this collection was created not by Hippocrates himself, but by many ancient Greek 
physicians and philosophers, most probably his students and followers. Hippocratic treatment 
was passive and moreover, as dissection of human body was permitted in ancient Grece, many 
deductions on diseases were based only on observations and incorrect. Next significant Greek 
physician, Galen of Pergamum (129 to 200 C. E.), not only formulated body disposition and 
human temper type interconnection with dominance of each of the bodily fluids, he described 
many anatomical observations based on necropsies he performed on animals (Schultz S. G., 
2002). Since Hippocratic medicine and Galen´s observations spread widely to Roman, 
Persian and later most European cultures, they constituted the principia of medicine and 
deeply influenced scientific advancement from ancient Greece up to beginning of 19th 
century (Conrad L. I. N., Michael; Nutton, Vivian ;  Porter, Roy; Wear, Andrew 1995). 
First challenges to humorism occurred during Byzantine Empire with high influence 
of religion on medicine (Conrad L. I. N., Michael; Nutton, Vivian ;  Porter, Roy; Wear, 
Andrew 1995). Galen´s study had become almost dogmatic and was not seriously challenged 
until 17th century. Then, Hippocratic medicine practices suffered more severe setback with 
arrival of renaissance and allowance of human body necropsies at universities for purpose of 
medical and knowledge advancement. Anatomical discoveries of Andreas Vesalius published 
in 1543 in “De Humani Corporis Fabrica” (On the Fabric of the Human Body), where he 
identified errors in Galen´s treatises (Abbott A., 2015, Mesquita E. T. et al., 2015), followed 
by William Harvey´s monograph “Exercitatio  Anatomica  de  Motu Cordis  et  Sanguinis  in  
Animalibus” (Anatomical  Essay  on the  Motion  of  the  Heart  and  Blood  in  Animals) 
published in 1628 (Schultz S. G., 2002), revolutionized physiology and medicine and 
contradicted Galenistic theories. Moreover, Harvey´s research set the basis of scientific 
methodology in systematic experimentation and computation opposed to previously 
performed observations. Complete discreditation of humorism occured in 1858 with 
publication “Die Cellularpathologie in ihrer Begründung auf physiologische und 
pathologische Gewebelehre” (Cellular Pathology) of German scientist Rudolf Ludwig Carl 
Virchow (Virchow R., 1858). Cell theory had already been established, however, Virchow´s 
significant contribution to the theory and promotion of microscopic insight into medicine and 
science designate him the founder of cellular pathology (Lin J. I., 1983). His observations 
completely opposed the theory of a balance of four bodily fluids determining human health. 
With sudden rapid advancement of cellular biology, microscopy and genetics since the 
middle of 19th century, humorism fell into shade and parted with modern science and 
conventional medicine (Conrad L. I. N., Michael; Nutton, Vivian ;  Porter, Roy; Wear, 
Andrew 1995). 
Even though humorism was left out of modern medical practices since, the perception 
of constancy in biological system, ironically basis of which was originally set in humorism, 
outlived even modern science. While French histologist Charles-Philippe Robin started to use 
phrase “milieu de l’intérieur” (the internal environment), which was comparable to the 
original Hippocratic balance between humors (Gross C. G., 2016), French physiologist 
Claude Bernard defined interstitial fluid in multicellular organisms as the “milieu intérieur”. 
He described the ability of extra-cellular fluid to maintain healthy condition in tissues and 
organs of the whole body and defined it as disease protective element (Bernard C., 1865, 
Bernard C., 1949). He stated that internal bodily environment stability was basal condition 
for healthy life (Bernard C., 1974). This principle of internal constancy was later named 
“homeostasis” by American physiologist Walter Bradford Cannon in 1926 (Cannon W. B., 
1926). The term comes from two Greek words: ὅμοιος (homoios), which means similar, and 
στάσις (stasis), which stands for standing still. Cannon defined homeostasis in 1929 as 
follows: “The coordinated physiological reactions which maintain most of the steady states 
in the body are so complex and are so peculiar to the living organism that it has been suggested 
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that a specific designation for these states be employed – homeostasis” (Cannon W. B., 1929). 
He built up his homeostasis regulation theory on Bernard´s scheme which emphasizes the 
need of constant values of material supply and environmental conditions. Cannon studied the 
flow of food and water intake, simultaneous excretion and maintenance of body temperature 
and blood pH and identified the importance of sympathetic pathway and hormonal secretion 
in regulation of all these processes (Cooper S. J., 2008). In 1956, Hungarian-Canadian 
endocrinologist Hans Selye introduced the concept of stress in physiology and biology 
(Goldstein D. S. and Kopin I. J., 2007, Selye H., 1956). He defined stress as a state “resulting 
in the nonspecific response of the body to any demand upon it” (Selye H., 1956). He actually 
expanded Cannon´s previously described theory of fight-or-flight response (Cannon, 1915). 
Modern concept of stress interprets it as a sensed threat to homeostasis with a specific 
response towards homeostasis restoration (McEwen B. S. and Stellar E., 1993). 
Since beginning of 20th century, homeostasis maintenance has been considered the 
driving force of regulation of physiological and cellular processes towards ideal steady states 
to prevent pathological consequences of homeostasis disturbance. 
1.1.1 From systemic to cellular homeostasis 
Homeostasis has become one of the 8 core concepts of biology (Modell H. et al., 
2015). Its upkeep is key process at different levels in biological systems, from the complexity 
of an organism down to each organ, tissue compartment and individual cells. At all of these 
levels, the process of regulation of variables (internal environment conditions, e.g. 
temperature, pH, concentration of ions) towards stress response follows the same pattern 
(Buchman T. G., 2002, Goldstein D. S. and Kopin I. J., 2007). First, a sensor detects values 
of the variable and a homeostat compares it with the set point (a dynamic range of acceptable 
values) (Goldstein D. S., 1995). If the variable comes to be out of respectable range, control 
apparatus generates response and engages an effector. Effector changes the variable back 
towards steady state for homeostasis restoration (Goldstein D. S. and Kopin I. J., 2007). In 
general, generation of response can be performed in two ways: a positive feedback, which 
speeds up the stimuli process/change in condition or a negative feedback, which reverses the 
initiating impulse (Cooper S. J., 2008). To set an example, when the environment temperature 
and our core body temperature (variable) drops below acceptable range, thermosensors in 
skin and hypothalamus recognize this change. Skeletal muscles, as the effectors, act pro heat 
production causing shivering in a negative feedback loop (Modell H., et al., 2015).  
Systemic homeostasis (at whole organism level) is ensured by autonomic nervous and 
endocrine system, which maintain variables such as core body temperature, osmolarity, blood 
pH, blood levels of ions, glucose, oxygen, etc. At tissue level, for example, the steady states 
of interstitial fluid volume, osmolarity and pH, cell positioning in tissue architecture, integrity 
of cell junctions are monitored (Chovatiya R. and Medzhitov R., 2014). In cell, variable 
changes in nutrient supply or protein folding and modifications (and many more processes – 
for few representative examples see Table 1) are detected by signaling proteins. If acceptable 
dynamic range of variables (nutrients, pH, all cellular processes) is violated, cell is stressed 
and engages stress response pathways towards cellular homeostasis restoration  or in extreme 
cases towards apoptosis (Chovatiya R. and Medzhitov R., 2014). Apoptosis of cells might 
lead to protection of steady state in tissue environment (for example, regulation of cell number 
in tumorigenesis prevention) or homeostasis preservation at the level of whole organism (e.g. 
control of T-cell repertoire in autoimmunity prevention, apoptosis of infected host cells) 
(Giovannetti A. et al., 2008, Hacker G., 2018). 
Table 1: Representative sensor molecules in cellular homeostasis. Adapted from (Chovatiya R. and 
Medzhitov R., 2014) 
Source of stress Sensor molecule 
ER stress ATF6, IRE-1α, PERK 
Genotoxic stress p53 
Heat shock HSF-1 
Hypoxia HIF-1α 
Oxidative stress NFR2 
Environmental stress NF-κB, MAPK pathways 
Amino acid deprivation ATF4, mTOR 
1.1.2 Cellular homeostasis 
Since the definition of homeostasis by Walter Bradford Cannon in 1929, it was 
initially studied at organ or whole organism level (Cannon W. B., 1929). However, 
a revolution concerning cellular homeostasis started with description of a dynamic state of 
proteins, the never-ending synthesis followed by degradation over and over again, depending 
on internal and external environment (Simpson M. V., 1953). Practically, it is mostly proteins 
that control and regulate not only cell cycle and functions of the cell, but even the osmolarity 
of internal and external cellular fluids, ion concentration in cytoplasm, etc. Protein turnover 
involves a variety of cellular processes, that are crucial for proper function of cells, starting 
with DNA damage repair for preservation of genetic information, followed by regulation of 
gene expression, control of transcription and translation of proteins, their modifications, 
transportation in cell, activity control and eventual protein degradation (Calamini B. and 
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Morimoto R. I., 2012). Half-lives of proteins may differ in orders of magnitude even when 
present in one cell. Regulatory proteins mostly have lifetime of several minutes, however, 
there are also so-called long-lived proteins that evade degradation (Toyama B. H. and Hetzer 
M. W., 2013). Some proteins, such as myelin and nuclear pore complex (Rodrijguez de Lores 
A. et al., 1971, Savas J. N. et al., 2012), last for days. Some, for example collagen as an 
extracellular protein or crystalline in eye lens, live up to years or even decades (Masters P. M. 
et al., 1977, Verzijl N. et al., 2000).  
Protein synthesis, from DNA via RNA to primary protein sequence, folding into a 3D 
structure and posttranslational modification of proteins are complex and variable processes, 
which can be impaired in a high number of ways. As native conformation of proteins is 
essential for sustaining of their biological function, protein homeostasis (proteostasis) is 
essential for health of the cell, or even whole organism from a broader perspective (Balch W. 
E. et al., 2008, Calamini B. and Morimoto R. I., 2012). Defects in the synthesis pathway, such 
as mutations (or even polymorphism), error-prone protein synthesis, physical or chemical 
stress causing protein misfolding resulting in protein aggregation, may cause loss- or gain-of-
function proteinopathies (e.g. cystic fibrosis or Alzheimer´s disease, respectively) (Cohen F. 
E. and Kelly J. W., 2003, Powers E. T. et al., 2009). As our organism ages, the activity of 
stress response signaling pathways declines. Additionally, long-lived proteins that bypass 
degradation process and turnover are prone to accumulation of damage. That results in 
functional impairment and cellular aging (Toyama B. H. and Hetzer M. W., 2013). The 
overall gradual loss of proteostasis leads to susceptibility to chronic diseases, metabolic or 
neurological dysfunctions and cancer (Balch W. E., et al., 2008, Kim Y. E. et al., 2013). 
1.2 PROTEIN HOMEOSTASIS MAINTENANCE 
Proteostasis network consists of quality control mechanisms and stress response 
pathways that maintain stable and functional proteome. This is achieved by constant 
regulation and control of protein synthesis and degradation and via protein folding and 
trafficking (Balch W. E., et al., 2008). At least around 1400 proteins are involved in 
proteostasis network in human cells, of which around 300 is a family of molecular chaperones 
and their regulators (Brehme M. et al., 2014, Kim Y. E., et al., 2013). The role of chaperones 
and folding enzymes in proteostasis network is to smooth energy barriers during acquisition 
of the native state of their substrates (Powers E. T., et al., 2009).  
There are several signaling pathways focusing on different stages and areas of 
proteostasis: DNA damage response, heat shock response, histone deacetylases system, 
oxidative-stress response, inflammatory defense pathways, autophagic-lysosomal system, 
unfolded protein responses (UPR) in endoplasmic reticulum and mitochondria, Ca2+ 
cytoplasm-endoplasmic reticulum gradient regulatory pathway connected to endoplasmic 
reticulum associated degradation (ERAD) and the ubiquitin-proteasome system (UPS) 
(Galluzzi L. et al., 2018, Powers E. T., et al., 2009, Walter P. and Ron D., 2011). Those 
relevant for our study are briefly introduced below. 
1.2.1 DNA damage response (DDR) or DNA repair 
DNA is constantly exposed to damaging agents or events of exogenous and 
endogenous origin. The exogenous causes can be, for example, xenobiotics or exposition to 
ultraviolet light, while chromatin remodeling, double-strand break (DSB) repair and redox 
homeostasis maintenance belong to main three endogenous damage-prone mechanisms 
(Turgeon M. O. et al., 2018). Unsuccessful repair of genetic lesions may have severe effect 
on physiological tissue and systemic homeostasis (Galluzzi L., et al., 2018). DNA damage 
response is represented by a complex network of pathways operating differently, based on 
the origin of damage and mechanism of repair. 
Base excision repair (BER) pathway focuses on DNA lesions that cause minor 
distortion to the double helix, such as oxidation, deamination or alkylation (Krokan H. E. and 
Bjoras M., 2013). The damaged base is removed by a DNA glycosylase (Lindahl T., 1974). 
Apurinic/apyrimidinic endodeoxyribonuclease 1 (APE1) recognizes the abasic site and 
recruits DNA polymerase β and DNA ligase 1 (LIG1) or LIG3 complexed with X-ray repair 
cross complementing protein 1 (XRCC1) to complete the repair process (Krokan H. E. and 
Bjoras M., 2013, Tell G. et al., 2009). Another possibility is that poly(ADP-ribose) 
polymerase 1 (PARP1) denotes single-strand break site, which is recognized by APE1, and 
BER pathway is initiated (Durkacz B. W. et al., 1980). 
DNA adducts and bulky structures that cause double helix deformation are resolved 
by nucleotide excision repair (NER) pathway. The damage is sensed by a protein complex 
consisting of DNA damage recognition and repair factor (XPC), UV excision repair protein 
RAD23B and centrin 2 (CETN2), followed by recruitment of TFIIH (transcription initiation 
factor IIH), which bears a helicase subunit XPD for lesion verification (Volker M. et al., 
2001). In case of ultraviolet (UV) irradiation damage, first, UV–DDB (UV radiation–DNA 
damage-binding protein) complex is recruited to the site, followed by recognition of XPC 
complex (Wakasugi M. et al., 2002). Once DNA is unwound, the undamaged strand is 
covered with replication protein A (RPA) for protection throughout the whole process (de 
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Laat W. L. et al., 1998). XPA protein scans the damaged strand for nucleotides with altered 
chemical structures and engages structure-specific endonuclease complexes XPF–ERCC1 
and XPG (encoded by ERCC5) into the repair process (Camenisch U. et al., 2006, Fagbemi 
A. F. et al., 2011). Finally, excised DNA gap is recognized by PCNA and replication factor 
C (RFC), which recruit synthesis and ligation enzymes such as DNA polymerase δ, ε or κ, 
and DNA ligase 1 or XRCC1– DNA ligase 3, depending on the state of the cell (Marteijn J. 
A. et al., 2014, Ogi T. et al., 2010). 
Base mismatches and small deletions or insertions are restored via DNA mismatch 
repair (MMR) pathway. The site of damage is recognized by MutSα in case of single base 
damage (or MutSβ for larger insertions/deletions) that recruits endonuclease complex of 
MLH1 and PSM2 (Kunkel T. A. and Erie D. A., 2015, Schaetzlein S. et al., 2013). PCNA 
sliding clamp then loads onto nascent DNA, activates MLH1, which incises the DNA in ATP-
dependent manner (Modrich P., 2006). Mismatch is then removed by exonuclease 1 
downstream of the recruitment protein complex and the cleaved DNA strand is resynthesized 
by polymerases and connected by ligases (Genschel J. et al., 2002, Schaetzlein S., et al., 
2013).  
Double-strand breaks of genomic DNA are repaired via two mechanisms, non-
homologous DNA end joining (NHEJ) and homology-directed repair (HDR). NHEJ is a more 
common pathway, which is able to restore chromosomal structure after DNA breakage, 
however at the same time causes deletion or insertion of a few nucleotides at one of the DNA 
ends, or both (Lieber M. R., 2010). Canonical NHEJ has a first and main actor, Ku protein 
that binds to broken DNA ends and recruits DNA-dependent protein kinase (Walker J. R. et 
al., 2001). Other enzymes, such as nucleases (e.g. artemis), polymerases (e.g. polymerases μ 
and λ) and ligases (e.g. DNA ligase IV) of this pathway, are assembled to this DNA:protein 
complex, according to the requirements of the breakage repair mechanism (Lee J. W. et al., 
2004, Ma Y. et al., 2002, Nick McElhinny S. A. and Ramsden D. A., 2003, Nick McElhinny 
S. A. et al., 2000). Alternative NHEJ is a “backup” pathway that is able to mediate end joining 
depending on microhomology (less than approx. 10 bp) (Wang H. et al., 2005). In contrast, 
HDR system is error-free. However, it requires a homology donor that is not present in diploid 
cells outside S and G2 phase of cell cycle (Lieber M. R., 2010, Vitale I. et al., 2017). HDR 
has three forms of mechanism, single-strand annealing, breakage-induced replication and 
most frequent homologous recombination (HR), which requires the longest homology 
sequence (San Filippo J. et al., 2008). Activation machinery of homologous recombination at 
site of DSB initiates PARP1 localization and DNA poly(ADP-ribosyl)ation  at the damage 
site (Van Meter M. et al., 2016). Then, a protein complex consisting of Mre11, Rad50 and 
Nbs1 (called the MRN complex in humans) is recruited to the site of damage (Haince J. F. et 
al., 2008). Resection of the 5´-end follows and RPA protein binds to the free 3´ overhang 
(szostak 1983). Rad51 recombinase recognizes the RPA coated DNA single strand and with 
help of other assisting proteins (e.g. BRCA1, BRCA2) searches for homology sequences at 
the sister chromatid (Prakash R. et al., 2015, Vitale I., et al., 2017). Repair process can be 
performed in two ways, the double Holliday junction model or the synthesis-dependent strand 
annealing (SDSA) pathway (Vitale I., et al., 2017). 
Translesion synthesis (TLS) is a process, which avoids DSB creation or replication 
fork collapse, when replication is stalled due to DNA damage (e.g. in case of thymine dimers) 
(Sale J. E., 2013). Proliferating cell nuclear antigen (PCNA) is ubiquitinated by a heterodimer 
of ubiquitin-conjugating enzyme E2A or B with E3 ubiquitin-protein ligase RAD18 (Bailly 
V. et al., 1994). This modification attracts polymerases from Y family to the DNA damage 
site (Sale J. E., 2012). These polymerases are able to facilitate the required insertion at the 
damage site, which common replication polymerases are not able to perform (Waters L. S. et 
al., 2009). These polymerases are error-prone, which is a high risk of mutagenesis, however, 
TLS is smoother process than other more challenging DNA damage responses, which could 
lead to cellular death. 
Another DNA damage response, which deals with DNA-protein crosslinks (DPCs) 
that escaped NER pathway, has been recently described (Stingele J. et al., 2015). DPCs, 
which stall replication fork and could lead to genome instability, are formed either when 
enzymes, e.g. topoisomerases, are covalently trapped in the otherwise transient DNA-protein 
intermediate or upon exposure to crosslinking agents, such as UV radiation or formaldehyde 
(Barker S. et al., 2005, Pommier Y. et al., 2006). In yeast models, metalloprotease Weak 
suppressor of smt3 (Wss1), is activated by interaction with Cdc48 (VCP/p97 in higher 
eukaryotes) and with DNA and cleaves off the bulky protein body of DPC leaving only a 
DNA-bound peptide behind (Balakirev M. Y. et al., 2015, Stingele J. et al., 2014). This leads 
to ssDNA accumulation, attraction of PCNA and TLS polymerases that produce mutations, 
but promote replication restart (Stingele J., et al., 2014). In higher eukaryotes, DPCs are 
removed from nascent DNA strands by two mechanisms: proteolytic cleavage of the protein 
part by similar mechanism as in yeast by a homolog of Wss1, SPRTN metalloprotease, or by 
ubiquitination of the trapped protein by E3 ubiquitin ligase TRAIP and subsequent 
degradation in proteasome (Larsen N. B. et al., 2018, Lopez-Mosqueda J. et al., 2016, Morocz 
M. et al., 2017, Stingele J. et al., 2016). 
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There are two main actors common for DNA repair pathways adjacent to DSBs or 
ssDNA damage - ataxia telangiectasia mutated (ATM) serine/threonine kinase and ataxia 
telangiectasia and Rad3-related protein (ATR) (Marechal A. and Zou L., 2013). ATM and 
ATR phosphorylate H2A histone family member X, which leads to activation of check point 
kinases 1 and 2. This results either in cell cycle arrest until the repair process is finished or in 
apoptosis via regulation of p53 protein in case the damage cannot be resolved (Vitale I., et 
al., 2017). 
1.2.2 Oxidative stress response 
Elevation of oxidation causing elements with toxic effect (oxidative stressors), such 
as reactive oxygen species (ROS), reactive nitrogen species, reactive sulfur species, reactive 
selenium species and reactive carbonyl species, leads to imbalance in redox homeostasis 
which might have pathogenic implication (Sies H. et al., 2017). Most abundant group is ROS 
(covers superoxide, hydroxyl and peroxide radicals), which arise from disruption of 
mitochondrial electron transport chain or activity of several enzymes, e.g. NADPH oxidase 
(Vaquero E. C. et al., 2004). Basal production of ROS is convenient as they act as second 
messengers in a variety of cellular signaling pathways. However, higher levels of ROS are 
detrimental as they cause damage to DNA, lipids and proteins (Martin K. R. and Barrett J. C., 
2002, McCord J. M., 1995, Rhee S. G., 1999, Rhee S. G., 2006, Sauer H. et al., 2001). 
Excessive generation of ROS has been reported to result in activation of transcription factors, 
such as NF-κB, mitogen-activated protein kinases (MAPK), activator protein 1 (AP-1) or 
factors activating apoptosis (Chen Q. et al., 1995, Jacobson M. D., 1996, Pahl H. L. and 
Baeuerle P. A., 1994, Schreck R. et al., 1991). 
Essential regulatory genes that are activated upon oxidative stress are nuclear factor 
erythroid-derived 2-related factor 1 and 2, NFE2L1/Nrf1 and NFE2L2/Nrf2 (Chan J. Y. et 
al., 1993b, Moi P. et al., 1994, Venugopal R. and Jaiswal A. K., 1998). They belong to the 
cap-and-collar (CNC) subfamily of basic-leucine zipper (bZIP) transcription factors together 
with p45 NF-E2, Nrf3, Bach1 and Bach2 genes in mice and humans. Members of this group 
were originally described as regulators of beta-globin gene activation bearing a 43-residue 
long homology region prior DNA-binding domain (Andrews N. C. et al., 1993, Biswas M. 
and Chan J. Y., 2010, Schultz M. A. et al., 2010). Nrf1 and Nrf2 of vertebrate form functional 
heterodimers with either member of cAMP response element binding protein family 
(CREBP), ATF4 or small Maf proteins, e.g. MafG, MafF or MafK, which regulate expression 
of oxidative stress related genes via binding to the antioxidant response elements (AREs) 
upstream of their sequence (Johnsen O. et al., 1998, Johnsen O. et al., 1996, Kaspar J. W. et 
al., 2009, Motohashi H. et al., 2004). Production of prooxidants is compensated by 
antioxidant gene expression (by Nrf1 or Nrf2) that are able to maintain redox homeostasis, 
such as glutathione peroxidase 1, cytochromes P-450, peroxiredoxin-1, thioredoxin-1, 
superoxide dismutase, heme oxygenase-1, NADPH-quinone oxidoreductase or enzymes 
involved in biosynthesis of the main antioxidant - glutathione (Biswas M. and Chan J. Y., 
2010, Kim Y. J. et al., 2007, Myhrstad M. C. et al., 2001, Nioi P. et al., 2003, Osburn W. O. 
and Kensler T. W., 2008, Wu G. et al., 2004). ARE (also called electrophile response 
sequence) is a cis-active sequence 5´-TGACXXXGC-3´ in the target gene promotor region 
(Friling R. S. et al., 1992, Rushmore T. H. et al., 1991, Telakowski-Hopkins C. A. et al., 
1988).  
Nrf2 is considered the main regulator of response to oxidative stress called the phase 
II response (Dinkova-Kostova A. T. et al., 2005). ARE sequences of genes regulated by Nrf2 
occur in promotors of around 1055 genes involved in not only oxidative stress, but as well in 
DNA repair, detoxification, cellular proliferation, signaling and immune response (Dodson 
M. et al., 2019, Silva-Islas C. A. and Maldonado P. D., 2018). The 605 residues of Nrf2 form 
a seven domain structure and provide modification and interaction sites important for 
regulation of Nrf2 activity. Neh1 domain in the C-terminal part is the DNA binding and Maf 
interaction site (Itoh K. et al., 1999, Li W. et al., 2008a). Under basal conditions, Nrf2 is 
present in an inactive form bound to cytoplasmic chaperone Keap1 via its N-terminal Neh2 
domain. Keap1 anchors Nrf2 to cytoskeleton and at the same time bridges it to Cul3-based 
E3-ubiquitin ligase for ubiquitination. Ubiquitinated Nrf2 is detached from Keap1 by 
p97-UBNX7-UFD1/NPL4 complex and subsequently degraded in proteasome – the half-life 
of Nrf2 is approx. 13 min (Cullinan S. B. et al., 2004, Itoh K., et al., 1999, Stewart D. et al., 
2003, Tao S. et al., 2017, Tong K. I. et al., 2006). Under oxidative stress, Nrf2 can be activated 
by two mechanisms: canonical and non-canonical (Silva-Islas C. A. and Maldonado P. D., 
2018). In the first mechanism, the lysines of Nrf2 are not available for ubiquitination and 
subsequent proteasomal degradation due to conformational change of the interacting Keap1, 
which arises from oxidation of Keap1 Cys residues by oxidizing compounds. In this case, 
Keap1 remains bound to Nrf2 and is unable to fish out newly synthesized Nrf2 molecules that 
escape proteasome and are subsequently activated (Baird L. et al., 2013, Itoh K. et al., 2003). 
In the non-canonical mechanism, Keap1 detaches Nrf2, which results in its translocation into 
nucleus and activation of antioxidant genes, instead of its proteasomal degradation (Holtzclaw 
W. D. et al., 2004, Kobayashi A. et al., 2004). A set of genes (e.g., p21, BRCA1) that are able 
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to bind either Keap1 or Nrf2, and thereby disrupt their interaction are responsible for this 
activation (Silva-Islas C. A. and Maldonado P. D., 2018). Nrf2 molecules that escape 
degradation are phosphorylated and acetylated prior to their translocation into nucleus via 
importin α5 and importin β1 (Huang H. C. et al., 2002, Joo M. S. et al., 2016, Kawai Y. et 
al., 2011, Theodore M. et al., 2008). A variety of additional modifications of Nrf2 are required 
for its binding to ARE sequences (Silva-Islas C. A. and Maldonado P. D., 2018). The pool of 
activated Nrf2 molecules in nucleus is regulated by E3 ubiquitin ligase Skp1-Cul1-F-box 
protein complex (SCF) together with β-transducin repeat-containing protein (β-TrCP). (β-
TrCP) works as an adaptor, which binds to sequence DpSGX(1-4)pS phosphorylated on 
serine residues, which is situated in Neh6 domain (Chowdhry S. et al., 2013, Rada P. et al., 
2011, Rada P. et al., 2012, Skowyra D. et al., 1997). This motif is conserved also in Nrf1 and 
Nrf3 proteins (Tsuchiya Y. et al., 2011). This brings Nrf2 to proximity with a RING E3 ligase 
Skp1, which ubiquitinates Nrf2 and thereby targets it for degradation.   
The role of Nrf2 in stress response leads to protection of cells from damage and death. 
However, Nrf2 may also be misused in cancer cells in reaction to radiotherapy or 
chemotherapeutics for activation of response pathways that result in resistance to apoptosis 
or proliferation (Wang X. J. et al., 2006). Both these factors make Nrf2 an attractive 
therapeutic target from different points of view (Rojo de la Vega M. et al., 2018). In spite of 
that, only one FDA approved compound that activates Nrf2, an electrophilic dimethyl 
fumarate, is used for treatment of relapsing multiple sclerosis (Satoh T. and Lipton S., 2017).  
Structure of Nrf1 is similar to Nrf2 to a certain extent, as they contain conserved 
sequences in the DNA binding region, a β-TrCP binding motif and Neh2 domain. Nrf1 Neh2 
is able to bind Keap1 in spite of the fact that Keap1 does not participate in the degradation 
nor activation cascade of Nrf1 (Kim H. M. et al., 2016, Wang W. and Chan J. Y., 2006, Zhang 
Y. et al., 2006). Life cycle of Nrf1 differs from that of Nrf2 even though it is based on similar 
principle (described in chapter 1.3.2.1.1 on page 54). Some target genes of Nrf1 and Nrf2 are 
regulated by both transcription factors; however, some are unique to the individuals (Kim H. 
M., et al., 2016). Ohtsuji and colleagues described distinct roles of Nrf1 and Nrf2 in regulation 
of ARE regulated genes on a number of mouse knockout models. Some antioxidant genes are 
responsive to both Nrf1 and Nrf2, however, some, e.g. metalothionein-1 and -2, are exclusive 
to activation by Nrf1 (Ohtsuji M. et al., 2008). Nrf1 activity is essential for proper hepatocyte 
function as was shown in full and liver specific knockout mouse models (Chen L. et al., 2003, 
Xu Z. et al., 2005). Nrf2 knockout mice show failure in adequate antioxidant gene induction 
in response to oxidative stress (Chanas S. A. et al., 2002, Itoh K. et al., 1997). Strikingly, Nrf1 
knockout mice die during embryonal development due to anemia before they reach 
embryonic day 13.5 (Chan J. Y. et al., 1998). As Nrf1/Nrf2 double knockout mice die earlier, 
at embryonic day 11.5, Nrf2 seems to (at least partially) provide compensation for Nrf1 
function (Leung L. et al., 2003, Ohtsuji M., et al., 2008). Nrf2 differs from Nrf1 in several 
ways: Nrf2 is not glycosylated, it activates a different subset of stress response genes, and 
even though it does regulate the expression of proteasomal subunits, it is upon oxidative stress 
conditions and not upon proteasomal inhibition opposed to Nrf1 (Kwak M. K. et al., 2003, 
Radhakrishnan S. K. et al., 2010, Steffen J. et al., 2010). It was therefore proposed that Nrf1 
counteracts constitutive oxidative stress opposed to Nrf2 that shall respond to severe stress 
states (Ohtsuji M., et al., 2008). As the role of Nrf1 reaches beyond oxidative stress response 
and is closely related to this study, its degradation, activation and other functions are described 
in detail in chapter 1.3.2.1.1 on page 54.  
1.2.3 Proteostasis maintenance pathways in ER 
1.2.3.1 Unfolded protein response 
Unfolded protein response pathway in ER, the center of protein secretion and surface 
display in cell, is main regulatory strategy, with which cells cope with the burden of misfolded 
protein accumulation in the ER lumen. Only in some specific cell types (e.g. immune system 
cells), the threshold for UPR activation is elevated in behalf of their function in systemic 
homeostasis (Frakes A. E. and Dillin A., 2017). UPR operates towards expansion of ER 
protein-folding capacity via three unique signal transduction mechanisms. These are each 
defined by ER-resident stress sensors: inositol requiring enzyme 1(IRE1), activating 
transcription factor 6 (ATF6) and protein kinase RNA (PKR)-like ER kinase (PERK) (Frakes 
A. E. and Dillin A., 2017, Walter P. and Ron D., 2011). All three UPR key components are 
transmembrane proteins that harbor luminal and cytosolic domains essential for their 
function. Luminal domains represent the sensor of folding homeostasis: they are bound to 
a chaperone binding immunoglobulin protein (BiP) and therefore inactive in stress-free 
environment. When the capacity of ER folding system is overwhelmed, misfolded proteins 
attract BiP, which frees the luminal domain of the sensor and activates it (Bertolotti A. et al., 
2000, Frakes A. E. and Dillin A., 2017, Shen J. et al., 2005). Moreover, UPR sensors can be 
activated by direct interaction with misfolded proteins (Walter P. and Ron D., 2011). 
Cytosolic domains provide response to activation via regulation of transcription or translation 
pathways (Frakes A. E. and Dillin A., 2017).  
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The most conserved and best-studied branch of UPR starts with activation of the 
bifunctional kinase/endoribonuclease IRE1. Upon activation, IRE1 undergoes 
autophosphorylation and subsequent oligomerization, which activates its ribonuclease 
domain. IRE1 targets X-box binding proteins 1 (XBP1) and performs cleavage leading to 
formation of a unique XBP1 splice variant. Truncated XBP1 isoform regulates expression of 
a variety of proteins necessary for folding assistance and lipid synthesis for membrane 
expansion (Calfon M. et al., 2002, Frakes A. E. and Dillin A., 2017, Lee A. H. et al., 2003). 
Unspliced version of XBP1 is translated and provides a feedback loop regulation by binding 
to the spliced form of XBP1 hence targeting it to proteasome (Yoshida H. et al., 2006). 
Another branch is controlled by ATF6. Upon activation, ATF6 is translocated into 
Golgi apparatus in vesicles, where its luminal domain and transmembrane anchor are cleaved 
off by site-1 and site-2 proteases (SP1 and SP2) (Haze K. et al., 1999, Schindler A. J. and 
Schekman R., 2009). The cytosolic N-terminal domain of ATF6 is translocated into the 
nucleus and induces expression of XBP1, chaperones (Hsp70 and Hsp90 family proteins) and 
genes involved in ERAD pathway (Hetz C. and Papa F. R., 2018, Lee A. H., et al., 2003). 
PERK kinase activation is the third possibility of UPR. When the luminal domain of 
PERK kinase is unbound, the protein undergoes autophosphorylation and 
homomultimerization. Cytosolic kinase domain then phosphorylates the α subunit of 
eukaryotic translation initiation factor 2 (eIF2α), thereby inhibiting guanine nucleotide 
exchange factor (eIF2B) and mRNA translation in toto (Harding H. P. et al., 1999). There are 
few important exceptions, for example the activating transcription factor 4 (ATF4), which is 
preferably translated under these conditions. ATF4 then targets genes such as pro-apoptotic 
transcription factor CHOP and GADD34 (growth arrest and DNA damage-inducible protein 
34) (Tsaytler P. et al., 2011). GADD34 encodes a protein phosphatase subunit PP1C, which 
dephosphorylates eIF2α and therefore autoregulates the activity of PERK kinase (marciniak). 
1.2.3.2 ERAD pathway 
ERAD is a quality control pathway that maintains ER homeostasis by 
retrotranslocation of terminally misfolded proteins into cytosol for subsequent degradation in 
cytosolic proteasomes (Qi L. et al., 2017). During retrotranslocation, substrates are 
ubiquitinated by a membrane bound E3 ligase (for more information see chapter 1.2.4.3) and 
pulled out of ER in an ATP hydrolysis driven process (for ERAD pathway scheme see 
Figure 1) (Ruggiano A. et al., 2014).  
Substrates for ERAD are recognized and recruited to the retrotranslocation complex 
at luminal site of ER membrane either after specific deglycosylation (trimming of mannose) 
by mannosidases or by ER resident chaperones, such as binding immunoglobulin 
protein/78-kDa glucose-regulated protein (BiP/GRP78), osteosarcoma amplified protein 9 
(OS9), XTP3-transactivayed gene B protein (XTP3B) or ER degradation enhancing alpha 
mannosidase-like protein 1 (EDEM1) (Bhamidipati A. et al., 2005, Christianson J. C. et al., 
2008, Cormier J. H. et al., 2009, Kim W. et al., 2005, Molinari M. et al., 2003, Oda Y. et al., 
2003, Plemper R. K. et al., 1997, Thibault G. and Ng D. T., 2012). Retrotranslocation channel 
is built by ER transmembrane domains of membrane-embedded E3 ubiquitin ligase 
complexes. Yeast Hrd1p and Doa10p E3 ligases are the most characterized complexes 
(Bordallo J. et al., 1998, Swanson R. et al., 2001), which are specializing in degradation of 
misfolded proteins: Hrd1p recognized and designates proteins with lesions in luminal, 
membrane or translocon-associated domains and Doa10p ubiquitinates proteins with errors 
in cytosolic and membrane structures (Ruggiano A., et al., 2014, Thibault G. and Ng D. T., 
2012). Mammals have several ERAD E3 ligases, Hrd1, Gp78, Rma1/Rnf5, Trc8, Rfp2, 
Rnf170 and Rnf185 (Claessen J. H. et al., 2012). The most conserved retrotranslocation 
complex in mammals is represented by Hrd1 E3 ubiquitin ligase and its cofactor Sel1L (Qi 
L., et al., 2017). Hrd1 harbors six transmembrane domains that form the dislocation channel 
and a RING finger domain with a C-terminal proline-rich region projecting into the 
cytoplasm. RING domain ubiquitinates not only misfolded substrates, but in addition, the 
dislocation channel is shaded in a regulatory process when RING domain autoubiquitinates 
Hrd1 itself (Baldridge R. D. and Rapoport T. A., 2016, Carvalho P. et al., 2010, Stein A. et 
al., 2014). Second partner of the dislocation complex is Sel1L, an integral ER membrane 
protein that possesses an N-terminal ubiquitin associated domain (UBA) that binds ubiquitin 
and an evolutionary conserved C-terminal ubiquitin regulatory X domain (UBX) that 
facilitates the recruitment of ATPase into proximity with the dislocation complex and 
substrate (Buchberger A., 2002, Buchberger A. et al., 2001, Hofmann K. and Bucher P., 1996, 
Schuberth C. and Buchberger A., 2005). There are other ER transmembrane proteins, such as 
Derlins and Herpud1, which bind to the Hrd1/Sel1L complex and assist the retrotranslocation 
process (Greenblatt E. J. et al., 2011, Kokame K. et al., 2000). Moreover, it has been shown 
recently that gp78 E3 ligase might second the Hrd1/Sel1L complex in solubilization of the 
substrates for further processing (Zhang T. et al., 2015). 
The act of substrate ubiquitination initiates enrollment of the valosin‐containing 
protein (VCP)/p97 (Cdc48 in yeast), a member of type II AAA+ (ATPases associated with 
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diverse cellular activities) family (Meyer H. et al., 2012). Apart from Hrd1/Sel1L complex 
interaction via a C-terminal VCP binding motif (VBM), other ER transmembrane proteins 
are also able to bind and recruit p97, e.g., the SHP domains in Derlin-1 and Derlin-2 and a 
VCP-interacting motif (VIM) in VIMP (Christensen L. C. et al., 2012, Greenblatt E. J., et al., 
2011, Lilley B. N. and Ploegh H. L., 2004, Neuber O. et al., 2005, Ye Y. et al., 2004). VCP 
uses ATP hydrolysis as a source of energy for pulling force by which it is able to extract 
modified substrates from organelle membranes (e.g., ER, mitochondria) or chromatin and 
target them to proteasome (Franz A. et al., 2016, Heo J. M. et al., 2010, Qi L., et al., 2017). 
The ATPase monomer consists of an N-terminal domain, which serves as an interaction site 
for ubiquitin and cofactor molecules, two conserved ATPase domains D1 and D2 that form a 
hexameric ring in a barrel-shape like structure around a central pore and a C-terminal 76 
amino acid long tail available for cofactor interactions (Davies J. M. et al., 2008, DeLaBarre 
B. and Brunger A. T., 2003, Meyer H. H. et al., 2000, Peters J. M. et al., 1992). ATP 
hydrolysis by D2 domain triggers a conformational change of the ring and thereby facilitate 
disassembly of molecular complexes (Pye V. E. et al., 2006). Substrate release from p97 is 
thought to be driven by ATP hydrolysis in the D1 domain (Bodnar N. O. and Rapoport T. A., 
2017).  
Components of ERAD pathway possess a variety of p97 interaction domains, e.g., 
VIM, 8 residue interacting motif called SHP box or UBX (Buchberger A., et al., 2001, Hitt 
R. and Wolf D. H., 2004, Sato B. K. and Hampton R. Y., 2006). Thanks to these domains, 
more than 30 cofactors of p97 in ERAD pathway are able to recruit p97 to dislocation 
complex or coordinate correct orientation of p97 and the substrate (Ye Y. et al., 2017). The 
N-terminal domain of p97 can bind modified substrate thanks to ubiquitin interaction sites 
held by p97 cofactors, for example nuclear protein localization homolog 4 (Npl4) and 
ubiquitin fusion degradation 1 (Ufd1) heterodimer (Meyer H. H., et al., 2000, Stein A., et al., 
2014, Ye Y. et al., 2003). The p97-Ufd1-Npl4 complex recognizes chains longer than 
a pentaubiquitin, preferably highly branched heterotypic chains (Blythe E. E. et al., 2017, 
Bodnar N. O. and Rapoport T. A., 2017). In fact, it is the combinations of cofactors assembled 
at p97 protein that determine the pathway p97 will engage (van den Boom J. and Meyer H., 
2018). The C-terminal tail of p97 is able to interact with other cofactors of ERAD pathway, 
like peptide-N-glycanase (PNGase) that harbors a PNGase/UBA domain (PUB), E3 ubiquitin 
ligase HOIP or substrate recruiters Ufd2 and Ufd3 (Bohm S. et al., 2011, Schaeffer V. et al., 
2014, Zhao G. et al., 2007). PNGase removes N-glycans from misfolded proteins that were 
retrotranslocated from ER into the cytosol by cleavage of the β-aspartyl-glucosamine bond 
(Blom D. et al., 2004, Tarentino A. L. and Plummer T. H., Jr., 1994). Phosphorylation of p97 
prevents interaction with PNGase and causes accumulation of ubiquitinated substrates (Li G. 
et al., 2008). p97 as well interacts with deubiquitinases such as YOD1 or Ataxin-3 that add 
another level of ERAD regulation into the pathway (Papadopoulos C. et al., 2017, van den 
Boom J. and Meyer H., 2018). Adaptor proteins such as Rad23 and Dsk2 play an important 
role in substrate delivery from p97 and DUB assembly to the proteasome. Their function is 
further described in chapter 1.2.4.5 on page 46 (Doss-Pepe E. W. et al., 2003, Li G. et al., 
2006). 
 
Figure 1: Scheme of endoplasmic reticulum associated pathway (ERAD) in mammals. Both 
glycosylated and non-glycosylated misfolded proteins are delivered to the ER transmembrane proteins that 
form a retrotranslocon complex – Hrd1/Sel1L, Derlins, Herpud1. Six transmembrane domains of 
Hrd1/Sel1L create a transmembrane channel for substrates that are ubiquitinated at the cytosolic site by the 
RING E3 ligase domain of Hrd1. Modified substrates are recognized by p97-Ufd1-Nlp1 complex, which 
provides further interaction with deubiquitinases. These modify the polyubiquitin chain for recognition by 
intrinsic or extrinsic proteasomal ubiquitin receptors or completely remove the ubiquitin moieties for 
substrate escape from the ERAD pathway.   
1.2.4 Ubiquitin-proteasome system 
Ubiquitin-proteasome system is the main machinery for degradation of short-lived 
cytosolic and nuclear proteins (Rubinsztein D. C., 2006). The core component of the pathway 
is a multisubunit protease complex called proteasome, which represents the main protease of 
the cell from the AAA+ family. Substrates destined for degradation are covalently modified 
with ubiquitin or polyubiquitin chains and therefore targeted to proteasome, where the 
ubiquitin tag is recognized, cut off, and the substrate is subsequently unfolded in ATP 
hydrolysis driven process and further cleaved into short peptides (Bard J. A. M. et al., 2018, 




Ubiquitin belongs to one of the main regulatory tools in cellular homeostasis. It is 
a highly conserved 8.5 kDa protein consisting of 76 residues. Ubiquitin folds into a globule 
that consists of five antiparallel β-sheets, a long α-helix a short 310-helix (see Figure 2A) 
(Vijay-Kumar S. et al., 1987). Main binding site on ubiquitin, which is important for its 
interaction with proteasome, is the Ile44 hydrophobic patch, represented by Leu8, Ile44, 
His68 and Val70 (Beal R. et al., 1996). Another hydrophobic surface, which is important for 
interubiquitin interaction along polyubiquitin chains or for interaction with deubiquitinases, 
is situated around Ile36 and includes residues Leu71 and Leu73 from C-terminal tail (Hu M. 
et al., 2002). Third patch that has been described by now, interacting with specific 
deubiquitinases, is localized around Phe4 and involves Gln2 and Thr12 as well (Hu M., et al., 
2002, Sloper-Mould K. E. et al., 2001). All three hydrophobic patches are shown in Figure 
2B. 
C-terminal glycine residue of ubiquitin can form a covalent isopeptide bond with 
lysine of a target protein. This post-translational modification, ubiquitination or 
ubiquitinylation, can activate/silence the activity of a protein, in case of transcription factors 
it can regulate expression of key molecules in their downstream pathways, or for histones 
alter expression profile of the cell, or contrarily aim the target towards degradation in the 
proteasome (Ciechanover A., et al., 1980, Goldknopf I. L. et al., 1977, Pickart C. M., 2000). 
Monoubiquitination has been described to have regulatory function in DNA repair processes 
and chromosome remodeling (Hoege C. et al., 2002, Robzyk K. et al., 2000, Ulrich H. D. and 
Walden H., 2010). Moreover, ubiquitin possesses seven lysines, which are essential for its 
function as they provide bonding sites for ubiquitin linkage between the C-terminal glycine 
of distal ubiquitin and the individual lysines (K8, K11, K27, K29, K33, K48 and K63) of the 
proximal ubiquitin (these residues are highlighted in Figure 2A). This possibility gives rise to 
different polyubiquitin chains that can harbor one or more types of linkages or even can be 
branched (Swatek K. N. and Komander D., 2016). Most common chain type is K48-linked 
polyubiquitin, which is the main protein degradation signal in the UPS (Swatek K. N. and 
Komander D., 2016). Another quite abundant type is K63-linkage with degradation free roles, 
for example in inflammatory signaling, where they function as a scaffold for recruitment of 
IKK complex and activation of NF-κB pathway (Chen Z. J. and Sun L. J., 2009, Kanayama 
A. et al., 2004). The role of K63 chains has been described as well in intracellular trafficking 
and DNA damage response (Komander D. and Rape M., 2012, Swatek K. N. and Komander 
D., 2016). K11-linked chains function as proteasomal degradation signal specifically in cell 
cycle regulatory pathway during mitosis when they are attached to the substrates by anaphase 
promoting complex/cyclosome (Bremm A. and Komander D., 2011, Wickliffe K. E. et al., 
2011). The K29-linked chains have been proposed to be regulators of protein degradation as 
they modify proteasomal ubiquitin receptor Rpn13 (see chapter 1.2.4.2, page 40) and 
autoimmune inflammatory response (Besche H. C. et al., 2014, Jin J. et al., 2016). K33-linked 
chains have role in protein trafficking and their recruitment to trans-Golgi network (Yuan W. 
C. et al., 2014). K6-linked chains belong to the less understood, however their function has 
been proposed in response to genotoxic stress and mitophagy in several studies (Durcan T. 
M. et al., 2014, Morris J. R. and Solomon E., 2004, Wu-Baer F. et al., 2003). Chains attached 
to K27 are probably the least characterized type, however there have been several studies 
recently that suggest their role as a scaffold for recruitment of the proteins of DNA repair 
process after double strand breaks and additional regulatory role in protein secretion (Gatti 
M. et al., 2015, Palicharla V. R. and Maddika S., 2015). Additional polyubiquitin chain type 
exists with linkage via interaction with the N-terminal methionine (M1-linkage), which is 
a positive regulator of NF-κB signaling and has important role in inflammatory and immune 
responses (Boisson B. et al., 2012, Kirisako T. et al., 2006, Rahighi S. et al., 2009).  
1.2.4.2 Proteasome 
Eukaryotic 26S proteasome is a proteolytic complex with molecular mass of 2.5 MDa, 
which consists of a central 20S barrel-shaped core particle (CP) and a 19S regulatory particle 
(RP) capping one or both ends of the barrel (see Figure 2C). The regulatory particle is 
responsible for recognition, deubiquitination and translocation of substrates into the 
degradation chamber of 20S core (Baumeister W. et al., 1988, Glickman M. H. et al., 1998a, 
Seemuller E. et al., 1995, Zwickl P. et al., 1999).  
The 670 kDa 20S core particle is composed of four heptameric rings with α and β 
subunits forming the two outer and two inner circles, respectively (see Figure 2C and D) 
(Groll M. et al., 1997, Seemuller E., et al., 1995). Alpha rings interact with the base of 19S 
RP. Highly conserved N-terminal domains of α subunits create a narrow entrance (approx. 
13 Å) into the CP even in open state to avoid degradation of properly folded proteins (Groll 
M. et al., 2000). Proteolytic chamber is assembled from β subunits in their precursor form 
(Zwickl P. et al., 1994). Three of the β subunits show catalytic activity depending on the type 
of residue they cut after: post-acidic or caspase-like (or post-glutamyl peptide hydrolase) β1, 
post-basic or trypsin-like β2 and post-hydrophobic or chymotrypsin-like β5 subunit (Groll M. 
et al., 1999, Heinemeyer W. et al., 1997). They are activated by proteolytic removal of their 
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N-terminal propeptides. This leads to exposure of a threonine residue at their N-terminus, 
which serves as a nucleophile during hydrolysis (Brannigan J. A. et al., 1995, Chen P. and 
Hochstrasser M., 1996, Dahlmann B. et al., 1992, Lowe J. et al., 1995, Seemuller E. et al., 
1996).  
The approx. 900 kDa 19S regulatory particle is formed by two subcomplexes, a base 
and a lid (see Figure 2D) (Glickman M. H. et al., 1998b). The nomenclature of all the RP 
subunits will be adducted here with its name in Saccharomyces cerevisiae and with its human 
gene name and protein name in brackets. The base of RP consists of three non-ATPase 
subunits, Rpn1 (PSMD2, S2), Rpn2 (PSMD1, S1) and Rpn13 (ADRM1) (Glickman M. H., 
et al., 1998b). Rpn1 and Rpn2 are receptors for ubiquitin and ubiquitin-like protein domains 
(UBLs) thanks to their α-solenoid domains. These are composed of 11 proteasome/cyclosome 
repeats, which are 35-40 residues long helix-turn-helix hairpins forming toroid-like structures 
that provide interaction surface of both RP subunits (He J. et al., 2012, Kajava A. V., 2002, 
Lupas A. et al., 1997). Rpn1 preferentially binds K6- and K48-linked ubiquitin chains with 
its toroid 1 site as described by Shi and colleagues (Shi Y. et al., 2016). This is the same site 
with which Rpn1 interacts with UBLs of UPS adaptor proteins such as Rad23 and Dsk2(for 
interaction site of Rpn1 with Rad23 UBL domain see Figure 2E) (Chen X. et al., 2016, 
Elsasser S. et al., 2002, Saeki Y. et al., 2002a, Shi Y., et al., 2016). Rpn2 interacts with the 
core particle, Rpn1, Rpn13 and two ATPase subunits Rpt4 and Rpt6 (Rosenzweig R. et al., 
2008, Rosenzweig R. et al., 2012). Rpn13 harbors a pleckstrin-like receptor for ubiquitin 
(Pru) domain at its N-terminus, which interacts with ubiquitin (preferentially K48-linked 
chains) and UBLs (very strong interaction with the UBL of hPLIC2) (Chen X., et al., 2016, 
Husnjak K. et al., 2008, Schreiner P. et al., 2008). Six ATPase subunits, Rpt1 (PSMC2, S7), 
Rpt2 (PSMC1, S1), Rpt3 (PSMC4, S6), Rpt4 (PSMC6, S10), Rpt5 (PSMC3, S6a) and Rpt6 
(PSMC5, S8), form a heterohexameric ring in the center of the base (Glickman M. H., et al., 
1998b). N-terminal alpha helices of Rpt subunits create coiled coil structures between the 
Rpt1/Rpt2, Rpt63/Rpt6 and Rpt4/Rpt5 dimers during assembly (Inobe T. and Genmei R., 
2015, Tomko R. J., Jr. et al., 2010). The oligonucleotide/oligosaccharide binding fold 
domains of Rpt subunits create an N-ring above the AAA+ domain ring positioned over the 
gate of the CP. The motor pulling force in the unfolding process is performed by highly 
conserved loops of the AAA+ domains, which protrude into the center of the hexameric circle 
(Erales J. et al., 2012, Maillard R. A. et al., 2011, Martin A. et al., 2008). There is another 
non-ATPase ubiquitin receptor creating a bridge between the base and the lid of assembled 
 
Figure 2: Structures of key components of ubiquitin-proteasome system. A) Structure of ubiquitin 
(cartoon representation): Ubiquitin harbors 7 lysine residues (in green) and an N-terminal methionine (blue) 
that can form specific linkages in polyubiquitin chains via bondage with C-terminal glycine (red). B) 
Surface representation of ubiquitin structure: Ubiquitin has a specific fold that provides three hydrophobic 
interaction patches: Phe4 (green), Ile36 (blue) and Ile44 (red). Side chains of significant interaction residues 
of the patches are shown. The figure was created in program PyMOL with PDB entry 1D3Z (Cornilescu G. 
et al., 1998, Schrodinger, LLC, 2015). C) Cryo-EM map of human 26S proteasome at resolution of 3.9 Å 
(Huang X. et al., 2016). D) Scheme of 26S proteasome from S. cerevisiae and position of individual subunits 
of the whole complex. Adapted from (Diaz-Villanueva J. F. et al., 2015). E) Close-up on the interaction of 
the UBL domain of Rad23 (yellow) with the T1 domain of Rpn1 (green) from S. cerevisiae. Similarly to 
the Ile44 patch of ubiquitin, Rad23 UBL possesses a hydrophobic interaction patch with adequate 
interaction residues P9, I45, V69 and M71 (red) (PDB entry 2NBW) (Chen X., et al., 2016). 
RP, Rpn10 (PSMD4, S5a) (Deveraux Q. et al., 1994). Rpn10 harbors an N-terminal von 
Willebrand factor type A domain that is responsible for interaction with RP subunits (Rpn1 
and Rpn2) and C-terminal ubiquitin interaction motifs (UIMs), that provide binding surface 
for ubiquitin and UBLs (Erales J., et al., 2012, Sakata E. et al., 2012, Verma R. et al., 2004). 
UIM is an amphipatic helix consisting of 20 amino acids in a defined sequence, which docks 
into the hydrophobic patch on ubiquitin with affinity ranging from 0.1 to 2 mM (Fisher R. D. 
et al., 2003, Hofmann K. and Falquet L., 2001, Young P. et al., 1998). The lid of RP consists 
of six proteasome-CSN-initiation factor 3 domain containing subunits Rpn3 (PSMD3, S3), 
Rpn5 (PSMD12), Rpn6 (PSMD11, S9), Rpn7 (PSMD6, S10), Rpn9 (PSMD13, S11) and 
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Rpn12 (PSMD8, S14) (Lander G. C. et al., 2012). Additionally, there are two Mpr1-Pad1 
N-terminal domain containing subunits Rpn8 (PSMD7, S12) and Rpn11 (PSMD14, Poh1, 
Pad1) (Lander G. C., et al., 2012, Rinaldi T. et al., 1998). There is another subunit, Sem1 
(PSMD9, Dss1, Rpn15), which functions as a ubiquitin receptor for K63- and K48-linked 
chains thanks to its intrinsically disordered region (Paraskevopoulos K. et al., 2014). 
1.2.4.2.1 Proteasome inhibitors 
Proteasome as a key component of regulatory protein degradation became a target for 
drug development, however most of the compounds are limited to laboratory use because of 
their non-specificity or poor metabolic stability (Adams J., 2003). The structure and 
specificity of inhibitors varies quite significantly. There are synthetic peptide aldehydes 
available, such as tripeptide aldehyde carbobenzoxy-Leu-Leu-leucinal called MG132 that 
targets several types of proteases such as serine proteases or calpain, in addition to reversible 
proteasome inhibition (Saito Y. et al., 1990, Tsubuki S. et al., 1996, Tsubuki S. et al., 1993). 
Lactacystin is a metabolite of Streptomyces, which undergoes hydrolysis in cells and its 
intermediate product β-lactone is responsible for covalent modification of the catalytic 
threonine residues in mammalian 20S core particles (Dick L. R. et al., 1996, Fenteany G. et 
al., 1995). The α1,β1-epoxy-ketone tetrapeptide epoxomicin isolated from Actinomycetes 
irreversibly inhibits all three types of proteolytic activity of the β subunits (Hanada M. et al., 
1992, Meng L. et al., 1999). The most successful proteasome inhibitor that made it into 
clinical use is bortezomib, a water-soluble reversible proteasome selective inhibitor of the 
chymotrypsin-like activity with Ki = 0.6 nM that belongs to a family of dipeptidyl boronic 
acids (Adams J. et al., 1999). It was introduced by Millenium Pharmaceuticals, Inc. under the 
name Velcade and used in therapeutic approaches in treatment of patients suffering from 
multiple myeloma and mantel cell lymphoma (Field-Smith A. et al., 2006). In addition, an 
analog of epoxomicin invented in Proteolix, Inc., carfilzomib, is another FDA approved 
anti-cancer drug used in relapsed or refractory multiple myeloma after previous treatment 
with bortezomib (Vij R. et al., 2012).  
1.2.4.3 Ubiquitination process 
Substrates of the UPS pathway shall possess two main recognition elements: 
a covalently attached polyubiquitin chain and an unstructured initiation region either at their 
terminus (20-30 residues) or represented by an internal flexible loop (Prakash S. et al., 2004, 
Takeuchi J. et al., 2007).  
In ubiquitination, the ubiquitin moiety must be first activated to be recognized and 
further utilized by individual enzymes of the cascade. This first step is performed by one 
predominant E1 ubiquitin-activating enzyme, which binds ATP and Mg2+ and catalyzes 
adenylation of the C-terminal glycine of ubiquitin. Adenylated ubiquitin is then attacked by 
the catalytic Cys of E1, which results in formation of macroergic thioester bond between Cys 
sulfhydryl and Gly carboxyl in the activated E1-ubiquitin complex (see Figure 3A). This is 
directly followed by adenylation of another ubiquitin molecule at the adenylation site. E1 
reactions are driven by dephosphorylation process of ATP into inorganic phosphate and AMP 
and are reversible (Ciechanover A. et al., 1981, Ciechanover A. et al., 1982, Haas A. L. and 
Rose I. A., 1982, Haas A. L. et al., 1983, Haas A. L. et al., 1982, Pickart C. M. and Rose I. 
A., 1985). The ubiquitin from Cys on E1 is transferred onto active Cys on recruited E2 
ubiquitin-conjugating enzyme (see Figure 3B) (Pickart C. M. and Rose I. A., 1985). Another 
enzyme, an E3 ubiquitin ligase, then associates with the E2-ubiquitin complex. There are 
several families of E3s that based on their domain composition operate in different ways. In 
general, there are two possible ways: E3 either binds the ubiquitin from E2 with its cysteine 
residue prior to transfer onto the substrate (e.g. HECT E3s, RBR E3s; see Figure 3D) or it 
works as a scaffold for bringing the E2-ubiquitin complex and substrate together into 
proximity and right conformation to facilitate the transfer of ubiquitin from E2 directly onto 
the substrate (e.g. RING E3s; see Figure 3C) (Huang L. et al., 1999, Wenzel D. M. et al., 
2011, Yokouchi M. et al., 1999). The ε-amino group of a lysine residue of the substrate attacks 
the thioester of the associated charged E2 or E3 and creates an isopeptide bond between 
ubiquitin and substrate (Scheffner M. et al., 1995). After bond formation, E2 is discharged 
and leaves E3 enzyme. Dissociation of E2 can be followed by association of the E3 with 
another charged E2 in second round of ubiquitination performed either on another lysine 
residue of the substrate or on the ubiquitin towards chain formation (Schulman B. A. and 
Harper J. W., 2009). As there are altogether two E1s, around 38 E2s and over 800 E3s 
encoded in human genome, it seems that it is the E3s that decide selection of the substrate 
(Jin J. et al., 2007, Li W. et al., 2008b, Ye Y. and Rape M., 2009, Zheng N. and Shabek N., 
2017). 
The requirements for the initiation of unstructured region are strict, as the polypeptide 
must be long enough to reach the pore in the AAA+ ring, which is 30-40 Å away from the 
entrance in the RP of proteasome (Aufderheide A. et al., 2015, Bard J. A. M., et al., 2018). 
Substrates that do not have the intrinsic initiation sequence are unfolded by a Cdc48 (VCP, 
p97) AAA+ unfoldase complex prior to proteasomal degradation, which is considered as 
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pre-processing of the substrates prior to proteasomal degradation (Bodnar N. O. and Rapoport 
T. A., 2017, Ye Y., et al., 2017).  
 
Figure 3: Scheme of substrate modification by ubiquitin. Collaboration of E1 (A), E2 (B) and E3 (C and 
D) enzymes of the UPS cascade results in ubiquitination of the substrate, which targets substrate protein 
towards degradation (E). After recognition of polyubiquitin chains by intrinsic or extrinsic ubiquitin 
receptors and removal of the ubiquitin moieties by DUBs (F), the substrate is ready to enter degradation 
chamber in the core particle of 26S proteasome where it is cleaved into short peptides. Adapted from 
(Weissman A. M. et al., 2011).  
1.2.4.4 Proteasome associated deubiquitinases 
There are two and three described deubiquitinases (DUBs) associated with yeast and 
mammalian proteasome, respectively. These DUBs cleave off the ubiquitin chain of the 
substrate prior its entrance into the AAA+ ring and unfolding (see Figure 3F). Rpn11 is 
Zn2+-dependent metalloprotease that belongs to the family of JAMM/MPN deubiquitinase 
family. According to electron microscopy studies, it is situated directly above the N ring in 
the RP base, which is suitable for its function as it hydrolyzes the bond between the substrate 
and the first ubiquitin of the chain (Aufderheide A., et al., 2015, Lander G. C., et al., 2012, 
Verma R. et al., 2002, Yao T. and Cohen R. E., 2002). Rpn11 forms a heterodimer with Rpn8, 
which changes its conformation and moves its Insert-1 loop region from an autoinhibitory 
closed state into active β-hairpin conformation, which allows its DUB activity (Worden E. J. 
et al., 2014). Yeast and mammalian proteasomes both have DUB Ubp6 (Usp14), which 
interacts with Rpn1 subunit and cleaves supernumerary ubiquitin chains en bloc (Aufderheide 
A., et al., 2015, Hanna J. et al., 2006, Lee B. H. et al., 2016). Ubp6 cuts K48-linked long 
chains in case the substrate is tagged with more than one polyubiquitin chain (Lee B. H., et 
al., 2016, Mansour W. et al., 2015). Activation of Ubp6 is dependent on the interaction of its 
UBL domain with toroid 2 interaction site of Rpn1 and interaction of its catalytic domain with 
the N-ring and the AAA+ ring, which together performs conformation change that removes 
inhibitory loops out of the active site (Aufderheide A., et al., 2015, Leggett D. S. et al., 2002, 
Shi Y., et al., 2016). Mammalian proteasomes additionally interact via their Rpn13 subunit 
with a ubiquitin C-terminal hydrolase Uch37 (alternatively named UCHL5) which removes 
distal K48-, K6- and K11-linked ubiquitin chains (Hamazaki J. et al., 2006, Lam Y. A. et al., 
1997, Qiu X. B. et al., 2006, Yao T. et al., 2006). Uch37 interacts with the deubiquitinase 
adaptor (DEUBAD) domain of Rpn13 bound to proteasome, which moves a loop that covers 
the active cysteine residue and amplifies the affinity for ubiquitin up to fivefold (Vander 
Linden R. T. et al., 2015). 
1.2.4.5 Extrinsic ubiquitin receptors 
In addition to the intrinsic ubiquitin receptors, there is a family of 
UBL/UBA-containing proteins called shuttling proteins or adaptor proteins of UPS, 
represented by Rad23 (hHR23A and hHR23B) and Dsk2 (hPLIC1, UBIQUILIN-1) 
(Bertolaet B. L. et al., 2001). Rad23 interacts with Rad4 or XPC, which stabilizes them and 
enables them to recognize of DNA lesions in nucleotide excision repair pathway (Dantuma 
N. P. et al., 2009, Guzder S. N. et al., 1998, Jansen L. E. et al., 1998, Masutani C. et al., 1994). 
Rad23 also functions as a shuttling protein for proteasomal substrates in ERAD, downstream 
of VCP/p97 complex (Richly H. et al., 2005). In addition it was reported to be involved in 
cell cycle regulation, spindle body formation and phosphate metabolism in budding yeast 
(Auesukaree C. et al., 2008, Biggins S. et al., 1996, Clarke D. J. et al., 2001). hPLIC1 has 
significant role in clearance of aggregated proteins by their targeting to autophagosomes and 
aggresome formation, and in neuroprotection on whole organism level in conditions such as 
Alzheimer´s disease or ALS (Deng H. X. et al., 2011, Lu K. et al., 2017, Stieren E. S. et al., 
2011).  
These proteins harbor N-terminal UBL domain that provides interaction with 
proteasomal receptors and a C-terminal ubiquitin associated domain (UBA) that binds 
polyubiquitin chains of substrates targeted for degradation (Chen L. et al., 2001, Elsasser S., 
et al., 2002, Funakoshi M. et al., 2002, Schauber C. et al., 1998, Verma R., et al., 2004, 
Wilkinson C. R. et al., 2001). Their UBL domains are built of a long α-helix, a 310-helix and 
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five antiparallel β-sheets, which form a hydrophobic patch responsible for their interaction 
with proteasomal subunits (Walters K. J. et al., 2002). UBA domains consist of three helices 
that form a bundle, its helices 1 and 3 interact with the ubiquitin Ile44 hydrophobic patch or 
UBL domains (Mueller T. D. and Feigon J., 2002, Mueller T. D. et al., 2004, Raasi S. et al., 
2004). Highly helical domain of Sti1-like family (or Rad4/XPC-binding domain in Rad 
homologs), which is responsible for interaction with DNA binding proteins during DNA 
damage response, was found in both above-mentioned representatives (Kaye F. J. et al., 2000, 
Masutani C. et al., 1997). For scheme of the domain architecture see Figure 4. 
Another member of this family is DNA damage-inducible protein 1 (Ddi1), which 
will be further described in detail in following chapters (Bertolaet B. L., et al., 2001, Clarke 
D. J., et al., 2001).  
1.3 DDI1-LIKE PROTEIN FAMILY 
Ddi1-like protein family members possess special domain architecture, which 
dedicates them to a variety of biological roles. Because of their conserved N-terminal UBL 
and C-terminal UBA domains and interaction with polyubiquitinated proteins and 
proteasomal subunits, they were first suggested to perform the role of shuttling factors of UPS 
(Kottemann M. C. et al., 2018, Morawe T. et al., 2011, Saeki Y., et al., 2002a). When 
compared to other shuttling proteins, Ddi1-like family harbors additional retroviral protease-
like domain (RVP) in the center of the protein. The fold of Ddi1-like protein RVPs is very 
similar to HIV-1 protease, it represents an aspartic protease with catalytic triad DT/SG, 
facilitates dimerization of full-length proteins and is highly conserved in all eukaryotes 
(Gabriely G. et al., 2008, Krylov D. M. and Koonin E. V., 2001, Kumar S. and Suguna K., 
2018, Sirkis R. et al., 2006, Siva M. et al., 2016, Trempe J. F. et al., 2016). Recently, a novel 
helical domain of Ddi (HDD) was structurally characterized in the linker region between UBL 
and RVP domains in Ddi1p of S. cerevisiae and human DDI2 protein (Siva M., et al., 2016, 
Trempe J. F., et al., 2016). For domain architecture see Figure 4. 
Loss of UBA domain occurred early during evolution in vertebrates, as the RSC1A1 
gene was inserted into the DDI1 locus, which gave rise to a UBA-possessing RSC1A1 
protein. Interestingly, mammals embed two DDI1-like genes in their genome, DDI1 and 
DDI2. DDI2 is quite similar to non-mammalian Ddi1-like genes and therefore is considered 
the original version of the gene. Mammalian DDI1 was most presumably duplicated in a 
retrotransposition event from the ancestral DDI2 (Siva M., et al., 2016).  
 
Figure 4: Domain architecture of shuttling proteins of UPS and Ddi1-like protein family. N-terminal 
UBL domains that interact with proteasomal receptors are in blue. Ubiquitin binding regions at C-terminal 
are highlighted in color: UBAs in red and UIMs in yellow. Highly helical domains of the shuttling proteins 
represented by XPC-binding domain in Rad23, Sti1-like domain in Dsk2 and HDDs for yDdi1p and hDDI2 
are colored orange. The unique RVP domains in Ddi1-like protein family are colored green. Sso1 binding 
region of yDdi1p is also highlighten (in lilac). 
Ddi1-like family members are involved in a variety of pathways: regulation of cell 
cycle progression, check point control, genome integrity or proteostasis maintenance and  
regulation of late exocytotic processes. Related to the role in UPS, interaction with Rpn10 
proteasomal subunit with Ddi1 of a fruit fly was first observed in a pull-down experiment, 
however NMR titration data from several studies did not confirm the original data (Morawe 
T., et al., 2011, Nowicka U. et al., 2015, Trempe J. F., et al., 2016, Zhang D. et al., 2009). 
First direct evidence of proteolytic activity of the RVP in Ddi1-like protein family was 
published in a study of Ddi1 from Leishmania major, which claimed that Ddi1 was able to 
cleave BSA together with several HIV-1 and cathepsin D substrates. However, this was not 
observed for human DDI2 (Perteguer M. J. et al., 2013, Siva M., et al., 2016). Effect of 
aspartic protease inhibitors on Ddi1-like proteins was identified by both in vivo and in vitro 
experiments, by impairment of deletion-rescue effect in DDI1 knockout in yeast strains and 
in enzymatic reactions with parasitic Ddi1 (Perteguer M. J., et al., 2013, White R. E. et al., 
2011a). The parasitic family of the trypanosomatid is mainly responsible for opportunistic 
infections. Several studies have shown that antiviral therapy in AIDS patients suffering from 
parasitic infection results in decrease of development of the opportunistic disease (Savoia D. 
et al., 2005, Skinner-Adams T. S. et al., 2004). Therefore, HIV-1 protease inhibitors are used 
in a variety of studies targeting the function of Ddi-1 protein family. 
Ddi1 in higher eukaryotes is essential for embryonal development. Rngo (Ddi1 
ortholog in Drosophila melanogaster) is highly expressed and ubiquitinated during embryonal 
neural development (Franco M. et al., 2011). Interestingly, Rngo was found to be specifically 
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ubiquitinated by E3 ligase Ube3a in fruit fly neurons, which is not a signal for degradation in 
the UPS (Ramirez J. et al., 2018).  Moreover, fruit flies with depleted od Rngo exhibit defects 
in oogenesis and die at pupal stages, while the phenotype cannot be rescued by an inactive 
protein mutant (D257A), which highlights the function of the RVP domain (Morawe T., et 
al., 2011). In Caenorhabditis elegans, Vsm-1 (v-SNARE master protein 1) inhibits 
synaptogenesis in nematodes, as Vsm-1-null roundworms exhibit profound synaptic density 
(Guthmueller K. L. et al., 2011). Recent study from Ruvkun laboratory revealed function of 
VSM-1 in activation of transcription factor SKN-1, which regulates expression of many 
proteasomal subunits (Lehrbach N. J. and Ruvkun G., 2016).  
Ddi1 from S. cerevisiae and both human DDI1 and DDI2 are described in more detail 
in following chapters. Studying roles of mouse Ddi1 and Ddi2 genes is one of the aims of this 
thesis. 
1.3.1 Ddi1 in Saccharomyces cerevisiae 
DDI1 gene of S. cerevisiae is encoded on chromosome V, position 456,319-457,605 
on the forward strand (YER143W, NCBI ID: 856886, SGD: S000000945). The protein 
consists of 428 amino acids (P40087) and harbors four domains, UBL, HDD, RVP and UBA 
(Geer L. Y. et al., 2010, The UniProt C., 2017, Zerbino D. R. et al., 2018).  
Ddi1p, as a shuttling protein of UPS, interacts with polyubiquitin chains and 
proteasomal subunit Rpn1, however the later interaction is very weak (Gomez T. A. et al., 
2011, Rosenzweig R., et al., 2012, Saeki Y. et al., 2002b, Wilkinson C. R., et al., 2001). 
Interestingly, Ddi1 interaction with ubiquitin was identified not only for the UBA as expected, 
but as well for the UBL domain. The interaction site was mapped onto the Ile44 patch of 
ubiquitin and analogous patch on UBL formed mainly by residues Ile13, Leu70 and Leu72 
(Nowicka U., et al., 2015). Our study showed that a dimer of full-length Ddi1 protein binds 
two molecules of K48-linked diubiquitin (Trempe J. F., et al., 2016). Another domain was 
discovered to be docked between the UBL and RVP domains, a helical domain of Ddi (HDD). 
Ddi1 HDD of S. cerevisiae consists of two alpha-helical structured regions connected with 
a 10-residue linker: a four helical bundle with conserved hydrophobic core at the N-terminus 
and a helix-turn-helix at the C-terminus. The N-terminal bundle of HDD exhibits structural 
similarity to several DNA binding domains of transcription factors, yet this possible function 
has not been verified (Trempe J. F., et al., 2016). This domain proposes a multifunctional 
potential for the function of Ddi1p as was confirmed for other shuttling proteins, as they 
indeed harbor Sti1-like domains that connect them to DNA repair processes (Kaye F. J., et 
al., 2000, Masutani C., et al., 1997, Schauber C., et al., 1998).  
Expression of Ddi1p is induced upon DNA damage, as its transcription is regulated 
by a DNA damage-inducible promoter. This promoter is bidirectional and it controls 
expression of either DDI1 or MAG1 (a 3-methyladenine DNA glycosylase with role in base 
excision repair) alternatively, in response to divergent DNA damage (Fu Y. et al., 2008, Liu 
Y. and Xiao W., 1997, Liu Y. et al., 1997, Zhu Y. and Xiao W., 1998). Upon 
MEC1-dependent DDR pathway activation, a mating type locus MAT allele switching 
enzyme Ho endonuclease is rapidly degraded. As Ho endonuclease accumulates in 
Ddi1p-deficient cells and moreover, it interacts with Ufo1, factor that binds and brings 
phosphorylated Ho endonuclease into proximity with E3 ubiquitin ligase prior proteasomal 
degradation. Ddi1p is therefore considered a regulatory component of the Ho endonuclease 
degradation (Ivantsiv Y. et al., 2006, Kaplun L. et al., 2000, Kaplun L. et al., 2003, Kaplun 
L. et al., 2005).  
Ddi1p was found to be involved in regulation of mitotic checkpoint control protein 
Pds1 degradation, which is required for partition of sister chromatids for G/M phase and 
anaphase onset (Clarke D. J., et al., 2001, Diaz-Martinez L. A. et al., 2006). It was identified 
as a suppressor of temperature sensitivity in PDS1 mutants (Clarke D. J., et al., 2001). 
Deletion of DDI1 gene in yeast cells results in augmentation of protein secretion into media, 
which determines Ddi1p as a negative regulator of exocytosis (White R. E. et al., 2011b). 
Ddi1p interacts with three SNARE proteins, an endocytic v-SNARE protein Snc2 and 
exocytic v-SNARE and t-SNARE proteins Snc1 and Sso1, respectively (Lustgarten V. and 
Gerst J. E., 1999, Marash M. and Gerst J. E., 2003). Ddi1p binds to Sso1 via a linker between 
RVP and UBA domains. Phosphorylation of autoinhibitory domain of Sso1 and of T348 in 
the interacting linker sequence of Ddi1p is as well a regulatory factor of exocytosis (Gabriely 
G., et al., 2008, Marash M. and Gerst J. E., 2003). Ddi1p was found to be one of regulatory 
genes required for the G protein α subunit exocytosis, which is essential for efficient mating 
(Dixit G. et al., 2014). 
Recently, a high throughput synthetic lethality screen in yeast exhibited genetic 
connection between DDI1 and WSS1, which encodes the metalloprotease responsible for 
DNA-protein crosslink removal (the process is described in chapter 1.2.1) (Costanzo M. et 
al., 2016). Double mutant Δddi1, Δwss1 strain of budding yeast is highly sensitive to DNA 
damage caused by hydroxyurea, as opposed to the single knockout mutant strains, which do 
not show any or mild sensitivity for Δddi1 and Δwss1 single mutants, respectively (O'Neill 
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B. M. et al., 2004) (laboratory of Dr. Grantz Šašková – unpublished data). It is the proteolytic 
activity and the four helical bundle of the HDD domain that are essential and sufficient for 
DNA repair response and, surprisingly, not the shuttling protein role of Ddi1p, as UBA and 
UBL domains are redundant for phenotype rescue (laboratory of Dr. Grantz Šašková – 
unpublished data). 
Recent publication revealed yeast Ddi1p as a natural substrate for metacaspases that 
cleave off its UBA domain under highly specific conditions. This processing that most 
probably modulates the function of Ddi1p, was observed as well for Ddi1-like protein in 
trypanosomes (Bouvier L. A. et al., 2018). 
1.3.2 DDI2 in homo sapiens 
Human DDI2 gene (ENSG00000197312, NCBI ID: 84301) is located on the first 
chromosome (15,617,500-15,669,044) on forward strand and consists of 10 exons, 9 of which 
comprise a protein coding transcript (ENST00000480945.5 - Ensemble release 95, 
NM_032341.5). This transcript encodes a DDI2 protein formed by 399 amino acids 
(Q5TDH0, NP_115717.3). No other transcription variants for DDI2 have been discovered 
hitherto (Geer L. Y., et al., 2010, The UniProt C., 2017, Zerbino D. R., et al., 2018). DDI2 is 
expressed quite ubiquitously in a variety of tissues in adult humans according to online 
databases. Its expression is significantly increased in several cell lines derived from 
carcinoma, e.g., prostate, breast or skin cancer (Uhlen M. et al., 2017). 
The structure of DDI2 was characterized in our laboratory in collaboration with J.-F. 
Trempe (Siva M., et al., 2016). Solution structure of N-terminal UBL domain reveals the 
conserved ubiquitin β-grasp fold typical for UBLs. Beta-sheet interaction site of DDI2 UBL 
is however moderately charged in comparison to negatively charged interaction patch of 
yDdi1 UBL, which is able to bind positively charged site on ubiquitin (Nowicka U., et al., 
2015, Siva M., et al., 2016, Trempe J. F., et al., 2016). This is surprising, as UBLs had not 
been previously reported to bind ubiquitin itself (Nowicka U., et al., 2015). A novel domain, 
helical domain of Ddi (HDD), was identified in the sequence between already described UBL 
and RVP domains. Residues 125 to 212 form four helices that pack into a compact α-helical 
bundle with hydrophobic core and an arginine rich region that has been reported to figure in 
DNA binding domains, such as XPC-binding domain of Rad23 (Kim B. et al., 2005, Lee J. 
H. et al., 2005, Siva M., et al., 2016). The RVP forms a constitutive dimer of the DDI2 
protein. DDI2 RVP structure adopts a typical aspartic-protease fold, however the substrate 
chamber is larger as flaps only distantly lay over the active site. The catalytic site of DDI2 
consists of DSGA motif (Siva M., et al., 2016). Additionally, a 24-residue region was 
identified at the C-terminus of DDI2 as potential ubiquitin binding sequence based on its 
similarity with conserved UIMs (Siva M., et al., 2016). This four domain architecture 
provides multifunctional potential: N-terminal UBL and C-terminal UIM could set the basis 
for the role of a shuttling protein in UPS, the activity of DDI2 RVP has already been recently 
identified (described below) and the DNA-binding potential of HDD unlocks door to a set of 
new possible roles. Recently, several studies revealed distinct functions of human DDI2 as 
described below. 
Koizumi and colleagues identified DDI2 as an activator of transcription factor 
NFE2L1 (NRF1) in siRNA screen and complementation experiments on human knockout 
and knock-in cell lines (Koizumi S. et al., 2016). Transcription factor NRF1 is a constitutively 
expressed protein that regulates basal and stress-induced expression of a broad spectrum of 
genes (Kim H. M., et al., 2016). Function of NRF1 (and its homolog NRF2) in oxidative 
stress response has been already briefly described in this work in chapter 1.2.2 on page 31. 
Additionally to antioxidant gene regulation, activated NRF1 targets ARE sequences of 
several proteasomal subunit genes and thereby is able to induce their expression (Biswas M. 
and Chan J. Y., 2010, Radhakrishnan S. K. et al., 2014). Under normal conditions, NRF1 is 
degraded in ERAD pathway. Koizumi and colleagues showed, that upon proteotoxic stress, 
DDI2 is activated and cleaves deglycosylated NRF1 that escapes degradation and is 
translocated into nucleus where it induces expression of proteasomal subunit genes in 
a “bounce back” response  (for scheme of the mechanism see Figure 6) (Biswas M. and Chan 
J. Y., 2010, Koizumi S., et al., 2016, Radhakrishnan S. K., et al., 2014, Radhakrishnan S. K., 
et al., 2010, Steffen J., et al., 2010). DDI2 cleaves NRF1 p120 form between the P1:Trp103 
and P1´:Leu104 onto the active p110 form, which is a possible cleavage motif of RVP domain 
(Koizumi S., et al., 2016, Radhakrishnan S. K., et al., 2014). In addition, proteolytic activity 
of Ddi1 in C. elegans and its activation potential for a SKN-1 protein, an ortholog of NRF1 
and NRF2, was recently described (Lehrbach N. J. and Ruvkun G., 2016).  
Another recently discovered substrate of DDI2, transcription factor NFE2L3 (NRF3), 
is post-translationally housed in the ER lumen and constitutively sequestrated by ERAD 
pathway, similarly to NRF1 (Chowdhury A. et al., 2017, Zhang Y. et al., 2009). DDI2 cleaves 
NRF3 between Trp111 and Leu112, in sequence of NHB2 domain homologous to NRF1 
NHB2 domain (Chowdhury A., et al., 2017). Detailed characterization of NRF1 and NRf3, 
plus their up-to-date pathway regulation coverage is provided in following chapter 1.3.2.1. 
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The findings of NRF1 and NRF3 activation by DDI2 arose from biological 
experiments; however, its proteolytic activity has not been yet characterized on molecular 
level or enzymatically. Despite the effort, no proteolytic activity has been detected for DDI2 
under normal conditions using a variety of biochemical methods, such as HPLC enzymatic 
analysis or PICS on mammalian-cell-peptide derived libraries (Siva M., et al., 2016).  
It was recently proposed that DDI2 and DDI1 may function as proteasomal shuttling 
factors for hitherto understudied replication termination factor 2 (RTF2) (Kottemann M. C., 
et al., 2018). Its only identified homolog, Rtf2 in S. pombe, is responsible for maintenance of 
fork stalling for preservation of unidirectional replication of the mating type locus (Inagawa 
T. et al., 2009). Human RTF2 associates with nascent DNA and most probably causes 
uncoupling of helicase from replicative polymerases (Dungrawala H. et al., 2015, Kottemann 
M. C., et al., 2018). The persistence of RTF2 on DNA in DDI1/DDI2-depleted cells under 
replication stress (hydroxyurea treatment) resulted in failure of full replication and cell cycle 
progression leading to cellular death. DDI1 and DDI2 were identified as key regulators of 
RTF2-dependent stalled replication fork recovery and RTF2-dependent maintenance of 
genome integrity (Kottemann M. C., et al., 2018). Moreover, immunoprecipitation and 
crosslinking experiments revealed interaction of DDI2 with several proteasomal 19S RP 
subunits and replication factors, such as PCNA, polymerase δ, members of MCM helicase or 
RPA (Kottemann M. C., et al., 2018). 
1.3.2.1 Substrates of hDDI2 
Recently discovered substrates of human DDI2 protease, NFE2L1 (NRF1) and 
NFE2L3 (NRF3), belong to the CNC/bZIP family of transcription factors (Chan J. Y., et al., 
1993b). Once translocated into nucleus, they form heterodimers with small Maf proteins or 
CREB protein, which bind to ARE sequences in promoters of their target genes and thereby 
induce their expression. 
Both proteins quite resemble the structure of their homolog NFE2l2 (NRF2) (see 
Figure 5). In addition to very well conserved Neh1 domain (CNC and bZIP regions), they 
harbor Neh3-, Neh6- and Neh5-like domains (Andrews N. C., et al., 1993, Zhang Y., et al., 
2009, Zhang Y. et al., 2014a). In addition, they possess an additional N-terminal domain 
(NTD) that includes so-called N-terminal homology box 1 (NHB1: residues 7-24 and 12-31 
in NRF1 and NRF3, respectively), which is rich in hydrophobic residues and mediates their 
anchoring to the ER membrane (Wang W. and Chan J. Y., 2006, Zhang Y., et al., 2006, Zhang 
Y., et al., 2009). NTD encodes a NHB2 domain, which comprises a cleavage site for DDI2. 
A savoir, NRF1 has almost identical domain organization as NRF3; however, they differ in 
sequence (Zhang Y., et al., 2009). In NRF1, there are two acidic domains (AD1 and AD2) 
near the N-terminus separated by Asp/Ser/Thr-rich region called NST, representing its 
glycosylation site (Zhang Y. and Hayes J. D., 2010, Zhang Y., et al., 2009, Zhang Y., et al., 
2014a). Out of these, NRF3 lacks the acidic region 1 (Zhang Y., et al., 2009).  
 
Figure 5: Domain organization of homologs NRF1, NRF2 and NRF3. The full-length NRF2 and NRF3 
proteins with three transcription variants of NRF1 (TCF11, NRF1a and LCR-F1) are shown. Several 
domains, such as CNC, bZIP, Neh6, Neh3, Neh5 and AD2 are very well conserved among all the enlisted 
variants and homologs. TCF11, NRF1a and NRF3 harbor the N-terminal NTD, which serves as anchor in 
the ER membrane and comprises cleavage site for DDI2 protease in the NHB2 region. Adapted from (Zhang 
Y., et al., 2014a). 
NRF1 protein harbors a serine-rich domain at its C-terminus close to the Neh1 domain (Chan 
J. Y. et al., 1993a, Zhang Y., et al., 2014a). In humans, there are two transcription variants 
harboring the DDI2 cleavage site in NHB2 domain for NFE2L1, a 772 residue long TCF11 
and 742 residue long NRF1a (see Figure 5). Another variant, LCR-F1/NRF1β, functions as 
transcription regulator as well. The individual splice variants are discussed in following 
chapter.  
As the expression profiles, roles and depletion phenotypes differ for NRF1 and NRF3, 
they are described individually below. 
1.3.2.1.1 NRF1 
NFE2L1 (NRF1) gene is located on chromosome 17, in the region 48,048,329-
48,061,487 on forward strand (ENSG00000082641 - Ensemble release 95, NCBI ID: 4779). 
It is a 6 exon gene exhibiting a number of splice variants (Geer L. Y., et al., 2010, The UniProt 
C., 2017, Zerbino D. R., et al., 2018). The longest transcript consists of 772 amino acids and 
is called TCF11. A splice variant without exon 4, which is 742 residues long is termed NRF1α 
(Luna L. et al., 1995). Both these isoforms generate protein products that can be detected as 
around 120 kDa. A shorter transcript of 572 amino acids called LCRF1 (or NRF1β, 
p65NRF1) with molecular weight approx. 65kDa might be product of alternative translation 
initiation derived from internal ATG codons (Chan J. Y., et al., 1993b). Domain organization 
of the three above mentioned splice variants is shown in Figure 5. LCRF1 is as well able to 
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heterodimerize with Maf proteins and bind ARE sequences (with weaker capacity), 
nevertheless it functions as a repressor of NRF2 activity (Caterina J. J. et al., 1994, Wang W. 
et al., 2007, Zhang Y. et al., 2014b). Transcript variant NRF1b, created via alternative 
promotor using an alternative exon 1, is 583 acids long with molecular weight around 100 
kDa (Kwong E. K. et al., 2012). The NRF1γ and NRF1δ, presumably proteasome-processed 
isoforms of NRF1, are shorter proteins of molecular mass of 36 and 25 kDa, respectively, 
representing dominant-negative inhibitors of NRF2 and long forms of NRF1 (Zhang Y., et 
al., 2014b, Zhang Y. et al., 2015). 
NRF1 expression is ubiquitous in adult humans. Higher levels of expression were 
detected in heart, kidney, skeletal muscle, brain and fat (Chan J. Y., et al., 1993a, Kim H. M., 
et al., 2016). mRNA levels of NRF1 are elevated in a number of cancer cell lines according 
to online databases. A regulatory SNP was reported by Hirotsu and colleagues, whose study 
indicates that rs3764400 correlates with increased NRF1 expression (Hirotsu Y. et al., 2014). 
In cells, NRF1 is expressed constitutively. Levels of expression are regulated by 
a variety of factors, from nutrients to stress stimuli. Aside from stress response, NRF1 
activation of proteasomal subunits can be modulated by mTORC1-mediated SREBP1 
transcription factor (Zhang Y. and Manning B. D., 2015, Zhang Y. et al., 2014c). Under 
normal conditions, NRF1 is degraded by ERAD pathway (for detailed description see chapter 
1.2.3.2 on page 35), which means that after translation and glycosylation in ER, it is 
subsequently retrotranslocated into cytosol via HRD1/SEL1L complex, deglycosylated by 
PNGase, ubiquitinated by HRD1, partially unfolded by VCP/p97 and degraded in the 
proteasome (Sha Z. and Goldberg A. L., 2014, Steffen J., et al., 2010). The half-life on NRF1 
protein in this ERAD cascade is approx. 12min (Steffen J., et al., 2010). Upon proteasomal 
inhibition, NRF1 is cleaved by DDI2 instead of its transport to proteasome and its C-terminal 
p110 (of approx. 110 kDa) active form is translocated into nucleus – in case of TCF11 variant 
of NRF1 cleavage (Biswas M. and Chan J. Y., 2010, Radhakrishnan S. K., et al., 2014). In 
humans, both TCF11 and NRF1a are processed by DDI2. The processed form of NRF1 is 
able to binds to ARE and induces expression of NRF1 downstream genes. This occurs not 
only under stressed but as well under normal conditions, as was described for some specific 
cell types, such as hepatocytes or neuronal tissue (Kim H. M., et al., 2016, Lee C. S. et al., 
2013, Lee C. S. et al., 2011). This basal function of NRF1 arises as well from knock-in 
HCT116 cell line experiments, where RVP domain inactive DDI2 D252N mutant knock-in 
cells showed decrease in proteasomal activity when compared to WT and DDI2 WT knock-in 
cells (Koizumi S., et al., 2016). Transcriptional activity of nuclear p110 NRF1 form is 
regulated by ubiquitination and subsequent degradation in proteasome facilitated by 
SKP1-β-TRCP complex that binds to the DSGLS recognition motif for β-TrCP, 
phosphorylated at serine residues (Tsuchiya Y., et al., 2011). Similarly, NRF1 can be 
phosphorylated by glycogen synthase kinase 3 in its Cdc4 phosphodegron sequence (residues 
350–354). This modification facilitates its interaction with Fbw7, another SCF 
(Skp1-Cul1-Fbox protein-Rbx1)-type ubiquitin ligase, which ubiquitinates NRF1 and targets 
it for proteasomal degradation (Biswas M. et al., 2011, Biswas M. et al., 2013). Additional 
level of NRF1 regulation is phosphorylation of S497 by casein kinase 2, which leads to 
decrease of proteasome gene expression (Tsuchiya Y. et al., 2013). Recent finding pointed 
out another control in transcription activity of NRF1 by RUVBL1/RUVBL2 heterohexamer 
in transcription complex TIP60 (Vangala J. R. and Radhakrishnan S. K., 2018). 
 
Figure 6: Activation of NRF1 and NRF3 transcription factors by DDI2 protein. A) Cascade 
of NRF1 processing under normal conditions. NRF1 is constitutively expressed, translocated into ER, 
retrotranslocated into the cytoplasm by HRD1/SEL1 and VCP/p97 complexes and subsequently degraded 
in the proteasome. B) Human DDI2 targeted sequences of NRF1 and NRF3 proteins. C) Upon proteotoxic 
stress, NRF1 (NRF3) is cleaved by DDI2 and the shorter form is translocated into nucleus where it binds 
to ARE and regulates its downstream gene expression.   
As transcription factor recognizing quite abundant ARE sequences, role of NRF1 has 
been reported in a variety of cellular pathways. Glutathione (GSH) synthesis pathway genes 
(glutamate-cysteine ligase, glutathione synthetase), glutathione S-transferase, 
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metallothionein-1 and -2, NADPH-quinone oxidoreductase 1, heme oxygenase 1 and 
glutathione peroxidase 1 belong to genes controlled by NRF1 in response to oxidative stress 
(described in chapter 1.2.2 on page 31) (Chan J. Y., et al., 1998, Chen L., et al., 2003, Kwong 
M. et al., 1999, Lu S. C., 2009, Myhrstad M. C., et al., 2001, Ohtsuji M., et al., 2008, Song 
M. O. et al., 2014, Venugopal R. and Jaiswal A. K., 1998, Xu Z., et al., 2005). In addition to 
activation of GSH synthesis genes, NRF1 is important for cellular glutathione level 
maintenance as well by repression of xCT expression, which regulates cysteine uptake by 
xc- transporters (Tsujita T. et al., 2014). Studies on mice and murine cell cultures have 
reported several other functions for mNrf1. Interestingly, GSH control indirectly regulates 
expression of proapoptotic Bik and Xpc functioning in NER in response to UVB DNA 
damage in keratinocytes (Han W. et al., 2012). Another study suggested the role of NRF1 in 
genomic integrity and chromosomal stability maintenance, as they found that depletion of 
NRF1 leads to downregulation of kinetochore and mitotic checkpoint genes Nuf2, Spc25, 
Sgo1 and Ndc80 (Oh D. H. et al., 2012). Mouse Nrf1 also belongs to control genes of cellular 
differentiation during formation of mineralized tissue: it activates Dspp (in heterodimer with 
C/EBP-β) and Osx genes in odontoblast and osteoblast differentiation, respectively, and 
Dmp1 in both processes (Jacob A. et al., 2014, Narayanan K. et al., 2004, Xing W. et al., 
2007). Involvement in muscle regeneration was proposed for mNrf1, as its mRNA levels 
were augmented in macrophages, neutrophils and myofibroblasts during early inflammation 
in response to muscle injury (Zhang S. T. et al., 2013). mNrf1 was found to feature in cellular 
immune response: it is able to reverse downregulation of nitric oxide synthase caused by 
a cytokine TGF-β (Berg D. T. et al., 2007), and moreover, it directly modulates expression 
levels of Tnf-α via its promoter (Novotny V. et al., 1998, Prieschl E. E. et al., 1998). mNrf1 
has important regulatory position in metabolism homeostasis. Concerning regulation of lipid 
metabolism, mNrf1 directly modulates expression of Lipin1, Pgc-1β, Apoer2 and Vldlr 
receptor genes, Fads3 desaturase gene and Alox5ap, which results in elevation of triacyl 
glycerides and alteration of fatty acid composition leading to non-alcoholic steatosis in 
mNrf1-depleted livers of transgenic mice (Hirotsu Y. et al., 2012, Tsujita T., et al., 2014). In 
glucose metabolism, mNrf1 is linked to glucose-stimulated insulin release and fasting 
hyperinsulinemia, as mNrf1 was found to regulate the expression of Gck, Glut2, Ldh1, Hk1, 
Aldob, Pgk1, Pklr, Fbp1, Pck1, and Gapdh genes (Hirotsu Y., et al., 2014, Zheng H. et al., 
2015). 
Regulation of proteasome subunit expression is probably the best studied function of 
NRF1. This function is more profoundly exhibited in so-called “bounce-back” response, 
when a set of proteasomal subunits is induced by NRF1 upon proteotoxic stress 
(Radhakrishnan S. K., et al., 2010, Steffen J., et al., 2010). Partial inhibition of proteasome 
leads to upregulation of proteasomal subunits, however once proteasomal function is 
abolished, suppression of NRF1 processing occurs (Sha Z. and Goldberg A. L., 2014). The 
target genes of NRF1 include subunit genes of all the proteasome components, in the 
regulatory particle (PsmC1, PsmC4, PsmD1, PsmD12, PsmD14), and in the core (PsmA3, 
PsmA7, PsmB3, PsmB4, PsmB6, PsmB7) (Radhakrishnan S. K., et al., 2010, Sha Z. and 
Goldberg A. L., 2014, Steffen J., et al., 2010). In addition, NRF1 regulates expression of 
ERAD pathway components Herpud1 and VCP/p97 (Ho D. V. and Chan J. Y., 2015, Sha Z. 
and Goldberg A. L., 2014). 
A number of knockout mouse model has been prepared for understanding the role of 
mNrf1 in vivo. Nrf1-null model exhibits late gestational embryonic lethality from abnormal 
fetal liver erythropoiesis (Chan J. Y., et al., 1998). Another study on mouse chimeras 
addressed function of mNrf1 to maintenance of hepatocytes (Chen L., et al., 2003). 
Hepatocyte specific Nrf1 knockout models show high levels of apoptosis leading to steatosis, 
inflammation and tumorigenesis (Lee C. S., et al., 2013, Ohtsuji M., et al., 2008, Xu Z., et 
al., 2005). Nrf1 deletion in neurons and glial cells leads to neurodegeneration, motor ataxia 
and forebrain atrophy developing with age (Kobayashi A. et al., 2011, Lee C. S., et al., 2011). 
mNrf1 depletion in osteoblasts resulted in reduction of bone mass, size and mechanical 
strength (Kim J. et al., 2010). On the contrary, a study of Hirotsu and colleagues with 
over-expression of mNrf1 in mice revealed insulin resistance of the transgenic mice. Insulin 
signaling is suppressed in liver and skeletal muscle by mNrf1 indirectly - via protein kinase 
B activation due to enhanced fatty acid oxidation (Hirotsu Y., et al., 2014). 
1.3.2.1.2 NRF3 
NFE2L3 (NRF3) is localized on chromosome 7, 26,152,240-26,187,125 on forward 
strand. It is a 4 exon gene (ENSG00000050344 - Ensemble release 95, NCBI ID: 9603) with 
one known splice variant (ENST00000056233.3, NM_004289.7) for a 694-residue long 
protein (Q9Y4A8, NP_004280.5) (Geer L. Y., et al., 2010, The UniProt C., 2017, Zerbino D. 
R., et al., 2018). For structure organization see chapter 1.3.2.1. and Figure 6.  NRF3 is 
expressed in a variety of human tissues according to up-to-date online databases; however, it 
exhibits high expression levels specifically in placenta (Chenais B. et al., 2005). In addition, 
transcript levels are increased in lymphoma, breast and testicular carcinoma and colorectal 
adenocarninoma cell lines (Chevillard G. and Blank V., 2011, Chowdhury A., et al., 2017). 
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The degradation of NRF3 is performed by HDR1/p97 connected ERAD pathway in 
cytosol and by SKP1-β-TRCP complex in nucleus such as was described for its homologs 
NRF1 and NRF2 (for degradation mechanism details see chapter 1.2.2 on page 31) 
(Chowdhury A., et al., 2017). 
NRF3 was found to be a negative regulator of NRF2 target antioxidant genes 
NAD(P)H:Quinone Oxidoreductase1 and peroxiredoxin 6 (Chowdhury I. et al., 2009, 
Sankaranarayanan K. and Jaiswal A. K., 2004). Cell cycle regulator U2AF homology motif 
kinase 1 (UHMK1) is another gene regulated by NRF3 in colon carcinoma cells, via which 
NRF3 could promote cell proliferation (Chowdhury A., et al., 2017). Pro-apoptotic role of 
NRF3 was identified in NRF3-dependent regulation of cell adhesion-related proteins function 
human keratinocytes upon exposure to UV radiation (Siegenthaler B. et al., 2018). Study of 
Wang and colleagues recently discovered correlation between NRF3 expression levels and 
metastasis in pancreatic cancer tissues. NRF3 expression levels were remarkably increased in 
cancerous tissue in comparison to adjacent non-cancerous tissue suggesting that it most 
probably acts as an oncogene in pancreatic cancer (Wang H. et al., 2018). Another role for 
NRF3 was identified in smooth muscle cell differentiation from stem cells. mNrf3 induces 
expression of smooth muscle cell markers, phospholipase A2, group 7 and pro-oxidant genes 
that produce ROS, which are essential for advancement of the differentiation process (Pepe 
A. E. et al., 2010, Xiao Q. et al., 2012).  
Nrf3 knockout mice do not show any developmental defects or growth abnormalities 
under non-challenging conditions, however they are sensitive to a variety of stressing stimuli 
(Derjuga A. et al., 2004). Nrf3 null mice showed profound weight loss after treatment with 
antioxidant BHT (butylated hydroxytoulene) in comparison with their WT littermates and 
developed acute lung and adipose tissue damage. Levels of Nrf1 and Nrf3 expression in WT 
mice decreased upon exposure to BHT as opposed to Nrf2 mRNA levels, which suggests that 
they represent different regulatory responses to these conditions (Chevillard G. et al., 2010). 
Another study showed that Nrf3 null mice are prone to lymphomagenesis of T-cell origin in 
response to chemical carcinogen treatment (Chevillard G. et al., 2011). As well, regulation of 
response to inflammation was suggested as one of the functions for mNrf3 transcription factor 
in connection to its compensatory role in Nrf2 deficient mice (Braun S. et al., 2002). 
Interestingly, double knockout Nrf3-/-/Nrf2-/- or Nrf3-/-/Nfe2-/- mice did not show any obvious 
phenotype as well as their single knockout parental strains (Derjuga A., et al., 2004). 
1.3.3 DDI1 in homo sapiens 
Human DDI1 is encoded by one exon gene (ENSG00000170967, NCBI ID: 414301) 
and therefore has one transcript (ENST00000302259.4 - Ensemble release 95, 
NM_001001711.2) that corresponds to the 396 residue long protein (Q8WTU0, 
NP_001001711.1) (Geer L. Y., et al., 2010, The UniProt C., 2017, Zerbino D. R., et al., 2018). 
Secondary structure predictions and sequence alignments of human DDI1 and DDI2 proteins, 
which share 72% sequence identity, suggest that DDI1 protein shall harbor three domains 
previously characterized for yDdi1 and DDI2: UBL, HDD and RVP (for sequence alignment 
see Figure 7 on page 100).  
Human DDI1 has been scarcely studied, which is reflected also in amount of data 
available in online expression databases. Its expression is restricted exclusively to testes in 
healthy adult humans, although its production is slightly elevated in melanoma and 
lymphoma cell lines. Interestingly, mutations in DDI1 were recently identified in patients 
suffering from familial neurodegenerative disorder, a variant of Alzheimer´s disease 
(Alexander J. et al., 2016). 
DDI1 is specifically ubiquitinated by an E3 ubiquitin ligase UBE3A in human 
neuroblastoma cells. Surprisingly, this modification does not target DDI1 for proteasomal 
degradation (Ramirez J., et al., 2018). A complex neurodevelopmental disease called 
Angelman syndrome is caused by mutations in a single gene encoding the UBE3A ligase, 
which suggest that its substrates might affect pathways essential for proper brain development 
(Buiting K. et al., 2016, Sadikovic B. et al., 2014). Ramirez and colleagues showed that 
expression of murine Ddi1 increases rapidly on embryonic day 16.5, which might mean 
a specific function for DDI1 at this stage of embryonal development (Ramirez J., et al., 2018). 
Moreover, it had been previously suggested that Ddi1 of C. elegans may regulate 
synaptogenesis (Guthmueller K. L., et al., 2011). Altogether, these findings point out possible 
relevance of DDI1 for development of Angelman syndrome (Ramirez J., et al., 2018). 
Another function has been recently described for DDI1 together with DDI2 (see 
chapter 1.3.2 on page 51), both of which participate in DNA damage response, specifically 
during recovery from replication stress at repair of stalled replication forks (Kottemann M. 







































Several studies identified members of the evolutionary highly conserved family of 
Ddi1-like proteins as important regulators of homeostasis maintenance in a variety of 
pathways, such as ubiquitin-proteasome system, DNA damage response or proteotoxic stress 
response. Despite the emerging evidence of their crucial role in these biological processes, 
Ddi1-like proteins have been poorly studied on the molecular level or in suitable biological 
systems. Therefore the work presented in the thesis will enrich up-to-date studies towards 
better understanding of the role and mechanism of function of several Ddi1-like protein 
family members.  
These objectives were set towards fulfillment of specific aims: 
1. Structure solution and characterization of the UBL domain of Ddi1p from S. 
cerevisiae using NMR spectroscopy. 
2. Characterization of the binding properties of UBL domain and ubiquitin-interacting 
motif of human DDI2 protein, in context of its possible function in ubiquitin-proteasome 
system using NMR spectroscopy. 
3. Expression profiling of murine homolog Ddi1 in developing mouse brain using in 
situ hybridization method.  
4. Generation and characterization of Ddi2 full knockout mouse strain as the most 
suitable animal model for studying the physiological function of human DDI2 protein. 
5. Generation and characterization of Ddi2 protease defective mouse model strain for 
deciphering the function of retroviral protease-like domain of Ddi2. 
6. Comparison and detailed analysis of the phenotypes of both gene-edited mouse 
model strains. 
7. Identification of possible pathways involving Ddi2 that are connected to phenotype 














































































































3.1.1 Chemicals and solutions 
acetic acid (Penta, Prague, Czechia) 
acrylamide (Sigma-Aldrich, St. Louis, USA) 
agarose (Serva, Heidelberg, Germany) 
Albumin standard (2 mg/ml) (Thermo Scientific, Waltham, USA) 
All Blue pre-stained protein standard (Bio-Rad, Hercules, USA) 
ammonium chloride (15N-labeled) (Cambridge Isotope Laboratories, Andover, USA) 
ammonium persulfate (Serva, Heidelberg, Germany) 
ampicillin (Sigma-Aldrich, St. Louis, USA) 
Aquatex (Millipore, Burlington, USA) 
BM purple (Roche, Basel, Switzerland) 
boric acid (Sigma-Aldrich, St. Louis, USA) 
bortezomib (UBPBio, Aurora, USA) 
bromphenol blue (Sigma-Aldrich, St. Louis, USA) 
calcium chloride (Penta, Prague, Czechia) 
cobalt dichloride (Sigma-Aldrich, St. Louis, USA) 
cOmpleteTM Mini, EDTA-free, Protease Inhibitor Cocktail (Roche, Basel, Switzerland) 
cupric chloride (Sigma-Aldrich, St. Louis, USA) 
D-biotin (Sigma-Aldrich, St. Louis, USA) 
deuterium dioxide (Merck, Billerica, USA) 
D-glucose (Sigma-Aldrich, St. Louis, USA) 
D-glucose (13N-labeled) (Cambridge Isotope Laboratories, Andover, USA) 
dimethyl sulfoxide (Sigma-Aldrich, St. Louis, USA) 
DirectPCR Lysis Reagent (Viagen Biotech, Inc, Los Angeles, USA) 
dithiotreitol (Sigma-Aldrich, St. Louis, USA) 
DMEM High Glucose w/o L-Glutamine (Biosera, Nuaille, France) 
DNA ladder 100 bp (Qiagen, Hilden, Germany) 
dNTP mix (Serva, Heidelberg, Germany) 
dry milk - Blotting-Grade Blocker (Bio-Rad, Hercules, USA) 
ethylenediaminetetraacetic acid (EDTA) (Sigma-Aldrich, St. Louis, USA) 
egtazic acid (EGTA) (Sigma-Aldrich, St. Louis, USA) 
ferrous chloride (Sigma-Aldrich, St. Louis, USA) 
fetal bovine serum (FBS) (Sigma-Aldrich, St. Louis, USA) 
formaldehyde (Penta, Prague, Czechia) 
gelatine (Penta, Prague, Czechia) 
GelRed Nucleic Acid Gel Stain (Biotinum, Fremont, USA) 
glycerol (Penta, Prague, Czechia) 
glycine  (Duchefa, Haarlem, Netherlands) 
hydrochloric acid (Penta, Prague, Czechia) 
Igepal CA-630 (Sigma-Aldrich, St. Louis, USA) 
IMDM medium (Thermo Fisher Scientific, Waltham, USA) 
imidazole (Sigma-Aldrich, St. Louis, USA) 
isopropanol (Penta, Prague, Czechia) 
isopropyl β-D-1-thiogalactopyranoside (IPTG) (Biosynth AG, Staad, Switzerland) 
kanamycin (Sigma-Aldrich, St. Louis, USA) 
LB agar (Sigma-Aldrich, St. Louis, USA) 
LB medium (Sigma-Aldrich, St. Louis, USA) 
L-glutamine (Sigma-Aldrich, St. Louis, USA) 
magnesium chloride (Sigma-Aldrich, St. Louis, USA) 
magnesium sulfate (Sigma-Aldrich, St. Louis, USA) 
MEM Eagle Vitamin Mixture 100X (Lonza Biotech, Kouřim, Czechia) 
MEM non-essential amino acid solution (Sigma-Aldrich, St. Louis, USA) 
2-mercaptoethanol (Sigma-Aldrich, St. Louis, USA) 
methanol (Penta, Prague, Czechia) 
N,N'-methylen-bis(acrylamide) (USB, Cleveland, USA) 
Nonidet P-40 (Sigma-Aldrich, St. Louis, USA) 
Nuclear Fast Red (Sigma-Aldrich, St. Louis, USA) 
opti-MEM medium (Thermo Fisher Scientific, Waltham, USA) 
Paraformaldehyde (Sigma-Aldrich, St. Louis, USA) 
Penicillin-Streptomycin 100X (Sigma-Aldrich, St. Louis, USA) 
Protein Assay Dye Reagent Concentrate (Bio-Rad, Hercules, USA) 
polyethylenimine (Sigma-Aldrich, St. Louis, USA) 
potassium chloride (Sigma-Aldrich, St. Louis, USA) 
potassium dihydrogen phosphate (Sigma-Aldrich, St. Louis, USA) 
potassium ferricyanide (Sigma-Aldrich, St. Louis, USA) 
potassium ferrocyanide (Sigma-Aldrich, St. Louis, USA) 
RNAlater® (Sigma-Aldrich, St. Louis, USA) 
silver nitrate (Lachema, Brno, Czechia) 
sodium azide (Sigma-Aldrich, St. Louis, USA) 
sodium carbonate (Penta, Prague, Czechia) 
sodium chloride (Lachema, Brno, Czechia) 
sodium deoxycholate (Sigma-Aldrich, St. Louis, USA) 
sodium dihydrogenphosphate (Lach-Ner, Neratovice, CZ) 
sodium dodecyl sulfate (Sigma-Aldrich, St. Louis, USA) 
sodium hydroxide (Penta, Prague, Czechia) 
sodium molybdate (Sigma-Aldrich, St. Louis, USA) 
sodium phosphate dibasic (Sigma-Aldrich, St. Louis, USA) 
sodium pyruvate 100mM 100X (Sigma-Aldrich, St. Louis, USA) 
sodium sulfate (Penta, Prague, Czechia) 
sodium thiosulfate pentahydrate (Penta, Prague, Czechia) 
sucrose (Sigma-Aldrich, St. Louis, USA) 
SYPRO® Orange Protein Gel Stain (Sigma-Aldrich, St. Louis, USA) 
TEMED (tetramethylethylendiamine) (Fluka, Buchs, Switzerland) 
thiamine hydrochloride (Sigma-Aldrich, St. Louis, USA) 
tris (tris(hydroxymethyl)aminomethane) (USB, Cleveland, USA) 
trypsin-EDTA solution (Sigma-Aldrich, St. Louis, USA) 
Tween 20 (USB, Cleveland, USA) 
X-gal (Thermo Scientific, Waltham, USA) 
zinc chloride (Sigma-Aldrich, St. Louis, USA) 
3.1.2 Antibodies 
Anti-Digoxigenin-AP, Fab fragments (Roche, Basel, Switzerland) 
Mouse monoclonal Anti-α-Tubulin antibody T6199 (Sigma-Aldrich, St. Louis, USA) 
Mouse monoclonal Anti-β-Actin antibody, clone AC-15 (Sigma-Aldrich, St. Louis, USA) 
Rabbit monoclonal anti- TCF11/NRF1 D5B10 #8052 (Cell Signaling) 
Rabbit polyclonal anti-Ddi2 antibody A304-630A (Bethyl) 
IRDye® 680 RD Goat anti-Mouse IgG (LI-COR Biosciences, Lincoln, USA) 
IRDye® 800 CW Goat anti-Rabbit IgG (LI-COR Biosciences, Lincoln, USA) 
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3.1.3 Cell cultures 
E. coli BL21(DE3)RIL (Novagen – Merck KGaA, Darmstadt, Germany) 
E. coli Top10 cells (Invitrogen, Carlsbad, USA) 
E. coli DH5α (Novagen – Merck KGaA, Darmstadt, Germany) 
HEK293offA2 cells (original strain ATTC, Manassas, USA) 
3.1.4 Commercial kits 
Agilent RNA 6000 Nano Kit (Agilent technologies, Santa Clara, USA) 
cell culture dishes and plates (Biotech, Prague, Czechia) 
DIG RNA Labeling Kit (SP6/T7) (Roche, Basel, Switzerland) 
mMESSAGE mMACHINE T7 Kit (Thermo Fisher Scientific, Waltham, USA) 
Mouse Direct PCR Kit (Bimake, Houston, USA) 
Poly(A) Tailing Kit (Thermo Fisher Scientific, Waltham, USA) 
RNase-free DNAse Set (QIAGEN, Hilden, Germany) 
RNeasy Mini Kit (QIAGEN, Hilden, Germany) 
RNeasy plus Micro Kit (QIAGEN, Hilden, Germany) 
QIAGEN Plasmid Maxi Kit (QIAGEN, Hilden, Germany) 
QIAGEN Plasmid Midi Kit (QIAGEN, Hilden, Germany) 
QIAprep Spin Miniprep Kit (QIAGEN, Hilden, Germany) 
QIAquick Gel Extraction Kit (QIAGEN, Hilden, Germany) 
TATAA GrandScript cDNA Synthesis Kit (TATAA Biocenter, Göteborg, Sweden) 
TATAA SYBR® GrandMaster® Mix (TATAA Biocenter, Göteborg, Sweden) 
Tissue-Tek® O.C.T. Compound (SAKURA Finetek USA Inc, Torrance, USA) 
Whatman filter paper, Grade 470 (GE-Healthcare, Chicago, USA) 
Zero Blunt® Cloning® Kit (Invitrogen, Carlsbad, USA) 
ZyppyTM Plasmid Minipirep Kit (Zymo Research, Irvine, USA) 
3.1.5 Enzymes 
Antarctic Phosphatase (New England BioLabs, Ipswich, USA) 
Benzonase® Nuclease (Novagen – Merck KGaA, Darmstadt, Germany) 
Pfu DNA Polymerase (Promega, Madison, USA) 
Phusion® HF Polymerase (New England BioLabs, Ipswich, USA) 
proteinase K (New England BioLabs, Ipswich,USA) 
BamHI, DpnI, EcoRI, KpnI, NdeI, NheI, SacII, SalI and XbaI (New England BioLabs, Ipswich, USA) 
T4 DNA Ligase (New England BioLabs, Ipswich, USA) 
3.1.6 Primers 
Table 2: List of primers used in this study. 
Primer name Sequence Use  
Ddi1Sc_16b_F 5´-ATCAACATATGGATTTAACAATTTC-3´ cloning 
Ddi1Sc_U_16b_R 5´- ATCAAGGATCCCTATCAGGAATTGGAAATCTTACCCC-3´ cloning 
Ddi1_F_AS1 5´-GTATTGTGTGCGTAGGGACC-3’ ISH probe cloning 
Ddi1_R_AS1 5’-TGAGTCTGTGAGCCGGTAGT-3’ ISH probe cloning 
Ddi1_F_AS2 5’-TGAGCTTGAGTCTGGTGTGC-3’ ISH probe cloning 
Ddi1_R_AS2 5’-GTGCCTCCTGAGCATATCAAG-3’ ISH probe cloning 
Ddi2F 5´-GTCTGGTCCTTGTCCGTGTT-3´ genotyping 
Ddi2R 5´-AGTCTGTCATCCCGAGTTGG-3´ genotyping 
Ddi2tm1b WT F 5´-GCATGGGCTTACAGTGGTTACTC-3´ genotyping 
Ddi2tm1b RV 5´-CTTACTAGTTGCACAGCTGATGACATC-3´ genotyping 
Ddi2 IN R 5´-GACTGTAAAACATAAGCCAC-3´ genotyping 
Ddi2 long R 5´-CCTGGCAACCTGAAATCAAG-3´ genotyping 
Ddi2 nested F 5´-GTGAGACCCTGACTCGGCAA-3´ genotyping 
DDI2_HDD_F 5´- ATCAACATATGCAGCAGTCCCACTCA-3´ cloning 
DDI2_KpnI_F 5´- CTTCCAGGTACCAAAGATGCTGCTCACC-3´ cloning 
Ddi2_OT_1_F 5´-TCCCTTTCATGAGGCCATTC    -3´ off-target screen 
Ddi2_OT_1_R 5´-AGCGCAGAGAATGAAAAAGC-3´ off-target screen 
Ddi2_OT_2_F 5´-TGCTGAATTAGTGCTTTCATGTGG-3´ off-target screen 
Ddi2_OT_2_R 5´-TACCATGCACACGCATCTCA-3´ off-target screen 
Ddi2_OT_3_F 5´-TTCTTTCCAACTAACCCACA-3´ off-target screen 
Ddi2_OT_3_R 5´-CTGGGATGAGAAGTTTTGAG-3´ off-target screen 
Ddi2_OT_4_F 5´-TGACCAATGTAGTGGATAG-3´ off-target screen 
Ddi2_OT_4_R 5´-TGGTGGATGTCAAGGATTAT-3´ off-target screen 
Ddi2_OT_5_F 5´-GAACCTGAGTCTTCTGCAA-3´ off-target screen 
Ddi2_OT_5_R 5´-AAGCACTCTACTGCTTTCC-3´ off-target screen 
Ddi2_OT_6_F 5´-GAGGAACCACCTAGGGCTGA-3´ off-target screen 
Ddi2_OT_6_R 5´-CAGGTCAGAGATGGGTCTGC-3´ off-target screen 
Ddi2_OT_7_F 5´-CTGGACACTGGCTCTTC-3´ off-target screen 
Ddi2_OT_7_R 5´-CGCAGTAGAAACATTGCAA-3´ off-target screen 
Ddi2_OT_8_F 5´-AGCATGGGTACCAATTCCAGA-3´ off-target screen 
Ddi2_OT_8_R 5´-TGCACCATGTAGACATTGACG-3´ off-target screen 
Ddi2_OT_9_F 5´-TCTCCCTTGCCCCTTTAG-3´ off-target screen 
Ddi2_OT_9_R 5´-TAATGGGGGAGTAGGACAGT-3´ off-target screen 
Ddi2_OT_10_F 5´-TATAAGCCTGGCCTTTCTTGT-3´ off-target screen 
Ddi2_OT_10_R 5´-TGTGCTCTCACACCCAC-3´ off-target screen 
Ddi2_OT_11_F 5´-GTTGCAGCTCACCTTGAACG-3´ off-target screen 
Ddi2_OT_11_R 5´-TTTGCCAGTCTCAGGTTGCT-3´ off-target screen 
Ddi2_OT_12_F 5´-TCTGCTGCATTGTTTTATTGC-3´ off-target screen 
Ddi2_OT_12_R 5´-CACAGGAACTTCTGGTGACTT-3´ off-target screen 
DDI2_RVP_R 5´- ATCAAGGATCCCTATCACTCTGGTAGCTC-3´ cloning 
DDI2_XbaI_R 5´- GATGCGGCCGTCTAGACTATCATGGCTTCTG-3´ cloning 
FseqpTRETight 5´-AGGCGTATCACGAGGCCCTTTCGT-3´ sequencing 
LacZ_R 5´-ACGGTTTCCATATGGGGATT-3´ genotyping 
M13 F 5 ́-GTAAAACGACGGCCAG-3 ́ sequencing 
M13 R 5 ́-CAGGAAACAGCTATGAC-3  ́ sequencing 
mDdi2 F cDNA 5´-AAATGCTGCTCACCGTGTAC-3´ cloning 
mDdi2 R cDNA 5´-AATCATGGCTTCTGACGCTC-3´ cloning 
mDdi2_F 5´-CACACAGAAGATTATTGGAAGG-3´ RT-PCR 
mDdi2_p905_F 5´-CAAGCTAGCATGCTGCTCACCG-3´ cloning 
mDdi2_p905_R 5´-AGTAAGAATTCCTATCATGGCTTCTGACGCTC-3´ cloning 
mDdi2_R 5´-CGTTTCAGCATGTCCAGACC-3´ RT-PCR 
mH2afz_F 5´-TAGGACAACCAGCCACGGA-3´ RT-PCR  
mH2afz_R 5´-GACGAGGGGTGATACGCTTT-3´ RT-PCR 
mTbp_F 5´-TATCTACCGTGAATCTTGGCTG-3´ RT-PCR 
mTbp_R 5´-TTGTCCGTGGCTCTCTTATTCT-3´ RT-PCR 
MutDDI2_XbaI_F 5´- GACCTTGAGAAATTTTCCAGAGTCCTGGTGGAGCAG-3´ mutagenesis 
MutDDI2_XbaI_R 5´- CTGCTCCACCAGGACTCTGGAAAATTTCTCAAGGTC-3´ mutagenesis 
RseqpTRETight 5´-TATTACCGCCTTTGAGTGAGCTGA-3´ sequencing 
T7 F 5´-TAATACGACTCACTATAGGG-3´ sequencing 
T7 R 5´-GCTAGTTATTGCTCAGCGG-3´ sequencing 
3.1.7 Vectors 
p905 (gift from Dr. Řezáčova laboratory at IOCB CAS, Prague, Czech Republic)  
pCRTM-Blunt (Thermo Fisher Scientific, Waltham, USA) 
pGEM-T® easy plasmid (Promega, Madison, USA) 
pET16b (Novagen – Merck KGaA, Darmstadt, Germany) 
pTreTight (gift from Dr. Konvalinka laboratory at IOCB CAS, Prague, Czech Republic) 
3.1.8 Consumables 
96-well transparent plate, F-bottom (P-lab, Prague, Czechia) 
Amicon® Ultra 0.5 mL (Millipore, Burlington, USA) 
Amicon® Ultra 15 mL (Millipore, Burlington, USA) 
dialysis membrane Spectrapor (Spectrum Laboratories – Repligen, Waltham, USA) 
Dumont micro forceps (Fine Science Tools, North Vancouver, Canada) 
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LightCycler® 480 Multiwell Plate 384 (Roche, Basel, Switzerland) 
LightCycler® 480 Multiwell Plate 96 (Roche, Basel, Switzerland)  
LightCycler® 480 Sealing Foil (Roche, Basel, Switzerland) 
Ni-NTA Superflow resin (QIAGEN, Hilden, Germany) 
nitrocellulose membrane (Bio-Rad, Hercules, USA) 
SuperdexTM 75pg 16/60 FPLC Column (GE Healthcare, Chicago, USA) 
SuperdexTM 200pg 16/60 FPLC Column (GE Healthcare, Chicago, USA)  
SterivexTM GP 0.22 µm filter unit (Millipore, Burlington, USA) 
3.2 INSTRUMENTS 
autoclave: MLS-3020U, Sanyo (Osaka, Japan) 
centrifuges:  Beckman Allegra X-15R, Beckman Coulter (Brea, USA)  
 Beckman Avanti J-30I, Beckman Coulter (Brea, USA) 
 Centrifuge 5415R, Eppendorf (Hamburg, Germany) 
 Fresco Heraus 21, IEC CL10, Thermo Scientific (Waltham, USA) 
 Megafuge 2.0R, Heraeus Instruments (Hanau, Germany) 
 Sorvall Evolution RC, Thermo Scientific (Waltham, USA) 
chromatography:  ÄKTAExplorer FPLC, Amersham Pharmacia Biotech - GE Healthcare (Chicago, USA)  
electrophoresis: Agilent 2100 Bioanalyzer, Agilent Technologies (Santa Clara, USA) 
 electrophoresis power supply EPS 301, GE Healthcare (Chicago, USA) 
 horizontal electrophoresis apparatus, Thermo Scientific (Waltham, USA) 
 Mini-PROTEAN® Tetra Vertical Electrophoresis Cell, Bio-Rad (Hercules, USA) 
 Mini Trans-Blot® Cell, Bio-Rad (Hercules, USA)  
homogenizers: TissueLyser II, Qiagen (Hilden, Germany) 
 EmulsiFlex-C3 homogenizer, AVESTIN (Ottawa, Canada) 
imaging systems: Odyssey® CLx Infrared Imaging System, LI-COR Biosciences (Lincoln, USA) 
 UV lamp UVT-20 SML, Herolab (Wiesloch, Germany) 
 Monochrome scientific grade camera Quantum ST4, Vilber Lourmat (Collegién, France) 
incubators: Thermocell Mixing Block MB102, BIOER Technology (China) 
 CO2 incubator MCO-19AIC, Sanyo (Osaka, Japan) 
 Innova44, New Brunswick Scientific (Enfield, USA) 
scales:  EK-400H, A&D Company, (Tokyo, Japan) 
 PLS 4000-2, KERN & Sohn GmpH (Postfach, Germany) 
 XA 116/X, Radwag (Sumperk, Czechia)  
microscopes: Stemi 305 EDU Microscope, Zeiss (Oberkochen, Germany) 
 Axio Imager Z2, Zeiss (Oberkochen, Germany) 
 AxioScan Z1, Zeiss (Oberkochen, Germany) 
 AxioZoom, Apotome module macroscope, Zeiss (Oberkochen, Germany) 
pH-meter:  pH 50, XS instruments (Carpi, Italy) 
sonicator: sonication bath S 30 Elmasonic, Elma (Singen, Germany) 
spectrophotometers:  
 spectrophotometer UNICAM UV 500, Thermo Scientific (Waltham, USA) 
 NanoDrop ND-1000, Thermo Scientific (Waltham, USA) 
 Infinite® microplate reader M1000 PRO, Tecan (Männedorf, Switzerland) 
 600 MHz Bruker Avance spectrometer, Bruker (Billerica, USA) 
 850 MHz Bruker Avance spectrometer, Bruker (Billerica, USA) 
thermocyclers:  TRIO 48, Biometra (Göttingen, Germany) 
 LightCycler®480 II, Roche (Basel, Switzerland) 
vortexes: MX-S,Dragonlab (Beijing, China) 
3.3 SOFTWARE 
Gimp 2.10.4 (The GIMP Development Team) 
GraphPad Prism 7.00 (GraphPad Software, La Jolla, California, USA) 
Image Studio Lite Software (LI-COR Biosciences, Lincoln, USA) 
Inkscape (The Inkscape Development Team) 
Microsoft Office (Microsoft Corporation ,Redmond, USA) 
Sparky (University of California, San Francisco, USA) 
Vector NTI 11 (Invitrogen, Carlsbad, USA) 
Topspin 3.2 (Bruker, Billerica, USA) 
 
3.4 METHODS 
3.4.1 DNA cloning and analysis 
Several protein constructs were used in this work for characterization of proteins 
recombinantly expressed in bacterial or human cell cultures. hDDI2 full-length protein and 
hDDI2 UBL were cloned into pET16b vector (Novagen) by Monika Sivá for studies intended 
for her diploma thesis. Protein constructs of hDDI2 ∆UIM and hDDI2 RVP-full C were 
cloned also into pET16b vector (Novagen) expression vector by Michal Svoboda and Klára 
Grantz Šašková. Plasmids encoding human ubiquitin without (in pET24a) and with 
N-terminal His-tag (in pHISTEV30a) was kindly provided as a gift from the laboratory of Dr. 
Ron T. Hay at University of Dundee. Monika Sivá cloned constructs of yDdi1 UBL, hDDI2 
HDD-RVP and both mouse Ddi2WT and Ddi2PD (∆254-296). Sequences of all constructs were 
designed and later analyzed using Vector NTI software (Invitrogen). 
3.4.1.1 DNA construct cloning into bacterial expression vectors 
First, common features of the cloning experiments are described for all the plasmid 
constructs. Primer sequences, DNA templates and DNA restriction with endonucleases is 
listed below for each construct individually.  
Amplification of coding sequences of all constructs was performed with Phusion® 
HF Polymerase (New England BioLabs). The reactions were mixed as follows: 10 µl of 5X 
Phusion® HF Buffer, 200 µM dNTPs (Serva), 0.4 µM of relevant primers, 100 ng of DNA 
template, 0.2 µl of Phusion® High-Fidelity DNA Polymerase and nuclease-free water 
addition up to 50 µl of total volume. PCR amplification was performed PCR Thermocycler 
(Biometra) as follows: DNA template denaturation at 98°C for 5 minutes; 35 cycles of 
denaturation at 98°C for 20 seconds, annealing at temperature corresponding to individual 
primer pairs for 30 seconds and elongation at 72°C for 60 seconds; and final incubation at 
72°C for 5 minutes. Amplified fragments were analyzed by agarose gel electrophoresis 
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(chapter 3.4.1.3) and subsequently digested with corresponding restriction endonucleases 
according to manufacturer´s manual for double digest. All digested products were again 
separated by horizontal agarose gel electrophoresis (control of vector linearization) (chapter 
3.4.1.3) and extracted from gel (chapter 3.4.1.4). Dephosphorylation of the linearized vector 
with Antarctic Phosphatase (New England BioLabs) and following ligation of DNA 
fragments into the linearized vector with T4 DNA ligase (New England BioLabs) were 
performed according to manufacturer’s instructions. Transformation of bacteria and 
preparation of plasmid DNA was performed as described in chapter 3.4.1.2. Purified pET16b, 
p905 and pTreTight plasmids encoding mDdi2 constructs were sequenced by GATC Biotech 
(Konstanz, Germany) using common sequencing primers T7 F, T7 R (pET16b, p905) or 
FseqpTRETight, RseqpTRETight (for primer sequences see Table 2 on page 69). 
yDdi1 UBL and hDDI2 HDD-RVP coding sequences were amplified using primers 
Ddi1Sc_16b_F, Ddi1Sc_UBL_16b_R and DDI2_HDD_F, DDI2_RVP_R, respectively (for 
primer sequences see table 2 on page XX). Plasmids encoding full-length yDdi1p and hDDI2 
full-length proteins from our laboratory were used as templates. Both PCR products and 
pET16b vector were cleaved with restriction endonucleases NdeI and BamHI (New England 
BioLabs).  
Plasmids pCR™-Blunt containing correct Ddi2WT and Ddi2PD coding sequences (for 
cloning of DNA sequences from cDNA see 3.4.5.14) were used as templates for amplification 
of the fragments and cloning into a bacterial expression vectors p905 and pTreTight.  
Primers mDdi2_p905_F and mDdi2_p905_R were used for amplification of the two 
variants of mDdi2 coding sequence. Restriction enzyme digestion of corresponding p905 
plasmid and two Ddi2 variants was performed with NheI and EcoRI restriction enzymes 
(New England BioLabs).  
Both pCR™-Blunt plasmids encoding mDdi2 variants were used as templates for 
site-directed mutagenesis producing silent mutation sequence non-cleavable by XbaI 
restriction endonuclease required for cloning of the DNA sequence into pTreTight vector. 
Reaction mixes contained 50 ng of the template plasmid, 1µM mutagenesis primers, 250 µM 
dNTPs (Serva), 2.5 U of Pfu DNA polymerase and 10X reaction buffer (Promega) and water 
addition up to 50 µl. The reactions were run on PCR Thermocycler (Biometra) as follows: 95 
ºC (30 s), 18 cycles of 95 ºC (30 s), 55 ºC (60 s), 68 ºC (5 min) and final elongation of 10 min. 
The site-directed mutagenesis reaction mixtures were digested by 20 U of DpnI (New 
England BioLabs) for 1 hour at 37 ºC and analyzed by horizontal agarose gel electrophoresis 
(chapter 3.4.1.3). Uncleaved plasmids were extracted from gel (chapter 3.4.1.4) and 
subsequently transformed into the E. coli Top10 competent cells (Invitrogen) as described in 
following chapter. Successful mutagenesis was identified by colony PCR, where 10 colonies 
from each agar plate after transformation were suspended in 10 µl of deionized water and 2 µl 
of the bacterial suspense were used as a template for PCR reaction described for cloning of 
all construct variants using Phusion® HF Polymerase (New England BioLabs) described at 
the beginning of this chapter. Primers DDI2_KpnI_F and DDI2_XbaI_R were used for 
mDdi2 variant DNA sequences amplification and subsequent sequencing by GATC Biotech 
(Konstanz, Germany). Correct sequences and pTreTight vector were digested by KnpI and 
XbaI. 
3.4.1.2 Transformation of bacteria and amplification of plasmid DNA  
The host strain E. coli DH5α (Novagen) was used for transformation and 
amplification of plasmids encoding Ddi1-like proteins used for NMR studies. In case of 
cloning mDdi2WT and mDdi2PD protein versions from cDNA into bacterial expression 
vectors, competent E. coli strain cells Top10 (Invitrogen) were used. The transformation was 
carried out as follows (Sambrook J., Fritschi, E.F. and Maniatis, T., 1989): 1 µl of ligation 
mixture was added to 30 µl of freshly unfrozen competent bacterial cells and left to incubate 
for 30 minutes on ice. Heat shock was performed at 42°C for 90 seconds, followed by cooling 
of the bacterial suspense down on ice for 5 minutes. Subsequently, the bacteria were incubated 
with approx. 400 µl of LB media (without antibiotic) at 37°C for 1 hour, then spread over the 
agar plates containing relevant antibiotic (100 mg/ml ampicillin or 40 mg/ml kanamycin) and 
incubated at 37°C overnight. 
After overnight incubation, freshly grown colonies were individually picked and 
inoculated into 12.5 ml, 100 ml or 500 ml of sterile LB medium supplemented with antibiotic 
(100 mg/ml ampicillin or 40 mg/ml kanamycin) for DNA minipreparation, midipreparation 
and maxipreparation, respectively. Bacteria were grown in a rotatory incubator Innova 4300 
(New Brunswick Scientific) at 37°C and 220 rpm overnight. Following day, the culture was 
centrifuged at 4000 g, 4°C for 10 minutes and cell pellets were further processed with 
Zyppy™ Plasmid Miniprep Kit (Zymo Research), QIAGEN Plasmid Midi or Maxi Kit 
(QIAGEN) according to the protocols provided by the manufacturers. Isolated DNA was 
eluted from columns with 40 µl of sterile water and its concentration and purity was measured 
using NanoDrop ND-1000 spectrophotometer (Thermo Scientific). Plasmids were sequenced 
by GATC Biotech (Konstanz, Germany). 
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3.4.1.3 Horizontal agarose gel electrophoresis 
Horizontal agarose gel electrophoresis was used as analysis method for visualization 
of reaction products during cloning and genotyping procedures. 1% agarose (Serva) gel 
prepared in TAE buffer (40 mM Tris-acetate, pH 8.4, 1 mM EDTA) containing DNA stain 
GelRed (Biotinum) dissolved 20000X was used for separation of all products. The gel was 
run at 120 V for 20 minutes or 80V for 40 minutes and the DNA was subsequently visualized 
under UV lamp (Herolab) and photographed by monochrome scientific grade camera 
Quantum ST4 (Vilber Lourmat). 
3.4.1.4 DNA isolation from agarose gel 
DNA extractions from agarose gel after separation via electrophoresis were 
performed using QIAquick Gel Extraction Kit (QIAGEN). Briefly, approximately 200 
miligrams of the gel was cut out and dissolved in 600 µl of buffer QG at 56°C for 10 min. 
After mixing with 200 µl of isopropanol, the DNA was further purified from the solution 
using microtubes and solution from the kit precisely according to the manufacturer´s protocol. 
At the end, the extracted DNA fragments were eluted from the microtube with 40 µl of sterile 
HPLC water via centrifugation at 13000 g for 1 min at 25°C. 
3.4.2 Protein analysis methods 
3.4.2.1 Sodium dodecyl sulfate – polyacrylamide gel electrophoresis 
The process of recombinant protein expression and subsequent protein purification 
was monitored by discontinuous SDS-polyacrylamide (SDS-PAGE) gel electrophoresis 
followed by silver staining of the proteins separated in the polyacrylamide gel. Analysis of 
tissue lysate content was mainly performed by discontinuous SDS-PAGE followed by 
Western blotting. All the samples for SDS-PAGE were collected in different amounts 
according to expected protein concentrations, fraction or lysate volumes, which is 
individually specified at the end of each purification or lysation method description.  
Samples collected for SDS-PAGE were mixed with SDS-PAGE loading buffer of 
360 mM Tris, pH 6.8, 30% glycerol, 10% SDS, 4% 2-mercaptoethanol, 0.01% bromophenol 
blue in 5:1 ratio, vortexed and boiled for 10 minutes.  
Polyacrylamide gels consisting of upper 5% stacking gel (250 mM Tris-HCl pH 6.8, 
5% (v/v) acrylamide solution (acrylamide with N,N'-bisacrylamide in a ratio 35.7:1), 0.1% 
(w/v) SDS, 0.1% (w/v) ammonium persulfate (APS), 0.02% (v/v) TEMED) and lower 10% 
or 18% resolving gel (375 mM Tris-HCl pH 8.8, 10% or 18% (v/v) acrylamide solution 
(acrylamide with N,N'-bisacrylamide in the ratio 35.7:1), 0.1% (w/v) SDS, 0.1% (w/v) 
ammonium persulfate (APS), 0.01% (v/v) TEMED) were used. Protein samples from 
purification processes were loaded onto an 18% polyacrylamide gel, while 10% resolving 
polyacrylamide gels were used for further Western blotting.  
Protein separation was performed in polyacrylamide gel immersed in SDS-PAGE 
running buffer 25 mM Tris pH 8.8, 250 mM glycine, 0.1% SDS in a vertical electrophoresis 
apparatus (Bio-Rad) at a constant voltage of 140V. All Blue pre-stained protein standard 
(Bio-Rad) was used as a molecular weight marker. Time of separation was different for 
individual methods, as required: approximately 1.5 hour for analysis of purification process 
or until the bromophenol blue dye/25kDa band of All Blue pre-stained protein standard 
(Bio-Rad) reached the bottom of the gel in case of tissue lysate analysis. 
3.4.2.2 Silver staining of proteins in polyacrylamide gel 
After termination of protein separation in a polyacrylamide gel, the gels were fixed 
with 12% (v/v) acetic acid, 50% (v/v) methanol and 0.02% (v/v) formaldehyde for 30 minutes 
while constant gentle shaking. After washing 3 times with 50% (v/v) methanol for 5 minutes, 
the gels were exposed with 0.02% (w/v) sodium thiosulfate pentahydrate for 1 minute and 
rinsed 3 times with distilled water. The impregnation was performed with 0.2% (w/v) silver 
nitrate and 0.02% (v/v) formaldehyde for 20 minutes, followed by rinsing with distilled water 
3 times. The gels were developed by incubation with 566 mM sodium carbonate, 16 μM 
sodium thiosulfate pentahydrate and 0.02% (v/v) formaldehyde while gentle shaking, until 
the protein bands became visible. After rinsing in distilled water, development was stopped 
by a 10-minute incubation with 12% (v/v) acetic acid and 50% (v/v) methanol. Resultant 
polyacrylamide gels were scanned for further analysis on a scanner (Canon). 
3.4.2.3 Western blotting analysis 
Protein expression in embryos and cell lines was monitored using Western blot 
analysis. Individual sample preparation, processing and sample loads onto polyacrylamide 
gels is described in chapters dedicated to individual above mentioned experiments. 
 In general, sample (tissue, embryo, cells) lysate after protein concentration 
measurement was mixed with lysis SDS-PAGE loading buffer (for content see chapter 
3.4.2.1) in ratio 5:1, vortexed and boiled for 10 minutes. SDS-PAGE procedure was 
performed identically according to the protocol described in Chapter 3.3.2.1. Wet 
electroblotting was performed in the Mini Trans-Blot® Cell (Bio-Rad) in 12.5 mM 
Tris-glycine pH 8.3, 10% (v/v) methanol at 100 V for 1 hour. Proteins were transferred onto 
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nitrocellulose membrane (Bio-Rad). The membranes were blocked with 5% dry milk 
(Bio-RAD) in TBST´ (50 mM Tris-HCl, 150 mM NaCl, 0.1% Tween 20) with 0.01% NaN3 
by overnight incubation at room temperature. All the following incubations with antibodies 
were performed while gentle shaking at 4°C. All the primary antibodies were diluted in the 
same blocking solution and incubated with the membrane for at least 4 hours. The membrane 
was then gently rinsed 3 times with TBST´ and incubated with secondary antibodies IRDye® 
800 CW Goat anti-Rabbit IgG (LI-COR) or IRDye® 680 RD Goat anti-Mouse IgG (LI-COR) 
diluted 1:30000 in 5% dry milk (Bio-Rad) in TBST´ with 0.01% NaN3 for 2 hours. The 
membrane was then washed 3 times in TBST´ (approx. 5 minutes), dried and photographed 
on Odyssey® CLx Imaging System (LI-COR). Scanned picture was processed in Image 
Studio Lite Software (LI-COR). 
List of primary antibodies used in this work: Rabbit polyclonal anti-Ddi2 antibody 
(Bethyl, A304-630A, dilution 1:1000), Mouse monoclonal Anti-α-Tubulin antibody 
(Sigma-Aldrich, T6199, dilution 1:2000), Rabbit monoclonal anti- TCF11/NRF1 (Cell 
Signaling, D5B10 #8052, dilution 1:1000), Mouse monoclonal Anti-β-Actin antibody, clone 
AC-15 (Sigma-Aldrich, dilution 1:5000). 
3.4.2.4 Protein concentration determination using Bradford protein 
assay 
Bradford protein assay (Bradford M. M., 1976) was used for determination of protein 
concentration in tissue or cell lysates and in samples acquired during individual protein 
purification steps. The measurement was performed in a 96-well plate format with total 
reaction volume of 200 µl per well. The calibration curve consisted of duplicates of Albumin 
standard (2 mg/ml, Thermo Scientific) dilutions at concentrations 0, 12.5, 25, 50, 100 and 200 
mg/ml. To acquire most accurate results, measured samples were diluted so that the 
absorbance of each reached approximately the middle of the calibration curve. Each well 
contained 20 µls of Albumin standard or appropriately diluted sample and 180 µls of Protein 
Assay Dye (Bio-Rad) 4.5× diluted in deionized water. The 96-well transparent flat bottom 
plate (P-lab) was used for the measurement. After addition of all reagent, the plate was left at 
room temperature for 5 minutes and then the absorbance at 595 nm was measured using the 
Infinite microplate reader (Tecan). Final protein concentrations were calculated using 
Microsoft Excel software. 
3.4.3 Recombinant preparation of proteins 
All the protein constructs were recombinantly expressed in host bacterial strain E. coli 
BL21(DE3)RIL (Novagen). Proteins with DNA construct cloned into pET16b (Novagen) 
bacterial expression vector were further purified via nickel affinity chromatography and 
size-exclusion chromatography as described in chapters 3.4.3.3 and 3.4.3.4, respectively. 
Mouse proteins that were cloned into p905 bacterial expression vector (gift from Dr. 
Řezáčova laboratory at IOCB CAS, Prague) were additionally submitted for cleavage with 
TEV protease for removal of the His-tag during the purification process as more closely 
described in chapter 3.4.3.5. Non-tagged ubiquitin was recombinantly expressed and 
provided by Michal Svoboda, all the remaining proteins were expressed and purified by 
Monika Sivá with help of Iva Flaisigová. 
All the collected fractions and samples were analyzed during each purification step 
by SDS-PAGE electrophoresis (see chapter 3.4.2.1.) followed by silver staining (chapter 
3.3.2.2). Each individual method used during particular purification process is described in 
the following chapters.  
3.4.3.1 Recombinant expression of proteins in E. coli 
After transfection and overnight growth, freshly grown bacterial colonies were 
suspended in 10 µls of LB medium (Sigma-Aldrich) and then inoculated into 3 liters of the 
LB media supplemented with ampicillin (100 mg/ml). The cell culture was grown in 
a-rotatory incubator at 37°C and 220 rpm. Protein expression was induced at OD595 
approximately 0.8 by final concentration of 0.75 mM IPTG. Culture was further grown at 
20°C and 220 rpm overnight. Bacterial cells were harvested by centrifugation at 6000 g, 10 
min, 10°C. The pellet was resuspended in 50 mM Tris pH 8.0, 50 mM NaCl, 1 mM EDTA 
buffer supplemented with cOmplete™ Mini, EDTA-free Protease Inhibitor Cocktail (Roche) 
and further homogenized at 1200 bar at 4°C using EmulziFlex-C3 homogenizer (AVESTIN, 
Canada). After centrifugation at 20 000 g, 20 min, 4°C, the supernatant was decanted and 
used for further purification process. 
3.4.3.2 Recombinant expression of isotopically labeled proteins for 
NMR 
Freshly grown bacterial colonies after transfection and overnight growth were 
suspended in 10 µl of minimal medium (M9) and then inoculated into 2 liters of minimal 
media supplemented with ampicillin (100 mg/ml). The minimal medium recipe has been 
previously described (Renshaw P. S. et al., 2004, Veverka V. et al., 2006). Depending on the 
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required isotope labeling, the medium contained 0.8 g/L [15N] ammonium chloride and/or 2 
g/L d-[13C] glucose. Cell culture was grown in a rotatory incubator at 37°C and 220 rpm. 
Protein expression induction, bacterial cell growth, harvest and homogenization was 
performed precisely as described in chapter 3.4.3.1. After centrifugation at 20 000 g, 20 min, 
4°C, the supernatant was used for further protein purification. 
3.4.3.3 Nickel affinity chromatography (proteins expressed from pET16b 
vector) 
Proteins were further purified from the supernatant by nickel affinity 
chromatography. Supernatants were incubated with 0.5 -1 ml of equilibrated Ni-NTA resin 
(QIAGEN) on a rocker at 4°C overnight. The suspense was centrifuged at 3000 g, 4°C for 
5 minutes; the supernatant was decanted and stored for another round of nickel affinity 
chromatography. The resin was washed 3 times by addition of 4 mls of wash buffer (50 mM 
Tris pH 8.0, 50 mM imidazole) and subsequently centrifuged (3000 g, 4°C, 5 min). 
His-tagged proteins were then eluted with 4 ml of elution buffer of higher content of imidazole 
(50 mM Tris pH 8.0, 250 mM imidazole) rocking 1 hour at 4°C. The supernatant after final 
centrifugation at the same conditions as previously was further used in the purification 
process. 
3.4.3.4 Size-exclusion chromatography 
Eluted fractions from nickel affinity chromatography were dialyzed against 50 mM 
sodium phosphate pH 7.4 supplemented with 0.5 % (v/v) glycerol. Any precipitates were 
removed by centrifugation (4000 g, 4°C, 10 min) and the supernatant was concentrated with 
Amicon Ultra centrifugal filters (Millipore) up to 10 – 20 mg/ml and filtered with a 0.22 µm 
filter unit (Millipore) prior application onto chromatography column. The concentrates were 
purified by size-exclusion chromatography on an FPLC (ÄKTA explorer, Amersham 
Pharmacia Biotech) using either the SuperdexTM 75pg 16/60 or 200pg 16/60 FPLC columns 
(GE Healthcare) depending on molecular mass of individual protein constructs. Protein 
concentration of all the collected relevant fractions was determined by Bradford protein assay 
(see chapter 3.4.2.4). 
3.4.3.5 Purification process of proteins expressed from p905 vector 
Mouse Ddi2WT and Ddi2PD proteins that were cloned into p905 bacterial expression 
vector (gift from Dr. Řezáčova laboratory at IOCB CAS, Prague) were purified with 
a different purification protocol. The recombinant expression and first round of nickel affinity 
chromatography were performed identically as described in chapters 3.4.3.1 and 3.3.3.3. 
Histidine-tag was cleaved off the mDdi2 proteins by TEV protease (1 mg/ml) during an 
overnight incubation at 4°C in 35:1 ratio of protein:TEV protease (TEV protease was 
recombinantly prepared in our laboratory by Jaroslav Kurfürst in a construct with N-terminal 
histidine tag). After overnight incubation, second round of nickel affinity chromatography 
was performed. Due to cleaved-off N-terminal histidine tag and His-tagged TEV protease 
bound to the Ni-NTA resin, Ni-NTA purification provided flow through fraction with mDdi2 
protein construct only. The flow-through was further used for dialysis for buffer exchange 
and size-exclusion chromatography as described above. 
3.4.4 NMR experiments and biophysical characterization of proteins 
All the spectra were acquired from 350 µl protein samples at 25°C on a 600 MHz or 
850 MHz Bruker Avance spectrometer (Bruker BioSpin GmbH) equipped with a triple 
resonance (15N, 13C, 1H) cryoprobe. 1D protein spectra were measured in 50 mM phosphate 
buffer at pH 7.4 with 0.5% glycerol. The 2D and 3D NMR spectra were acquired from protein 
samples in identical phosphate buffer with deuterium/hydrogen content of 5% D2O/95% H2O 
if not stated otherwise. All the spectra were processed using Topspin 3.2 (Bruker). 
3.4.4.1 One dimensional NMR spectroscopy 
The one dimensional 1H HSQC spectra of all the protein constructs used in NMR 
experiments and in characterization of murine mDdi2WT and mDdi2PD proteins were acquired 
at concentrations from 50 to 100 mM, which varied according to the concentration used later 
in other experiments. 
3.4.4.2 NMR spectra acquisitions and spectra assignment for structure 
determination 
The spectra for yeast Ddi1 ubiquitin-like domain structure determination were 
acquired from samples of 0.5 mM 13C/15N-labeled protein as described previously (Renshaw 
P. S., et al., 2004, Veverka V., et al., 2006). 15N/1H HSQC, HNCO, HNCACB, 
CACB(CO)NH spectra were collected for sequence-specific backbone assignment. Aliphatic 
side-chain carbon resonances and corresponding protons were assigned from 
HCCH-TOCSY, 15N-edited NOESY, 13C-edited NOESY and 15N-edited TOCSY spectra. 
Aromatic ring proton resonances were assigned from 2D-TOCSY and 2D-NOESY spectra. 
3D 15N/1H NOESY-HSQC and 13C/1H HSQC-NOESY spectra were used for 1H-1H distance 
constraints calculations. All the 2D and 3D NOESY spectra were acquired with NOE mixing 
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time of 120 ms and the TOCSY spectra were acquired with mixing time of 60 ms. Raw data 
were processed for further calculations by Dr. Václav Veverka at the IOCB CAS. All the 
resonance assignments were carried out manually in program Sparky (Goddard T. D. a. K., 
D. G. , 2008). 
3.4.4.3 Protein structure calculations 
Preliminary structures were produced from NOE-derived restraints from 3D 15N- and 
13C-edited NOESY spectra. First of all, the family of converged structures for yeast Ddi1 
UBL domain was calculated using Cyana 2.1 program (Guntert P. et al., 1997, Herrmann T. 
et al., 2002). Secondly, program TALOS+ was used for generation of backbone torsion angle 
constraints from assigned chemical shifts (Shen Y. et al., 2009). The calculations additionally 
included hydrogen bond constraints. These involved residues with slowly exchanging amide 
protons. Simulated annealing combined with redundant dihedral angle constraints (REDAC) 
was performed in five cycles (Guntert P. and Wuthrich K., 1991), which produced a set of 43 
converged structures with no eminent restraint violations (distance constraint violations and 
van der Waals violations below 0.2Å, dihedral angle constraint violations below 5°) and the 
lowest Cyana target function. This structure set underwent further refinement in explicit 
solvent with YASARA forcefield. Final analysis of the family of structures was carried out 
using the programs Molmol, iCING and PyMol (Doreleijers J. F. et al., 2012, Koradi R. et 
al., 1996, Schrodinger, LLC, 2015). 
3.4.4.4 Characterization of protein-protein interaction using NMR 
First, a series of double and triple resonance spectra were collected for 
sequence-specific backbone assignment of hDDI2 UBL, hDDI2 RVP full-C protein construct 
and UBQ. All spectra were processed using the program Sparky (Goddard T. D. a. K., D. G. 
, 2008). Changes induced in the positions of backbone signals of 15N-labeled proteins in 
15N/1H HSQC spectra were used for monitoring the interaction site. Most significant shifts of 
the backbone amide groups of individual residues were used for binding site mapping. The 
formula ∆𝛿 = √(∆𝛿𝐻)2 + (∆𝛿𝑁 × 0.2)2  was used for definition of weigthed-average 
chemical shift perturbations. A non-linear one site specific binding model was used for 
titration curve fitting in program GraphPad Prism. In case of single addition of the binding 
partner, the minimal shift approach was used for assessment of the changes in signals 
(Veverka V. et al., 2008). 
The UBQ/hDDI2-UIM peptide titration experiment was performed by acquisition of 
2D HSQC spectra of 0.1 mM UBQ in 50 mM sodium phosphate buffer, pH 6.0, containing 
3.9% DMSO without or with addition of hDDI2-UIM peptide to final concentrations of 0.69, 
1.4, 2, 2.75 and 3.45 mM in individual samples. Cut-off for evaluation of the CSPs used for 
this experiment was set to 0.12. 6 best-fitting curves of shift changes for individual residues 
were used for calculation of the Kd. Control binding experiment with DDI2-scrambled UIM 
peptide was performed under the same conditions with 1.9 mM peptide (final concentration). 
Both peptides were synthesized, purified by reverse-phase HPLC and subsequently 
lyophilized in the core facility of IOCB CAS, Prague. They were dissolved in DMSO prior 
titration experiments.  
The protein-protein interactions were characterized from changes in 15N/1H HSQC 
spectra of 15N-labeled 0.1 mM UBQ in 50 mM sodium phosphate buffer, pH 7.4, without and 
with 1, 2, and 5-fold molar addition of non-labeled hDDI2 RVP full-C and vice versa.  
The interaction of hDDI2 UBL with UBQ, 2D HSQC spectra of 0.042 mM 
15N-labeled DDI2 UBL were acquired without and with 1, 2, 4, 6, 8, and 10-fold molar 
addition of non-labeled UBQ in 20 mM phosphate buffer, 0.5 mM DTT. Numerical cut-off 
for evaluation of the CSPs was set to 0.075. The 10 best-fitting curves from shifts of individual 
residues throughout titration were used for calculation of the Kd. Reverse experiment was 
performed with 0.05 mM UBQ with single 6-fold molar addition of hDDI2 ΔUIM protein 
construct in 50 mM phosphate buffer, 0.5 mM DTT. Spectra acquisition of 0.05 mM UBQ 
without and with 6-fold addition of DDI2 HDD-RVP construct was used as a control 
experiment.  
To identify intramolecular interaction of hDDI2 UBL domain and its flexibility in 
full-length protein structure, two measurements were performed: 2D HSQC spectra of 0.05 
mM full-length hDDI2 protein and hDDI2 UBL domain were acquired individually and 
superimposed. Intramolecular DDI2 UBL/DDI2 UIM interaction was verified by acquisition 
and superimposition of 2D HSQC spectra of 0.22 mM 15N-labeled hDdi2 full-length protein 
and 2D HSQC spectra of 0.093 mM hDDI2 ΔUIM in 50 mM sodium phosphate buffer, pH 
7.4, with 0.1 mM DTT. Interaction of hDDI2 UBL with hDDI2-UIM peptide was studied by 
acquisition of 2D HSQC spectra of 0.05 mM protein in 50 mM sodium phosphate, pH 7.4, 
with addition of hDDI2-UIM peptide to a final concentration of 1.9 mM. A control 
experiment with single addition of hDDI2-scrambled UIM peptide reaching 1.2 mM final 
concentration was performed. 
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3.4.4.5 Thermofluor assay - differential scanning fluorimetry (DSF) 
Murine Ddi2WT and Ddi2PD proteins were examined for their proper folding and 
stability using thermofluor assay on a LightCycler® 480 II (Roche). The measurement was 
performed with 20 µM proteins on a 96-well plate in 50 mM phosphate buffer at pH 7.4 with 
0.5% glycerol with 5000x diluted SYPRO® Orange protein gel stain (Sigma-Aldrich) in total 
reaction volume 25 µl. The protocol was set as follows: after the pre-cooling temperature was 
held at 20°C for 10 min, the fluorescence itself was measured during continuous temperature 
increase from initial 20°C up to final 95°C with 82 acquisitions per 1°C accrue. The 
temperature increment was set at rate 0.01°C per second. The experiment was completed at 
95°C for 10 s followed by 20°C for 10 s. LightCycler® 480 Software (Roche) was used for 
final calculation of the melting temperatures. Protein stability analysis was performed in 
collaboration with Michal Svoboda. 
3.4.5 Methods linked to studies in mice and cell cultures 
3.4.5.1 Generation of Ddi2tm1b and Ddi2protease defective mouse strains 
Ddi2tm1b (full name: C57BL/6NCrl-Ddi2tm1b(EUCOMM)Hmgu/Ph) mouse strain was 
generated on the C57BL/6NCrl background at the IMG CAS and registered for phenotyping 
at the International Mouse Phenotyping Consortium (IMPC). The origin of the line is from 
ES clone HEPD0660_5_E02, which belongs under The European Conditional Mouse 
Mutagenesis Program (EUCOMM). This ES cell clone bears a Ddi2tm1a(EUCOMM)Hmgu cassette 
with promoter-driven neomycin selection. We started to work with this mouse line in 
collaboration with Czech Centre for Phenogenomics hosted by the IMG CAS. Colony of 
Ddi2tm1b strain was established by scientific staff of the IMG CAS. 
Ddi2protease defective (full name: C57BL/6NCrl-Ddi2em1/Rase) strain was generated by 
Transcription Activator-Like Effector Nuclease (TALEN)-mediated genome editing 
performed by Dr. Petr Kašpárek at the IMG CAS. TALENs specifically recognizing the 
intron 5 and intron 6 of Ddi2 gene were designed using TAL Effector Nucleotide Targeter 
2.0 (Cermak T. et al., 2011, Doyle E. L. et al., 2012). TALENs were assembled using the 
Golden Gate Cloning system (Cermak T., et al., 2011) and cloned into the ELD-KKR 
backbone plasmid as described elsewhere (Flemr M. et al., 2013). TALENs recognizing 
5’ site and 3´ site of target sequence within intron 5 contained the following repeats: HD NG 
NG HD NI HD NG NN NN NN NN HD NI NN HD NN NG and HD HD NI HD HD NI NI 
HD NI NN NI NI NI NI NG, respectively. TALENs recognizing target sequence within intron 
6 contained the following repeats: for 5’ site NN NG NN NG HD HD NG NG NN NG NN 
NG NI HD NN NN NN and for recognizing 3’ site HD HD HD HD NI NN NG NN HD NG 
NN HD HD HD NG HD NG NN. Each plasmid was linearized with NotI and transcribed 
using the mMESSAGE mMACHINE T7 kit (Thermo Fisher Scientific). Polyadenylation of 
resulting mRNAs was performed using the Poly(A) Tailing kit (Thermo Fisher Scientific) 
and mRNA was purified with the RNeasy mini kit (QIAGEN). TALEN mRNAs, 10 ng/μl 
for each TALEN were microinjected into male nucleoli of zygotes isolated from C57BL/6N 
mice (Kasparek P. et al., 2014). The mice were further maintained on C57BL/6N background. 
All work with mice was approved by the Animal Care Committee of the IMG CAS 
according to institutional and national guidelines of Czech Central Commission for Animal 
Welfare and in accordance with European directive 2010/63/EU. 
3.4.5.2 Establishment of Ddi2protease defective mouse colony, colony 
management and timed crossings 
Four founder mice (F0) bearing successful exon 6 deletion were identified and the 
deletion region was sequenced by GATC Biotech (Konstanz, Germany). Genomic DNA 
(gDNA) extraction and subsequent deletion region amplification, agarose gel separation and 
gel extraction were performed as described in chapters 3.4.5.4. All four F0 mice were bred 
with C57Bl/6NCrl wild-type (WT) mice for production of F1 generation. After analysis of 
F1 generation by sequencing of deletion region of gDNA, only offspring of founder ID 38 
were chosen for colony establishment. Mouse colony was established at F1 generation by Dr. 
Kašpárek and it was onward maintained on C57BL/6NCrl background by Monika Sivá. Mice 
were bred to F4 and F5 generation according to a breeding scheme where heterozygous mice 
were backcrossed to C57Bl/6NCrl wild-type mice. Heterozygous mice from F4 and F5 
generation were bred with heterozygous mice to obtain offspring for experiments (embryo or 
adult mice). C57Bl/6NCrl WT mice were provided by the Animal Facility of IMG CAS. 
Breedings for timed embryo sample collection were precisely planned. After breeding 
setup, females were checked for plug every morning. The noon of the day of vaginal plug 
detection was estimated as embryonal day 0.5 (E0.5). Additionally, the females were 
weighted on the day of breeding onset, on the day of plug and after 6 and 8 days from plug 
date by specially trained staff at the Animal Facility of IMG CAS. Plugged females were 
considered pregnant individually according to weight gain. 
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3.4.5.3 Off-target screen of TALEN-mediated gene alterations 
A cohort of F1 generation mice used for further colony establishment were screen for 
off-target sites of TALENs used for Ddi2protease defective strain generation. Twelve sites within 
chromosome 4 with higher off-target score for all possible combinations of ELD and KKR 
heterodimers of TALENs were predicted in TAL Effector Nucleotide Targeter 2.0 (Doyle E. 
L., et al., 2012). These sites were analyzed for protein coding sequences using Ensembl online 
database. They were amplified by PCR from genomic DNA extracts (chapter 3.4.5.4) of F1 
generation mice and sequenced by GATC Biotech (Konstanz, Germany). All primers were 
designed and examined using online tools Ensembl, UCSC in silico PCR and NCBI 
PrimerBlast and BLAST (Geer L. Y., et al., 2010, Kent W. J. et al., 2002, Zerbino D. R., et 
al., 2018). Their sequences are listed in Table 2. Monitored DNA fragments were amplified 
in PCR reaction using Phusion® High-Fidelity DNA Polymerase (New England BioLabs). 
The reaction mix contained 10 µl of 5X Phusion® HF Buffer, 200 µM dNTPs (Serva), 0.4 
µM primers (see Table 2), 1 µl of genomic DNA extract, 0.2 µl of Phusion® High-Fidelity 
DNA Polymerase and nuclease-free water addition up to 50 µl of total volume. PCR 
Thermocycler (Biometra) was used for amplification with cycles programed as follows: DNA 
template denaturation at 98°C for 5 minutes; 33 cycles of denaturation at 98°C for 20 seconds, 
annealing at 58-65°C (depending on melting temperatures of primer pairs designed for each 
off-target site) for 20 seconds and elongation at 72°C for 30 seconds; and final incubation at 
72°C for 5 minutes. Amplified fragments were separated by agarose gel electrophoresis 
(chapter 3.4.1.3), extracted from gel (chapter 3.4.1.4) and sequenced using the same primers 
that were used for amplification by GATC Biotech (Konstanz, Germany). 
3.4.5.4 Genomic DNA extraction and genotyping of Ddi2protease defective and 
Ddi2tm1b mouse strains 
Tail or ear biopsies were taken from three-week-old pups at weaning at the Animal 
Facility of the IMG CAS. Yolk sac or embryonal body samples for genotyping were collected 
during embryo harvest and dissection. Genomic DNA was isolated using DirectPCR Lysis 
Reagent (Viagen). Each mouse tail and embryo sample was immersed with 50 µl or 30 µl of 
DirectPCR and 0.5 µl or 0.25 µl of 10 mg/ml Proteinase K (New England Biolabs), 
respectively. After overnight incubation at 55 °C, the activity of Protease K was stopped by 
5x dilution with sterile HPLC water. 
Genomic DNA extract was subsequently used as template for PCR using Mouse 
Direct PCR Kit (Bimake). Genotyping of Ddi2protease defective strain mouse and embryo samples 
was performed with a pair of Ddi2F and Ddi2R primers amplifying 1572 bps for WT allele 
and 1072 bps for exon 6 deleted allele form. PCR reaction mix contained 10 µl of M-PCR 
OPTI mix (component of Mouse Direct PCR Kit containing Taq DNA polymerase, dNTPs 
and reaction buffer), final concentration of 0.25 µM Ddi2F and Ddi2R primers, 1 µl of 
template of genomic DNA and water addition up to total volume of 20 µl. PCR cycles were 
preset and run on a PCR Thermocycler (Biometra) as follows: DNA template denaturation at 
94°C for 3 minutes; 35 cycles of denaturation at 94°C for 20 seconds, annealing at 55°C for 
30 seconds and elongation at 72°C for 60 seconds; and final incubation at 72°C for 5 minutes.  
Two forward primers LacZ F, Ddi2tm1b WT F and one reverse primer Ddi2tm1b RV 
were used for genotyping of Ddi2tm1b samples. PCR reaction mix contained 10 µl of M-PCR 
OPTI mix (component of Mouse Direct PCR Kit containing Taq DNA polymerase, dNTPs 
and reaction buffer), final concentration of 0.25 µM LacZ F and Ddi2tm1b WT F primers, 
final concentration of 0.375 µM Ddi2tm1b RV primers, 1 µl of template of genomic DNA 
and water addition up to total volume of 20 µl. The PCR reaction was performed as follows: 
DNA template denaturation at 94°C for 5 minutes; 35 cycles of denaturation at 94°C for 30 
seconds, annealing at 55°C for 40 seconds and elongation at 72°C for 75 seconds; and final 
incubation at 72°C for 5 minutes. The set of 3 primers amplified fragments of 1080 bps for 
Ddi2 wild-type allele and 640 bps for Ddi2tm1b allele. 
Thanks to M-PCR OPTI mix content, 2 µl of the PCR mix could be used for analysis 
of the amplification by agarose gel electrophoresis (chapter 3.4.1.3) with no need for loading 
buffer. The gel was run at constant voltage of 80V for 40 minutes. DNA fragments were 
visualized and analyzed under UV lamp (Herolab). Gel was photographed by monochrome 
scientific grade camera Quantum ST4 (Vilber Lourmat). 
3.4.5.5 Genotyping of early embryonal stages using nested PCR 
In case of early developmental stage Ddi2protease defective strain embryo genotyping (9.5), 
another round of nested PCR was introduced to avoid contamination of the tissue samples by 
maternal blood or tissue during embryo dissection and MEF culture isolation.  
Three primers were designed for two nested reactions: a forward primer 
Ddi2 nested F, Ddi2 long R and Ddi2 IN R reverse primers. The pair of Ddi2 nested F and 
Ddi2 long R primers in NESTED 1 reaction amplified fragments of 650 bps for WT allele 
and 150 bps for exon 6 deleted allele, while the pair of Ddi2 nested F and Ddi2 IN R in 
NESTED 2 reaction amplified a 350 bp long fragment in case of WT allele, however no DNA 
amplification product in case of exon 6 deletion.  
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Both NESTED reaction mixtures were prepared separately as follows: 10 µl of M-
PCR OPTI mix (Bimake), final concentration of 0.25 µM primers, 1 µl of 200x diluted 
Ddi2protease defective genotyping PCR reactions after amplification from chapter 3.4.5.4 as 
template and water addition up to total volume of 20 µl. The PCR reaction was performed 
similarly to genotyping in chapter 3.4.5.4, as follows: DNA template denaturation at 94°C for 
5 minutes; 27 cycles of denaturation at 94°C for 20 seconds, annealing at 55°C for 30 seconds 
and elongation at 72°C for 40 seconds; and final incubation at 72°C for 5 minutes. Amplified 
fragments were analyzed by agarose gel electrophoresis as described in chapter 3.4.1.3. 
3.4.5.6 Embryo harvest  
Pregnant mouse was sacrificed by cervical dislocation. The uterus was collected, 
washed from blood in sterile preheated (37°C) PBS in a 50 ml falcon tube and placed onto 
100 mm Petri dish with preheated sterile PBS. Individual embryos were withdrawn from 
uterus with a pair of Dumont micro forceps (Fine Science Tools) under stereomicroscope 
Stemi 305 EDU Microscope (Zeiss). Yolk sac and amnion were separated from the 
embryonal body and stored as sample for genotyping. Embryo proper was either put into a 
pre-tarred microtube and frozen at -80°C for protein expression analysis, or fixed in 4% PFA 
for further RNA in situ hybridization experiments, or put into 500 µl of RNAlater solution 
(Ambion) for gene expression studies using qPCR. The sample for mRNA isolation was left 
2 hours on the table to soak and then put to fridge for further soaking and short time storage. 
Whole-mount imaging of embryos was performed by Kallayanee Chawengsaksophak. 
3.4.5.7 Isolation and culturing of primary mouse embryonal fibroblasts  
The pregnancy of mice was monitored by weight gain: females were weight on the 
day of start of the breeding, on the day of plug and after 6 and 8 days from plug date. In case 
the female gained over 2 grams, it was considered pregnant. Mouse embryonic fibroblasts 
(MEFs) were isolated from embryos on embryonal day 10.5. The MEF medium used for 
culturing of primary cell line consists of DMEM High Glucose w/o L-Glutamine (Biosera), 
10% heat-inactivated fetal bovine serum (Sigma-Aldrich), 2 mM L-glutamine 
(Sigma-Aldrich), 100X Penicillin-streptomycin (Sigma-Aldrich) and freshly added 100X 
MEM non-essential amino acid solution (Sigma-Aldrich)  and 100X 100 mM sodium 
pyruvate (Sigma-Aldrich). 
Embryos at specific stage of embryonal development were harvested as decribed in 
chaper 3.4.5.6. Trunk of each embryonal body was washed from organs and placed into 
individual well with 100 µl of sterile preheated PBS in a 24-well plate. Yolk sac and head 
were separated from the embryonal body, washed in PBS and collected into sterile microtube 
as samples for genotyping. Trunk of each embryo was lysed separately by pipetting at least 5 
times up and down with a 200 µl tip, followed by a thinner 20 µl tip and eventually lysed in 
a 26G gauge with 1ml injection. The 100 µl lysate was then transferred into 1ml of freshly 
prepared MEF medium in a well in 12-well plate (pre-coated with 0.1 % gelatin). Media was 
completely changed 2 days after isolation.  
Medium was further exchanged every second day in ratio of original:new medium 
1:3. The culture was passaged at minimum of 90% confluence onto plates pre-coated with 
0.1 % gelatin as follows: P0 – isolated cells, P1 – from a well of 12-well plate onto one 60 
mm Petri dish, P2 – from one 60 mm Petri dish onto 2x 100 mm Petri dish, P3 – one 100 mm 
Petri dish onto four 100 mm Petri dishes. For passage, MEF medium was withdrawn, cells 
were washed with preheated PBS and trypsinized twice with relevant amount of 
trypsin-EDTA solution for 2 minutes. Trypsinization was stopped with addition of MEF 
medium, cells were centrifuged at 250 g for 3 minutes, resuspended in MEF medium and 
placed onto a Petri dish. Final passage 3 was used for experiments.  
3.4.5.8 Messenger RNA isolation 
All the samples were individually weighted in sterile RNase free tared tubes. 
Messenger RNA isolations were performed using RNeasy Plus Micro Kit (QIAGEN) or 
RNeasy Mini Kit (QIAGEN), depending on whether the weight of sample was below 5 mg 
or 30 mg, respectively. Tissue samples were homogenized in 80 µl (RNeasy Plus Micro Kit) 
or 350 µl (RNeasy Mini Kit) of RLT Buffer with freshly added 1% β-mercaptoethanol using 
TissueLyzer II (Retsch) at frequency 30 Hz (1800 oscillations per minute) for 3 minutes. An 
RNase free iron ball was placed into the tubes for proper homogenization. Following 
procedures were performed according to further manufacturer´s instructions in both kit cases. 
DNase digestion was performed on gDNA Eliminator Mini Spin Columns (QIAGEN) when 
RNeasy Plus Micro Kit was used. In case of RNeasy Mini Kit, the RNase-free DNAse set 
(QIAGEN) was used according to manufacturer´s guide for on-column DNA digestion during 
RNA isolation. Purified RNA was eluted from columns with RNase-free water (QIAGEN) 
and stored at -80°C for further processing.  
3.4.5.9 Quality control of mRNA and reverse transcription 
The quality of isolated mRNA was characterized using Bioanalyzer RNA 6000 Nano 
assay (Agilent). Individual mRNA samples were diluted to reach concentrations (5–500 
ng/μl) valid for measurement of RNA integrity number (RIN) in Total NANO RNA assay. 
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Twelve mRNA samples were run on each chip. Cleaning and setting up of the instrument and 
the experiment itself were performed exactly as described in manufacturer´s instructions in 
Agilent RNA 6000 Nano Kit Guide. Only RNA samples with RIN above 7 were used further 
in gene expression studies (chapter 3.4.5.10) and cloning of Ddi2 gene variants (chapter 
3.4.5.14).  
Messenger RNA was transcribed to cDNA using a reverse transcription set TATAA 
GrandScript cDNA Synthesis Kit (TATAA Biocenter). Individual reaction were performed 
according to manufacturer´s instructions in total volume of 20 µl with addition of 0.25 µg of 
mRNA. A reverse transcription negative control was prepared for samples dedicated for gene 
expression studies with qPCR by replacement of enzyme with nuclease-free water in reaction 
mix. 
3.4.5.10 Quantitative PCR 
Primer design, validation and qPCR experiments were carried out by Eva Rohlová 
and Filip Franko from the Gene Core facility at the IBT CAS in the BIOCEV center. 
Sequences of primers used for housekeeping genes Tbp and H2afz, and for Ddi2 are listed in 
Table 2 on page 69. Reactions were run in duplicates on 384 plates (including interpolate 
calibration) on LightCycler® 480 (Roche) using TATAA SYBR® GrandMaster® Mix 
(TATAA Biocenter). Templates were diluted 5X into the final reaction volume of 10 µl. 
Reaction was performed as follows: 95°C (1 min), 45 cycles of  95°C (5 s), 60°C  (30 s) and 
72°C (10 s), and a final temperature gradient from 60°C to 95°C for melting curve acquisition.  
Analysis of the results was performed by Monika Sivá and Vendula Novosadová from 
CCP hosted by IMG CAS, in Excell (Microsoft Office). Ddi2 expression was analyzed 
relatively to H2afz expression, which was identified as appropriate stable reference gene for 
this screen. 
3.4.5.11 Preparation of tissue lysates 
Embryos were lysed in 30 up to 80 µl of RIPA buffer (20 mM Tris pH 7.4, 150 mM 
NaCl, 1 mM EDTA, 1% deoxycholate) with addition of cOmplete™ Mini, EDTA-free 
Protease Inhibitor Cocktail (Roche), depending on the weight of individual embryos. 
Tissue was homogenized in 80 to 300 µl of RIPA (depending on embryo weight) with an 
iron ball using TissueLyzer II (Retsch) at frequency 30 Hz (1800 oscillations per minute) 
for 3 minutes. The homogenized suspense was diluted in RIPA buffer with addition of 
igepal to 1% and thoroughly mixed by pipetting up and down. Lysates were centrifuged 
at 16000 g for 15 minutes at 4°C. Supernatants were measured for protein concentration 
using Bradford protein assay (chapter 3.4.2.4) and used for preparation of SDS-PAGE 
samples as described in chapter 3.4.2.1. 
3.4.5.12 MEF treatment and harvest for gene expression studies 
MEF cultures for protein expression analysis by Western blotting were harvested 
without treatment or with treatment of inhibitor bortezomib (UBPBio) for 16 hours with 10 
µM, 2.5 µM Botezomib diluted in DMSO or DMSO itself for control. Inhibitor treatments 
were performed on MEF cultures at minimum of 90% confluency of passage 3 in duplicates. 
For analysis of gene expression by qPCR, incubations with 1 µM Botezomib, DMSO for 16 
hours or no treatment were prepared in triplicates. 
MEF cells were harvested as follows: MEF medium was withdrawn, cells were 
washed with preheated PBS and trypsinized twice with relevant amount of trypsin-EDTA 
solution for 2 minutes. Trypsinization was stopped with addition of MEF medium (for 
composition see chapter 3.4.5.7). Cell suspension was centrifuged at 1200 rpm for 3 minutes 
(in pre-tarred microtubes), the pellet was washed with 200 µl of PBS and centrifuged at 1200 
rpm for 3 minutes twice, weight at analytical scales and frozen until lysation. Further 
processing for gene expression analysis by qPCR or Western blotting is described in chapters 
3.4.5.8 – 3.4.5.10 and 3.4.2.3, respectively. 
3.4.5.13 Preparation of cell lysates for Western blotting  
Cell pellets of MEF or HEK293offA2 were lysed in SDS sample buffer without dye 
(60 mM Tris pH 6.8, 60 nM SDS, 0.3 mM β-mercaptoethanol) with cOmplete™ Mini, 
EDTA-free Protease Inhibitor Cocktail (Roche) and with 1 µl of (15x diluted) Benzonase® 
(Novagen) by pipetting up and down several times, left 40 minutes on ice, sonicated three 
times at maximal frequency for 20 sec in cold-water sonication bath (Elma) with 1 min pause 
on ice after each sonication. Pipetting up and down was used again for each sample, and then 
the lysates were centrifuged at 16000 g for 20 minutes at 4°C. Pellets were discarded and 
protein concentration was measured from supernatant by Bradford protein assay (chapter 
3.4.2.4). SDS-PAGE loading samples were prepared by addition of SDS-PAGE loading 
buffer dye (see chapter 3.4.2.1) to lysate in ratio 5:1, vortexed and boiled for 10 minutes. For 
description of Western blotting procedure see chapter 3.4.2.3. 
3.4.5.14 Analysis of Ddi2exon6 +/- and Ddi2exon6 -/- mRNA products 
The sequence of truncated mRNA product after exon 6 deletion in F1 generation mice 
was verified by mRNA extraction from mouse ears biopsies collected at the mice facility. 
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Expression of protein versions in heterozygous and homozygous mice was verified on mRNA 
level in embryos of all three genotypes at stage E10.5. The collection of material, mRNA 
isolation, quality control and cDNA synthesis were performed as described in chapters 
3.4.5.6, 3.4.5.8 to 3.4.5.9.  
Protein coding sequences of mDdi2WT and mDdi2PD (Ddi2exon6 -/- encoded product) 
were amplified by PCR using a pair of primers mDdi2 F cDNA and mDdi2 R cDNA, 
encoding 5´and 3´ends of wild-type Ddi2 gene. The reaction mix contained 10 µl of 5X 
Phusion® HF Buffer, 200 µM dNTPs (Serva), 0.4 µM primers, 1 µl of cDNA, 0.2 µl of 
Phusion® High-Fidelity DNA Polymerase and nuclease-free water addition up to 50 µl of 
total volume. PCR Thermocycler (Biometra) was used for amplification with cycles 
programed as described for Phusion® High-Fidelity DNA Polymerase in chapter 3.4.1.1 with 
annealing temperature at 63°C. Amplified fragments for all three genotypes were analyzed 
by agarose gel electrophoresis (chapter 3.4.1.3).  
The mDdi2WT and mDdi2PD coding sequence fragments amplified from cDNA as 
described in chapter XX were extracted from agarose gel after analysis and cloned into 
pCR™-Blunt vector using Zero Blunt® Cloning® Kit (Invitrogen) according to 
manufacturer´s instructions. After ligation, the ligation reactions and negative control reaction 
were transformed into competent E. coli strain Top10 (Invitrogen) similarly as described in 
chapter 3.4.1.2. Next day, 5 colonies from each agar plate were picked, cultured with LB 
medium containing 40 µg/ml kanamycin overnight at 37 ºC and purified according to protocol 
described in chapter 3.4.1.2. Purified plasmids were sequenced by GATC Biotech (Konstanz, 
Germany) using primers M13 F and M13 R (for primer sequences see Table 2 on page 69).  
3.4.5.15 Overexpression of mDdi2 variants in human HEK293 cells 
Plasmids pTreTight encoding mDdi2 variants were amplified in DNA 
maxipreparation as described in chapter 3.4.1.2 and were transfected into HEK293offA2 cells 
containing Tet-Off expression system provided by laboratory of Dr. Jan Konvalinka. 
HEK293offA2 cells were cultured in 12 well plates with 2 ml of IMDM complete medium 
(IMDM (Thermo Fisher Scientific) supplemented by 10% FBS and 40 mM L-glutamine). 
They were transfected with 400 μl of transfecting mix consisting of opti-MEM medium 
(Thermo Fisher Scientific), 7.5 μg of plasmid DNA and 10% (v/v) polyethylenimine 
(Sigma-Aldrich) at confluence of approx. 70%. The cells were incubated at 37 ºC and 5% 
CO2 until harvested, which happened 4, 8, 16, 24, 32, 40 and 48 hours after transfection.  
Harvest was performed by resuspendation of the cells in the IMDM complete medium 
followed by centrifugation for 3 minutes at 250 g and washing with sterile pre-heated PBS 
twice. Cells were frozen at –20°C until further use. 
3.4.5.16 In situ hybridization studies 
The adult mice were mated as described in chapter 3.4.5.2. Embryos at the embryonal 
stage E9.5, E10.5, E14.5 and E16.5 were collected from pregnant CD-1 female mice and 
fixed in 4% PFA as described in chapter 3.4.5.6. Embryos at the age of E9.5 and E10.5 were 
processed in both whole mount and paraffin sections forms. The samples for whole mount 
method were frozen in methanol at -20°C straight after PFA fixation. Whole embryos at the 
two earlier stages and heads of the latter two used for ISH on sections, were dehydrated, 
embedded in paraffin, cut to 7 µm sagittal sections and rehydrated as described in standard 
protocols (Wilkinson D. G. and Nieto M. A., 1993). Tissue hydration, proteinase K treatment, 
acetylation and the pre-hybridization procedures were performed with DEPC water as 
described previously (Wilkinson D. G. and Nieto M. A., 1993). The hybridization was 
performed with DIG labelled probes diluted in the hybridization buffer (1.25X saline-sodium 
citrate, pH 7.0, 50% formamide, 0.1% Tween-20, 100X Denhardt´s solution, heparin (50 
µg/ml), tRNA (50 µg/ml), salmon sperm DNA (50 µg/ml)) overnight at 70°C. Samples were 
developed using anti-DIG antibody conjugated with alkaline phosphatase and BM purple 
alkaline phosphatase substrate precipitating solution (Roche). Prior imaging on Zeiss 
ApoTome microscope, all the samples were post-fixed with 4% PFA and the slides were in 
addition mounted in Aquatex. ISH experiments were performed by Monika Sivá and 
Michaela Procházková. 
Probes for specific recognition of murine Ddi1 mRNA and control sense probes were 
designed from the coding sequence of mDdi1 (NM_027942.1), which was synthetized by 
GenScript (New Jersey, USA) and ligated into pCR™-Blunt vector using Zero Blunt® 
Cloning® Kit (Invitrogen) according to manufacturer´s instructions. Two sequences were 
amplified for preparation of two anti-sense and two corresponding sense probes with 
following primers: for Ddi1 probe set No.1 with length 1018 bps, Ddi1_F_AS1 and 
Ddi1_R_AS1 and for Ddi1 probe set No.2 with length 993 bps, Ddi1_F_AS2 and 
Ddi1_R_AS2. The amplification and PCR product purification were performed similarly as 
described in chapter 3.4.1.1. Both sequences were cloned individually into pGEM-T® easy 
plasmid (Promega) for blue/white colony selection and the white colonies were picked and 
cultivated as described in chapter 3.4.1.2 by our collaborator Michaela Procházková at the 
CCP at IMG CAS. Glycerol stocks were prepared from 225 µl of sterile 80% glycerol and 1 
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ml of LB broth with certain bacterial clone and stored at -80°C, the rest was purified with 
QIAprep Spin Miniprep Kit (QIAGEN) and sequenced by GATC Biotech (Konstanz, 
Germany).  
The plasmid DNAs containing correct Ddi1 sequences were used for synthesis of 
probes. First, the DNA was amplified by bacteria cultivation in 100 ml of LB media with final 
concentration of ampicillin 100 µg/ml inoculated with bacterial glycerol stock and plasmid 
DNA purification as described in chapter 3.4.1.2. For preparation of anti-sense probes or 
control sense probes, 10 µg of both plasmid DNAs were digested with either SacII or SalI 
endonuclease, respectively. The restriction enzyme DNA cleavage was performed by 
incubation at 37°C for at least two hours in a mix relevant for the specific endonuclease as 
instructed by the manufacturer. Sequences of antisense probes are shown in Table 3 below.    
Table 3: Sequences of anti-sense probes for ISH 







































Each probe was prepared by in vitro transcription, which was performed in a mix 
containing 4 µl of 5x Transcription buffer, 2 µl 100 mM DTT, 2 µl of DIG RNA labeling 
mix, 1 µl RNase inhibitor, 2 µl relevant RNA polymerase, 1 µg of linearized DNA template 
and addition of sterile RNase-free water up to 20 µl (components of DIG RNA Labeling Kit 
(SP6/T7) from Roche). The mixture was incubated at 37°C for 4 hours and the probes were 
purified using RNeasy Mini Kit (QIAGEN) according to the RNA cleanup protocol. 
Concentration of each probe was measured on NanoDrop ND-1000 spectrophotometer 
(Thermo Scientific). 
Sp6 RNA polymerase was used for synthesis of anti-sense probes from the two DNA 
templates linearized by SacII endonuclease. T7 RNA polymerase was used for sense probes 
synthesis after linearization by SalI endonuclease. All four probes were used for ISH, 
however only data from probe Ddi1 AS1 are shown in Figure 13 in chapter 4.2.1.  
3.4.5.17 Phenotyping of adult mice 
Phenotyping of adult mice of both Ddi2tm1b (C57BL/6NCrl-Ddi2tm1b(EUCOMM)Hmgu/Ph) 
and Ddi2protease defective (C57Bl/6NCrl-Ddi2em1/Rase) strains was performed at the CCP hosted 
by IMG CAS according to the international mouse phenotyping consortium (IMPC) pipeline 
workflow and standard operating procedures (for workflow see Scheme 1 below). Jan 
Procházka was in charge of the phenotyping team, Monika Sivá assisted during sample 
uptake of Ddi2protease defective strain mice. 
 
Scheme 1: Pipeline workflow according to the international mouse phenotyping consortium. 
Adapted from https://www.mousephenotype.org/impress/procedures/44 (cited on February 20th 2019) 
(IMPC). 
For phenotyping screen of Ddi2tm1b strain, a cohort of 7 Ddi2+/- males and 8 Ddi2+/- 
females was used. The mice were studied for body composition and weight, behavioral tests, 
cardiovascular and lung function tests, glucose metabolism (IpGTT), hematology and 
biochemistry, gross pathology and histology after termination. The values and results were 
compared to results of phenotyping of a large (over 200 mice) C57Bl/6Ncrl cohort housed at 
the same facility. 
Ddi2protease defective strain mice (8 of each sex and genotype available for adult mice) at 
the age of 16 weeks were subjected to screening of glucose metabolism (IpGTT), 
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biochemistry, hematology, gross pathology and histology. The results for Ddi2exon6 +/- mice 
were compared with the values of Ddi2exon6 +/+ and C57Bl/6Ncrl in-house WT mice.  
3.4.5.18 Mapping of Ddi2 expression using LacZ staining 
Embryos at the embryonal stage E9.5, E12.5, E14.5 and E17.5 were harvested (as 
described in chapter 3.4.5.6) from pregnant C57Bl/6Ncrl female mice mated with Ddi2tm1b +/- 
males or from Ddi2tm1b heterozygous crosses.  
Embryos for whole mount staining were first fixed in 4% PFA for 30 minutes and 
subsequently rinsed in 1 M phosphate buffer pH 7.5, 0.5 M EGTA, 0.01% sodium 
deoxycholate, 2 mM MgCl2, and 0.02% Nonidet P-40 three times for 10 minutes. Whole 
embryos were immersed in X-gal staining solution (0.1 M phosphate buffer pH 7.5, 0.02% 
Nonidet P-40, 0.01% sodium deoxycholate, 5 mM potassium ferricyanide, 5 mM potassium 
ferrocyanide, 2 mM MgCl2 and 1mg/ml X-Gal (Thermo Fisher Scientific)) and stained 
overnight at 37°C in dark. Embryos were then rinsed in PBS and post-fixed in 4% PFA prior 
imaging.  
Embryos intended for cryo-sections were embedded in 30% sucrose/PBS overnight, 
frozen in OCT and cut to 10 µm sagittal sections according to CCP in-house standard 
operating protocols and frozen until staining. Sectioning was performed by embryology unit, 
CCP. Slides were washed in 1 M phosphate buffer pH 7.5, 0.5 M EGTA, 0.01% sodium 
deoxycholate, 2 mM MgCl2 0.02% Nonidet P-40 for 10 minutes each. Staining was 
performed overnight at 37°C in dark in identical solution as used for whole-mount staining. 
Slides were washed in PBS, post-fixed in 4% PFA for 10 minutes and washed twice in PBS 
for 10 minutes. Slides were then counter-stained with Nuclear Fast Red (Sigma-Aldrich), and 
mounted in Aquatex. Staining and imaging on Zeiss AxioImager Z2 (sections), Zeiss 
AxioScan Z1 (sections) and Zeiss AxioZoom with Apotome module macroscope (whole 












































































































This dissertation represents part of a comprehensive study performed in the laboratory 
of Dr. Grantz Šašková, focusing on revealing the biological role/s of Ddi1-like protein family. 
The author, Monika Sivá, has contributed with her work to several ongoing projects: 
structural study of Ddi1p of S. Cerevisiae (chapter 4.1.2), interaction studies of human DDI2 
protein using NMR spectroscopy (chapter 4.1.3), expression profiling of murine homolog 
Ddi1 in developing brain (chapter 4.2.1) and characterization of two diverse Ddi2-deficient 
mouse models (chapters 4.2.2). The thesis is therefore divided into two main chapters 
focusing on the study of Ddi1-like proteins on molecular level (Chapter 4.1.) and Ddi1-like 
proteins in biologically relevant models (Chapter 4.2). Combined together, the results from 
both perspectives will pave the way to the overall understanding of the biological roles played 
by members of Ddi1-like protein family. 
 
 
4.1 CHARACTERIZATION OF DDI1-LIKE PROTEINS ON MOLECULAR LEVEL 
Ddi1-like proteins throughout the eukaryotes exhibit high level of conservation in 
domain organization and structural features, as briefly discussed in the introduction chapter 
1.3 on page 47. Sequence alignments of proteins of Ddi1-like family that are part of this study 
are shown in Figure 7A. All the hereby-studied proteins exhibit high sequence identities in 
the N-terminal UBL and central RVP domains, even though yDdi1p shows only around 35% 
sequence identity with each of the four mammalian orthologs individually. The high sequence 
identity applies as well to the HDD domain region preceding the RVP of the human and 
mouse orthologs, based on high residue identity with the hDDI2 HDD and on secondary 
structure predictions of the latter (data not shown). The overall identity of the full-length 
mammalian proteins is quite high, hDDI2 shares 72% of identical residues with hDDI1, and 
71% with the murine Ddi1 homolog, which both seem to lack the C-terminal UIM motif (see 
Figure 7A). Murine Ddi2 harbors the UIM sequence and interestingly, it shares 96% sequence 
identity with hDDI2, thus supporting the use of Ddi2 knockout mice as appropriate model for 
studying biological function of hDDI2. The overall high conservation of the domain 
architecture suggest more or less conserved function/s of the proteins, which are being 
elucidated further. Constructs of the recombinant proteins and synthesized peptides used in 
this work are depicted in Figure 7B. 
 
Figure 7: Ddi1-like protein family members studied in this thesis. A) Sequence alignment of 
Ddi1-like proteins from S. cerevisiae, H. sapiens and M. musculus. Highly conserved domains are 
distinguished by color: N-terminal ubiquitin-like domain (UBL) in green, helical domain of Ddi1-like 
proteins (HDD) in blue, retroviral protease-like domain (RVP) in red and C-terminal ubiquitin-associated 
domain (UBA) in violet. Very well conserved area of helical domain of Ddi1-like proteins is underlined. 
Catalytic active site residues inside the RVP domains are highlighted in bold. C-terminal 
ubiquitin-interacting motif (UIM) is in bold letters. Sequence encoded by exon 6 in mouse Ddi2 protein is 
shown in black rectangle. All sequence identity calculations were performed in Clustal Omega online tool 
(Chojnacki S. et al., 2017). B) Schematic picture of protein constructs and peptide sequences used in this 
work. Individual domains are distinguished by color, UIM is represented as a blue zig-zag at the C-terminus. 
N-terminal histidine tag of proteins cloned into pET16b expression vector are colored in blue. mDdi2 WT 
and mDdi2PD proteins were cloned into two vectors, p905 and pTreTight with His-tag and FLAG-tag at 
N-terminus showed in green. 
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4.1.1 Individual domains of Ddi1-like protein family members display 
high structural conservation 
The conservation of Ddi1-like protein family members shown in sequence alignment 
in Figure 7A clearly designates the structure of individual members to be alike. Therefore, 
structural alignment of individual domains of all hereby-studied Ddi1-like proteins was 
performed using structures that were either solved in our laboratory (including yDdi1 UBL 
solved by Monika Sivá, see following chapter) or that are available in PDB. Superimposition 
of the UBL domains of yDdi1 and mDdi1 to hDDI2 shown in Figure 8A, revealed RMSD 
for backbone 1.22Å and 1.34Å, respectively. As apparent from both sequence and structure 
alignments (Figure 8B), the similar region of hDDI2 HDD and yDdi1 HDD is represented by 
the four helix bundle (in case of yeast ortholog at the N-terminal residues 89 – 141),  
 
Figure 8: Ddi1-like proteins have highly conserved domain architecture among species. A) 
Ubiquitin fold is very well conserved among the UBLs of hDDI2 (magenta, 2N7D), yDdi1p (cyan, 2N7E) 
and mDdi1 (yellow, 1V5O, unpublished). B) Superimposition of hDDI2 HDD (magenta, 5K57) with HDD 
of yDdip (cyan, 5KES). C) Superimposition of RVP domain structures from hDDI2 (magenta, PDB entry 
4RGH), Ddi1p (cyan, PDB entry 4Z2Z) and hDDI1 (wheat, PDB entry 3S8I, unpublished). D) Solution 
structure of UBA domain of yDdi1p (PDB entry 2MR9). Structures adapted from (Nowicka U., et al., 2015, 
Siva M., et al., 2016, Trempe J. F., et al., 2016). Superimpositions and RMSD calculations were performed 
in program PyMOl (Schrodinger, LLC, 2015). 
displaying RMSD of 2.96Å in superimposition (Siva M., et al., 2016, Trempe J. F., et al., 
2016). The HDD of yDdi1p harbors additional two helices at its C-terminus compared to 
hDDI2 HDD. RVP domains exhibit remarkable conservation in the structured parts, the 
β-sheets and α-helices, the only difference is in the unstructured loops (flaps) covering the 
active site cavity, caused by their flexibility (see Figure 8C) (Siva M., et al., 2016, Trempe J. 
F., et al., 2016). The yDdi1 RVP and hDDI1 RVP superimposed to the hDDI2 RVP with 
RMSD of the backbone residues of 0.7Å and 0.35Å, respectively. Figure 8D shows the 
3-helix bundle representing the UBA of yDdip, the primary ubiquitin interaction site, which 
is not present in the human and mouse orthologs (Nowicka U., et al., 2015). 
Overall, the structural superimposition of individual domains revealed almost 
identical fold in case of RVP and UBL domains and highly similar fold for the four helical 
bundle of HDD. Based on these results, we decided to compare also functional properties of 
these domains on molecular level. Part of the analyses, performed specifically by Monika 
Sivá, is described in detail in following chapters. 
4.1.2 Structural characterization of ubiquitin-like domain of Ddi1 from 
S. cerevisiae 
The structure of Ddi1 UBL from baker´s yeast was solved using nuclear magnetic 
resonance. Protein construct encoding the yDdi1 UBL domain (residues 1-80), was cloned 
in-frame with N-terminal histidine tag (for the construct sequence see Figure 7 on page 100). 
The protein was expressed with yields of 1.67 mg and 1.12 mg per liter of medium for 
15N-labeled and 13C/15N-labeled protein, respectively. 
Proper folding of the protein construct was verified with acquisition of 1D HSQC 
spectrum. Nearly complete 15N, 13C and 1H-resonance assignments were acquired for yDdi1 
UBL with N-terminal histidine tag and the structure was solved with high precision. A family 
of 43 converged structures was obtained with the RMSD to the mean structure at the ordered 
residue range (residues 1-78) for the backbone and heavy atoms 0.41Å and 0.81Å, 
respectively. The yeast Ddi1 UBL contains four β-sheets (β1:13I-19V, β2: 1M-7N, β3: 
70L-75G, β4: 43H-46Y), one α-helix (25L-35D) and a 310-helix (60L-63L) as shown in 
Figure 8A. Despite its low sequence identity with ubiquitin (23.61% according to program 
Clustal Omega) (Chojnacki S., et al., 2017), it adopts the ubiquitin fold (see Figure 9A, B and 
C). The β-sheet patch (Figure 9A) could serve as a potential interaction site as we further 
discuss in our publication Trempe et al., 2016 (Trempe J. F., et al., 2016). NMR constraints 
and structural statistics for the yDdi1 UBL domain are summarized in Table 4 below.  
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Figure 9: Solution structure of ubiquitin-like domain of Ddi1p from S. cerevisiae. Adapted from 
(Trempe J. F., et al., 2016). A) Solution structure of yDdi1 UBL (PDB entry 2N7E) bears ubiquitin fold. 
Resonance assignments were carried out manually in program Sparky (Goddard T. D. a. K., D. G. , 2008), 
calculations were carried out in programs Cyana 2.1 (Herrmann T., et al., 2002), TALOS+ (Shen Y., et al., 
2009) and YASARA forcefield. B), C) Superimposition of yDdi1-UBL with human ubiquitin (PDB entry 
1D3Z) from two different views (Cornilescu G., et al., 1998). Structure drawing and alignment was 
performed in program PyMOL (Schrodinger, LLC, 2015). 
 
Table 4: NMR constraints and structural statistics for yDdi1 UBL. Adapted from (Trempe J. F., et al., 
2016). 
Non-redundant distance and angle constrains  
Total number of NOE constraints 1634 
Short-range NOEs (i, i+1) 880 
Medium-range NOEs (i,i>1 i≤4) 290 
Long-range NOEs (i, i ≥5) 464 
Tosion angles 128 (64 and 64  
Total number of restricting constraints 
per restrained residue 
20.7 
Maximum constraints violations and r.m.s  
Upper distance limits (Å) 0.07 ±0.02 0.0019 ±0.0005 
Van der Waals contacts (Å) 0.14 ±0.02  
Torsion angle ranges (°) 3.71 ±0.22 0.475 ±0.036 
Average CYANA target function (Å2) 0.17 ±0.02 
Ramachandran plot 
 Residues within the most favoured region 86% 
 Residues within the additionally allowed region 14% 
 Residues within generously allowed region 0% 
 Residues within the disallowed region 0% 
r.m.s.d. to the mean structure ordered 100-177 all residues 
Backbone heavy atom (Å) 0.41 ± 0.06 1.71 ± 0.37 
All heavy atom (Å) 0.81 ± 0.07 
2.07 ± 0.36 
 
4.1.3 Characterization of human DDI2 binding properties 
4.1.3.1 DDI2 and its interaction with ubiquitin 
To investigate the function of human DDI2 as an adaptor protein in the 
ubiquitin-proteasome system, in line with the published functional studies of the yeast Ddi1 
ortholog, a series of hDDI2 - ubiquitin interaction experiments were performed using NMR. 
I focused on a detailed evaluation of two possible UBQ binding sites of human DDI2 protein: 
a UIM motif at the C-terminus identified by us (Siva M., et al., 2016)and a UBL at the 
N-terminus that was previously described for the yeast Ddi1 UBL domain as an alternative 
UBQ binding site (Nowicka U., et al., 2015). 
First, titration experiments with 15N-labeled ubiquitin and hDDI2-UIM peptide 
(residues 376-395 of human DDI2; see Figure R7A and B, page 100) were performed where 
a 35-fold molar excess of the peptide (final concentration of the hDDI2-UIM peptide was 
3.45 mM) was reached as shown in Figure 10A. Chemical shift perturbation of individual 
amino acids were plotted at the endpoint of the titration (Figure 10D) and the residues with 
most significant shifts were zoomed in in the spectra overlay in Figure 10A. The Kd of 
2.2-3.3 mM was calculated from 6 residues (K6, A46, G47, Q49, H68 and L71) with a 1:1 
stoichiometry model for specific binding (Figure 10C) which were mapped onto the structure 
of ubiquitin (PDB entry 1D3Z, (Cornilescu G., et al., 1998))in Figure 10B. Based on these 
and other additional CSPs identified in this experiment (L8, R42, K48), we concluded that 
the interaction site differs from the common Isoleucine 44 interaction patch on ubiquitin 
(Bertolaet B. L., et al., 2001, Sloper-Mould K. E., et al., 2001).  
To verify the specificity of the interaction of hDDI2-UIM peptide with UBQ, a similar 
experiment was performed with hDDI2-scrambled UIM peptide (for sequence see Figure 7, 
page 100). In the titration experiment, 1.9 mM final concentration of the hDDI2-scrambled 
UIM peptide was reached with no CSPs observed. The plot of CSPs for a 2.2 mM addition 
of hDDI2-UIM peptide and a 1.9 mM addition of the control hDDI2-scrambled UIM peptide 
(see Figure 10E) reveals the difference and confirms the specificity of the weak interaction 
between UBQ and the UIM sequence at the C-terminal end of hDDI2 protein.  
Furthermore, we wanted to investigate this UBQ/hDDI2-UIM peptide interaction on 
a protein level, using more appropriate model. CSPs experiment with a 15N-labeled ubiquitin 
with a 1-, 2- and 5-molar excess of a non-labeled hDDI2 RVP full-C protein construct 
(residues 212-399; see Figure 7) and a reverse experiment with 15N-labelled hDDI2 RVP 
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full-C and non-labelled UBQ were performed. In the first titration, weak, yet specific changes 
for amino acids T7, R42, K48, Q49 and L71 (see Figure 10F, G and H) were observed, 
Figure 10: Characterization of interaction between ubiquitin and C-terminal UIM of human DDI2 
protein using NMR spectroscopy. Adapted from (Siva M., et al., 2016). A) Overlay of 2D HSQC spectra 
of ubiquitin acquired during titration with hDDI2-UIM peptide (individual additions of peptide are 
distinguished in color). B) Mapping of amino acids with most significant shifts in amide signals on UBQ 
structure (Cornilescu G., et al., 1998). C) Titration curves of ubiquitin residues with largest CSPs upon 
interaction with hDDI2-UIM peptide. D) Plot of chemical shift perturbations of individual amino acids at 
35-fold molar excess of hDDI2-UIM peptide. E) Plot of CSPs of ubiquitin residues at addition of hDDI2-
UIM peptide up to final concentration of 2.2 mM (blue) and of hDDI2-scrambled UIM peptide up to 1.9 
mM (red). F) 2D HSQC spectra of 15N-labeled UBQ (blue) with 5-fold molar addition of non-labeled 
hDDI2 RVP full-C (red). G) Mapping of most significant shifts of UBQ residues (PDB entry 1D3Z) 
(Cornilescu G., et al., 1998) upon interaction with non-labeled hDDI2 RVP full-C. H) Very weak, however 
specific CSPs of UBQ backbone amide signals upon interaction with hDDI2 RVP full-C. I) Reverse 
mapping of the interaction on 2D HSQC spectra of 15N-labeled hDDI2 RVP full C (blue) with 5-fold molar 
addition of non-labeled UBQ (red). J) Plot of CSPs of the hDDI2-UIM sequence locus upon UBQ binding. 
Red crosses in CSP plots mark residues that could not be used for evaluation. The figure was created in 
programs GraphPad Prism and Pymol (GraphPad S., Schrodinger, LLC, 2015). 
which again suggests a different interaction site from the I44 patch on ubiquitin (Bertolaet B. 
L., et al., 2001, Sloper-Mould K. E., et al., 2001). In the reverse experiment, with 1-, 2- and 
5- fold molar addition of UBQ, the CSPs in the backbone signals for residues of the hDDI2 
RVP full-C were mapped onto the UIM sequence at the C-terminus of hDDI2 as shown in 
Figure 10I and 10J, which confirms the previous results of the UBQ/hDDI2-UIM peptide 
interaction. 
Next, I focused on detailed evaluation of the second possible ubiquitin binding site. 
According to Nowicka and colleagues, yDdi1 UBL domain from S. cerevisiae binds ubiquitin 
(Nowicka U., et al., 2015). This surprising finding led our team to speculation about an 
alternative shuttle mechanism performed by yDdi1p and human DDI1 and DDI2 proteins. 
Therefore, NMR titration experiments with 15N-labeled hDDI2 UBL and up to 10-fold molar 
addition of non-labeled UBQ (Figure 11A, p XX) were performed to decipher the possibility 
of UBQ/hDDI2 UBL interaction. CSPs were plotted for individual amino acids (Figure 11D) 
and the most significant perturbations were mapped onto the structure of hDDI2 UBL as 
shown in Figure 11B (PDB entry 2N7D, (Siva M., et al., 2016)). C7, V8, T16, F17, V21, 
F25, F30, Q46, D70 and I73 chemical shifts were used for calculation of the Kd, which 
resulted in the 0.42-1.1 mM range (Figure 11C). The reverse titration experiment with 
15N-labeled UBQ and 6-fold molar addition of non-labeled hDDI2 protein lacking UIM 
peptide at the C-terminus (hDDI2 ∆UIM; for sequence see Figure 7B, page 100) revealed the 
interaction site on UBQ (Figure 11E - G). The interaction was mapped onto the Isoleucine 44 
patch as shown on the UBQ structure in Figure 11F (PDB entry 1D3Z, (Cornilescu G., et al., 
1998)). To verify the localization of the interaction, additional control experiment with a 
6-fold molar addition of hDDI2 protein lacking both N-terminal UBL domain and C-terminal 
UIM (hDDI2 HDD-RVP; for construct see Figure 7, page 100) to ubiquitin was performed. 
No significant chemical shift perturbations in the backbone amide signals of UBQ were 
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observed (Figure 11H and I), proposing very weak interaction of the hDDI2 UBL with UBQ 
as opposed to the yeast Ddi1 UBL/UBQ interaction (Nowicka U., et al., 2015). 
 
Figure 11: Characterization of UBQ – hDDI2 UBL interaction using NMR spectroscopy. 
Adapted from (Siva M., et al., 2016). A) 2D HSQC titration spectra overlay of 15N-labeled hDDI2 UBL 
with up to 10-fold molar addition of non-labeled UBQ (individual additions of UBQ are distinguished in 
color). B) Mapping of the UBQ interaction site on hDDI2 UBL structure (PDB entry 2N7D) (Siva M., et 
al., 2016) in red. C) Titration curves of shifts of hDDI2 UBL amino acids, that were used for Kd calculation. 
D) Plot of CSPs in hDDI2 UBL residues at the endpoint of titration with UBQ. Red crosses mark residues 
that could not be used for evaluation. E) 2D HSQC titration spectra of 15N-labeled UBQ prior (blue) and 
after addition of 6-fold molar excess of non-labeled hDDI2 ∆UIM protein construct (red). Signals of amides 
of most shifted amino acids are zoomed in and F) mapped onto the structure of UBQ (PDB entry 1D3Z) 
(Cornilescu G., et al., 1998). G) Plot of CSPs of UBQ residues upon interaction with hDDI2 ∆UIM.  H) 
No significant chemical shift perturbations were observed in 2D HSQC spectra of 15N-labeled UBQ (blue) 
upon 6-fold molar addition of hDDI2 HDD-RVP (red) lacking the N-terminal UBL domain and C-terminal 
UIM motif. I) Plot of CSPs of backbone amides of UBQ upon addition of hDDI2 HDD-RVP. Red crosses 
in CSP plots mark residues that could not be used for evaluation. Amino acids that could not be used in 
mapping on protein structures are colored in black. The figure was created in programs GraphPad Prism 
and Pymol (GraphPad S., Schrodinger, LLC, 2015). 
4.1.3.2 Investigation of possible intramolecular interactions of hDDI2 
To compare the binding properties of UBL domain of human DDI2 with the yeast 
Ddi1 UBL, we acquired and superimposed 2D HSQC spectra of 15N-labeled full-length 
hDDI2 protein and its UBL domain itself. We observed quite significant shifts in the 
backbone amide signals of the hDDI2 N-terminus (see Figure 12A), which clarifies the 
positioning of the hDDI2 UBL domain inside the full-length protein dimer. In contrast to the 
yDdi1 UBL domain localization as described by Nowicka and her colleagues (Nowicka U., 
et al., 2015), the UBL domain of hDDI2 does not extend out of the protein body. 
 
Figure 12: Examination of intramolecular interactions of hDDI2 protein using NMR 
spectrometry. Adapted from (Siva M., et al., 2016). A) hDDI2 UBL does not extend away from the body 
of the hDDI2 protein. 2D HSQC spectra of hDDI2 UBL (blue) superimposed with the 2D HSQC signals of 
the full-length protein (green) show differences in signals of the UBL, suggesting a rather compact structure 
for the full-length protein. The few amino acids lacking the difference are marked with red circles. B) The 
N-terminal UBL domain of hDDI2 does not bind C-terminal UIM peptide derived from hDDI2 protein. The 
overlay of 2D HSQC spectra of full-length hDDI2 protein (green) with 2D HSQC spectra of hDDI2 ∆UIM 
(red) does not reveal shifts in the signals of UBL domain. C) 2D HSQC spectra of hDDI2 UBL before 
 109 
(blue) and after addition of the UIM peptide derived from the hDDI2 C-terminus (red) with final 1.9 mM 
concentration. D) Plot of CSPs after addition of hDDI2-UIM peptide (blue) and after addition of the 
hDDI2-scrambled UIM peptide (red) to a final concentration of 1.2 mM. The figure was created in programs 
GraphPad Prism and Pymol (GraphPad S., Schrodinger, LLC, 2015). 
The possible intramolecular interaction of the N-terminal UBL domain with the 
C-terminal UIM motif of hDDI2 was further investigated. First, 2D HSQC spectra of 
15N-labeled full-length hDDI2 were acquired and superimposed with the 2D HSQC spectra 
of the truncated hDDI2 ∆UIM, where no difference was observed for the backbone amide 
signals for the UBL domain (see Figure 12B). NMR titration experiments with 15N-labeled 
hDDI2 UBL domain with hDDI2-UIM peptide up to a final concentration of 1.9 mM were 
performed and revealed slight shifts in the backbone amide signals of UBL residues (see 
Figure 12C). However, a negative control experiment with addition of 1.9 mM hDDI2-
scrambled UIM peptide resulted in the identical CSPs (Figure 12D). This suggests that hDDI2 
UBL most likely does not bind to the UIM motif and so the full-length protein does not adopt 
a head-to-tail conformation. 
In summary, our NMR titration studies revealed weak, yet specific ubiquitin 
interaction motif (UIM) at the C-terminus of human DDI2 protein and similarly very weak 
interaction of hDDI2 UBL with ubiquitin as opposed to yDdi1 UBL binding properties to 
ubiquitin. Based on our results, human DDI2 UBL does not extend from the “protein body” 
unlike its yeast counterpart and the full-length DDI2 protein never adopts a head-to-tail 
conformation, employing RVP domain as a central dimer interface and enclosing N-terminal 
UBL with C-terminal UIM in an autoinhibitory mode. This led us to conclusion that although 
yeast Ddi1 and human DDI2 proteins are structurally highly similar, at least some of the 
functional properties are not preserved and the proteins could differ in their biological roles.   
4.2 INVESTIGATION OF THE ROLE OF DDI1-LIKE PROTEINS USING 
BIOLOGICAL SYSTEMS 
In order to decipher biological role/s played by Ddi1-like proteins, we decided to use 
mouse models due to their experimental feasibility and based on their high sequence 
conservation when compared to human Ddi1-like proteins. 
Mice possess two homologs of Ddi1-like genes. Ddi2 (ENSMUSG00000078515, 
NCBI ID: 68817) is localized on the reverse strand of chromosome 4 
(141,677,549-141,723,419), has one 10-exon transcript (ENSMUST00000102484.4, 
NM_001017966.2) and encodes a 399-residue long protein (A2ADY9, NP_001017966.1). 
Ddi1 (ENSMUSG00000047619, NCBI ID: 71829) (Ensemble release 95) is localized on the 
reverse strand of chromosome 9 (6,262,733-6,269,846) and encodes only one exon 
(ENSMUST00000051706.5, NM_027942.1) of a 408-residue protein (Q9DAF3, 
NP_082218.1) (Geer L. Y., et al., 2010, The UniProt C., 2017, Zerbino D. R., et al., 2018). 
These two homologs share 71% sequence identity (Chojnacki S., et al., 2017). As already 
mentioned in the introduction to Ddi1-gene family, Ddi1 was generated from the original 
Ddi2 gene as a copy via retrotransposition event during evolution (see chapter 1.3) (Siva M., 
et al., 2016).  
Only scarce data is available on the expression of Ddi1 and Ddi2 in M. musculus. 
While Ddi2 is quite ubiquitiously expressed, Ddi1 was found only in testes of adult mice. In 
this work we show and comment specific expression of Ddi1 in developing embryonic brain, 
which – in context with other observations described in our publication (Ramirez J., et al., 
2018) - sheds light on its possible physiological function. Murine Ddi1 and Ddi2 proteins 
share 81% and 96% sequence identity with human DDI1 and DDI2 proteins, respectively 
(Chojnacki S., et al., 2017) (sequence alignment in Figure 7 on page 100). This further 
supported our choice to use mouse as a suitable model for studying the function of human 
DDI2 gene on its closest homolog. In order to do so, two mouse models were established, a 
full knockout of Ddi2 and a protease domain defective model. Generation of these models, 
allele characterization and phenotyping screen together with expression studies of Ddi1 are 
described in detail in following chapters. 
4.2.1 Investigating the possible biological role of human Ddi1 protein 
Our collaborators from the laboratory of Dr. Ugo Mayor have identified hDDI1 as 
a substrate of UBE3A in human neuroblastoma SH-SY5Y cells that is highly ubiquitinated 
without being targeted to the proteasome. Moreover, they found out that mDdi1 expression 
rises rapidly at a specific stage of mouse embryonal development, E16.5 (Ramirez J., et al., 
2018). To better understand the function of mDdi1 as a highly specifically expressed gene 
(similarly to hDDI1), we performed Ddi1 expression analysis by in situ hybridization in the 
developing brain of CD-1 mouse embryos. We focused on 4 different developmental stages 
– E9.5, E10.5, E14.5 and E16.5. As can be seen in Figure 13A-D, Ddi1 is expressed in all 
parts of the developing brain (telencephalon, diencephalon, mesencephalon and 
rhombencephalon) at the stage E9.5 and E10.5 as shown by both whole mount ISH or on 
sagittal sections. Throughout later developmental stages, the expression localizes more into 
mesencephalic and telencephalic structures. At stage E14.5, the signal for Ddi1 mRNA 
cumulates in the upper hill (colliculus tectum) and ventricular zone of pallium  
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Figure 13: Spatial expression profiling of Ddi1 gene in mouse brain during embryonal development. 
Adapted from (Ramirez J., et al., 2018). A) and B) Ddi1 is expressed in all parts of developing brain 
(telencephalon, diencephalon, mesencephalon and rhombencephalon) at embryonal stage E9.5 as shown on 
a whole mount and section ISH. The same pattern can be seen at stage E10.5 again for whole mount (C)) 
and for sagittal sections (D)). E) Sagittal section of embryonal brain at stage E14.5: Expression of Ddi1 is 
situated in pallial part of telencephalon (F) detail of pallium) and colliculus midbrain tectum (G) midbrain 
and hindbrain detail). H) and I) Specific expression of Ddi1 in isocortex and ventricular layer of olfactory 
bulb at stage E16.5. J) Detail of scan I: red stars highlight tubular structures, probably capillaries. 
K)  Negative control whole mount ISH staining with a Ddi1 sense probe at embryonal stage E9.5. 
L)  Non-specific background signal for Ddi1 sense probe is slightly increased at E10.5 for whole mount 
ISH. M) and N) Negative control ISH firmly confirms the specificity of Ddi1 expression studies performed 
on sagittal sections at stages E14.5 and E16.5, respectively. Abbreviations: T – telencephalon, D – 
diencephalon, M – mesencephalon, R – rhombencephalon, C – cerebellum, CMT – colliculus midbrain 
tectum, TL – thalamus, P – pallium, SP – subpallium, HT – hypothalamus, BG – basal ganglia, OB – 
olfactory bulb, IC – isocortex, NC – nasal cavity. 
(see Figure 16E-G). According to our collaborators, the expression of Ddi1 in mouse 
embryonal brain reaches the highest level at stage E16.5 (Ramirez J., et al., 2018). The 
expression at this stage is localized in the ventricular layer and cortical plate of isocortex and 
the ventricular layer of olfactory bulb, while all these structures develop from telencephalon 
(see Figure 13H-J). As was suggested in (Ramirez J., et al., 2018), the expression could be 
situated in the neuroblast cells that undergo division and migration towards the external layer 
of isocortex.  
We have observed increase in false positive signal of sense probe used for whole 
mount ISH at embryonal stage E10.5 as shown in Figure 13L. However, this embryonal stage 
was not crucial for our findings. It was rather used for presentation of expression localization 
throughout brain development until the essential stage at E16.5, where the expression was as 
quantified by qPCR experiments (Ramirez J., et al., 2018). Negative controls at other 
embryonal stages did not show any unusual elevation of background signal for whole mount 
ISH at E9.5 and for ISH on sections at E14.5 and E16.5 (Figure 13K, M and N).  
Our expression profiling described the localization of the mDdi1 mRNA in the 
neuronal tissue of developing brain for the first time ever. In connection to the fact that hDDI1 
is a unique, highly ubiquitinated substrate of UBE3A ligase without being targeted for 
proteasomal degradation, our study contributed to the formulation of hypothesis that hDDI1 
specifically expressed in neuronal tissue (most probably also developing brain), might be of 
relevance in clinical research of Angelman syndrome. 
4.2.2 Deciphering the biological role of DDI2 using mouse models 
4.2.2.1 Introduction and nomenclature of our mouse models 
Full knockout strain, C57BL/6NCrl-Ddi2tm1b(EUCOMM)Hmgu/Ph mouse strain was 
created from original ES clone HEPD0660_5_E02, which belongs under The European 
Conditional Mouse Mutagenesis Program (EUCOMM) at the CCP hosted by IMG CAS. It 
records a loss of critical exon (exon2) of Ddi2 gene resulting in frame-shift (see Figure 14B 
and C) (for more details see chapter 4.2.2.2). This strain will be further named as Ddi2tm1b. 
Genotypes will be distinguished as Ddi2+/+, Ddi2+/- and Ddi2-/-.  
Ddi2 protease defective model C57Bl/6NCrl-Ddi2em1/Rase was generated at IMG CAS 
in the laboratory of Dr. Radislav Sedláček by TALEN-mediated excision of exon 6 of Ddi2 
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gene (em1/Rase) by Dr. Petr Kašpárek. This alteration of Ddi2 gene resulted in alteration of 
the protein product and hence loss of its proteolytic activity and dimerization capability (see 
Figure 14D). Further information is stated in chapters 4.2.2.3. C57Bl/6NCrl-Ddi2em1/Rase 
strain will be further named Ddi2protease defective model. Genotypes will be labeled as 
Ddi2exon6 +/+, Ddi2exon6 +/- and Ddi2exon6 -/-. The truncated protein construct is named mDdi2PD 
(standing for protease defective). 
 
Figure 14: Schematic diagram of Ddi2 gene alterations for generation of both mouse models, the 
Ddi2tm1b and Ddi2protease defective. A) Wild-type allele of murine Ddi2 gene consists of 10 exons. B) Scheme 
of Ddi2tm1a cassette inserted into ES cells for Ddi2 knockout mouse strain production. C) Scheme of 
Ddi2tm1b cassette resulting in a frame-shift transcription. D) TALEN-induced excision of exon 6 in Ddi2 
gene resulting in protease domain alteration of the transcribed protein. 
4.2.2.2 Generation of Ddi2tm1b strain and genotyping 
C57BL/6NCrl-Ddi2tm1b(EUCOMM)Hmgu/Ph mouse strain was generated at the IMG CAS 
using Ddi2tm1a(EUCOMM)Hmgu (further mentioned as Ddi2tm1a) embryonal stem cells which were 
created by ESCs manipulation. Heterozygous Ddi2tm1a (see Figure 14B) adult mice were 
crossed with homozygous mice bearing ubiquitous expression of Cre-recombinase 
(Gt(ROSA)26Sortm1(ACTB-cre,-EGFP)Ics). The offspring heterozygous for Ddi2 cassette and 
heterozygous for Cre-recombinase were further crossed with C57Bl/6NCrl to acquire F0 
generation of C57BL/6NCrl-Ddi2tm1b(EUCOMM)Hmgu/Ph.  
As shown in Figure 15A, critical exon 2 of Ddi2 gene was removed in this model, 
which creates a frame-shift and a null model. In contrast to Ddi2tm1a, the promoter-driven 
neomycin selection cassette was removed and Ddi2 exon 2 was replaced with LacZ reporter 
for visualization of gene expression. 
Genomic DNA for genotype estimation was extracted from tail biopsies collected at 
weaning or from yolk sac tissue collected at embryo harvest. Genotyping was designed to 
distinguish between wild-type Ddi2 gene (1080 bps) and exchange of exon 2 with a LacZ 
reporter (640 bps) using a set of three primers: one common reverse primer and two different 
forward primers, the first one targeting sequence inside Ddi2 that is cleaved out by Cre 
recombinase in Ddi2tm1b, and the other one complementary with sequence inside LacZ (Figure 
15A). Hence, it was possible to distinguish between wild-type, heterozygous and 
homozygous mice after one PCR reaction (Figure 15B).  
 
Figure 15: Ddi2tm1b strain: design and evaluation of the results. A) Wild-type allele of murine 
Ddi2 gene (close up on first three exons) and Ddi2tm1b gene scheme. Target sequences for primers designed 
for genotyping of Ddi2tm1b mouse strain are highlighted. B) Agarose gel showing genotyping results.  
4.2.2.3 Ddi2protease defective mouse strain generation by TALEN-mediated 
Ddi2 gene alteration and its genotyping strategy 
Ddi2protease defective (C57Bl/6NCrl-Ddi2em1/Rase) mouse strain was generated by Dr. Petr 
Kašpárek at IMG CAS using TALENs designed to target introns 5-6 and 6-7, which resulted 
in excision of exon 6 of Ddi2 gene (design and experiment described in detail in chapter 
3.4.5.1).  
Two independent microinjections into mouse zygotes were performed. 51 mice in F0 
generation were genotyped for nuclease-mediated alteration of Ddi2 gene (Figure 14D). Four 
founder mice (IDs: 21, 30, 33 and 38) bearing exon 6 deletion were identified. The deletion 
resulted in shortage of the gene in approx. 550 bps (depending on the non-homologous end 
joining in the intron sequence). Targeted area was sequenced for each founder mouse 
(individual sequences are shown in Figure 16A), which were further crossed with wild-type 
partner to gain F1 generation. All of these mice were able to reproduce, however, we found 
out that one of the founder mice (ID: 33), was not able to produce offspring with desired exon 
6 deletion, which meant that it did not bear Ddi2 alteration in the germline cells. As all the 
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remaining founders produced offspring with no obvious phenotype and with identical 
truncation of mRNA as a result of gene alteration, only offspring of founder 38 was selected 
for Ddi2protease defective colony establishment.  
Genomic DNA was acquired from tail biopsies collected at pup weaning or from yolk 
sac tissue collected at embryo harvest. Genotyping was performed as described in chapter 
3.4.5.4. Primers were designed to anneal with sequences of Ddi2 introns 5-6 and 6-7 outside 
the TALEN-targeted area. The PCR amplification product for wild-type allele was 1572 bp 
long and the allele with deletion of 550 base pairs (without exon6) resulted in 1072 bp length 
(see Figure 16B and C). Additional triplet of primers was used in nested PCR for 
determination of genotype of embryos under E9.5 or in cases of probable contamination by 
maternal sample as shown in Figure 16C. 
 
Figure 16: Ddi2protease defective strain: design of the TALEN-mediated Ddi2 alteration and 
genotyping strategy. A) Sequencing results of the TALEN-altered area of Ddi2 gene in four founder 
mice. B) Genotyping design of Ddi2protease defective strain. C) Agarose gel showing both first round PCR and 
two rounds of nested PCR required for genotyping of Ddi2protease defective mice. 
4.2.2.4 Ddi2 deficiency results in embryonic lethality 
Heterozygous Ddi2tm1b crossings failed to produce Ddi2-/- offspring, which reveals the 
embryonic lethality phenotype of Ddi2tm1b mouse strain. Ddi2-/- embryos show development 
retardation from E12.5 and die prior E14.5 as observed from timed harvest of embryos (see 
Figure 17A). Only one heavily retarded embryo with beating heart was harvested at E14.5 
(3 out of 4 Ddi2-/- embryos were already dead and undergoing resorption). No difference 
considering development timeline (normal number of somites at harvest on certain embryonal 
day) or retardation was observed for Ddi2-/- embryos prior stage E11.5 when compared to 
their Ddi+/+ or Ddi2+/- littermates. Heterozygous littermates develop normally and shown no 
obvious phenotype after birth or in adulthood under non-challenging conditions (see chapter 
4.2.2.7). 
Surprisingly, Ddi2exon6 -/- embryos from heterozygous Ddi2exon6 crossings die in earlier 
stage of development, prior to E12.5 (see Figure 17B, for comparison of two mouse knockout 
models see Figure 17C). This might be the result of failure of Ddi2 protein production in 
Ddi2-/- (data not shown) as opposed to the expression of modified version of mDdi2 protein 
in Ddi2exon6 -/- (see Figure 17D). The development of Ddi2exon6 -/- up to E9.5 stage is normal 
compared to the WT littermates, however their yolk sac shows diminished vascularization 
(see Figure 17E). Moreover, embryos of harvests at E10.5 and E11.5 exhibit excessive growth 
retardation in both placenta and embryo proper, they lack mandible and heart development is 
delayed, even though they are still alive (see Figure 17F). Prenatal and adult heterozygous 
mice show no obvious phenotype, which is further discussed in chapter 4.2.2.7. 
It is probable that the WT allele of Ddi2 is capable of compensation for the Ddi2-/- 
allele and the Ddi2exon6 -/- allele during embryonal development, as no anomalous phenotype 
was observed for heterozygous embryos.  
 
Figure 17: Ddi2 null and protease defective mice die during embryonal development. A) 
Table of embryo genotypes at different developmental stages of harvests from Ddi2+/- crossings. Ddi2-/- 
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embryos die prior E14.5. B) Table of embryo genotypes of timed harvests from Ddi2exon6 +/- crossings.  
Ddi2exon6 -/- embryos die at E12.5. C) Kaplan-Meier plot of survival of both Ddi2 mouse deficient models. 
D) Ddi2exon6 -/- embryos produce a protease defective protein mDdi2PD (∆254-296), however it seems this 
truncation destines the protein to rapid degradation. E) Fresh preparation of Ddi2exon6 -/- (down) embryo and 
placenta compared to the tissue of Ddi2exon6 +/+ (up) littermate at E9.5. F) Image of Ddi2exon6 -/- (down) 
embryo and placenta compared to Ddi2exon6 +/+ (up) littermate at E11.5 reveals retardation in the Ddi2exon6-/- 
fetus. Images of fresh preparation were acquired by Kallayanee Chawengsaksophak. 
4.2.2.5 Characterization of the mDdi2 protease defective protein  
To characterize the mDdi2PD (protease defective) protein construct expressed in 
Ddi2exon6 +/- and Ddi2exon6 -/- mice and to compare it with the mDdi2WT protein, mRNA was 
isolated from Ddi2exon6 +/+  and Ddi2exon6 -/- embryos at stage E9.5. Coding sequences of both 
proteins were amplified from cDNA and cloned into bacterial expression vectors p905 and 
pTreTight.  
Recombinantly expressed and purified proteins were tested for proper folding using 
1D NMR spectroscopy and differential scanning fluorimetry (DSF). As shown in Figure 18A, 
mDdi2WT and mDdi2PD protein 1D spectra correspond to proteins with acquired secondary 
structures. However, the DSF experiment revealed aggregation of the mDdi2PD protein, as no 
melting temperature peak could be detected contrary to the mDdi2WT (melting temperature 
was determined to 58.7 °C) (see Figure 18B).  
 
Figure 18: Characterization of mDdi2PD protein expressed in Ddi2exon6 +/- and Ddi2exon6 -/- mice. 
A) Overlay of 1D NMR spectra of mDdi2WT (blue) and mDdi2PD protein (red). B) Melting peaks of 
mDdi2WT (yellow) and mDdi2PD (grey) proteins show impaired folding/aggregation of the truncated protein 
version. C) HEK293offA2 cells are not able to acquire high level of overexpression of mDdi2PD protein 
compared to mDdi2WT. Cells transfected with pTreTight vector encoding mDdi2PD, mDdi2WT or an empty 
vector were harvested after 4, 8, 16, 24, 32, 40 and 48 hours. β-actin was used as a loading control. 
As shown in Figure 17D, we were able to detect mDdi2PD protein with anti-DDI2 
antibody recognizing the C-terminus of human DDI2 and its mouse ortholog, however only 
with very low signal just above background. We were not able to detect the mDdi2PD specific 
peptide in Ddi2exon6 +/- and Ddi2exon6 -/- embryo lysates in MS experiments (data not shown). 
We therefore tested how normal cells (HEK293offA2) cope with overexpression of the 
mDdi2PD protein construct. We transfected HEK293offA2 cells with mDdi2PD, mDdi2WT 
encoding or,  empty vector and harvested cells in triplicates at different time points - 4, 8, 16, 
24, 32, 40 and 48 hours after transfection. Interestingly, the increase in expression of the 
mDdi2PD protein was smaller when compared to mDdi2WT protein (see Figure 18C). Based 
on these studies, it seems mDdi2PD protein is partially misfolded in the RVP domain region 
after translation, it might form aggregates and be quickly degraded. 
4.2.2.6 Colony management for both Ddi2tm1b and Ddi2protease defective 
mouse strains 
Colony of Ddi2tm1b strain was established and common genotyping at weaning was 
performed by scientific staff of the IMG CAS; Ddi2protease defective colony was managed and 
genotyped by Monika Sivá (author). As both models result in embryonic lethality, 
heterozygous Ddi2+/- or Ddi2exon6 +/- mice were backcrossed with C57Bl/6NCrl wild-type 
mice for colony maintenance. Adult mice and embryos for phenotyping were collected from 
litter from heterozygote × heterozygote crossings. 
4.2.2.7 Adult mice phenotyping and Ddi2 expression studies 
The phenotyping of adult mice of both Ddi2-altered strains was mainly performed by 
our colleagues from Czech center for Phenogenomics hosted by the IMG CAS under the 
supervision of Jan Procházka. 
Ddi2tm1b strain mice were subdued to standard screening which follows the 
international mouse phenotyping consortium pipeline (IMPC). These tests did not show any 
obvious difference or abnormality of the Ddi2+/- mice. However, we observed problem in 
fertility in Ddi2+/- mice crossings, where the pairs often failed to conceive despite positive 
vaginal plug.  
Ddi2protease defective strain mice were subjected to smaller range screening of glucose 
metabolism (IpGTT), biochemistry, hematology, gross pathology and histology. No obvious 
phenotype features were observed in the adult Ddi2exon6 +/- mice when compared to 
Ddi2exon6 +/+ and C57Bl/6Ncrl in-house WT mice. 
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4.2.2.8 Expression of Ddi2 during embryonal development 
To better understand the lethal phenotype of Ddi2-/- and Ddi2exon 6 -/- embryos during 
their development, we performed a qPCR experiment for estimation of Ddi2 expression at 
the individual developmental stages and mapping of Ddi2 expression via lacZ reporter gene 
in the Ddi2+/- embryos. 
The Ddi2 mRNA levels are increased 2-fold at embryonic stage E9.5 when compared 
to the basal expression levels at E10.5 and E11.5 (see Figure 19A).  
Ddi2+/- embryos were used for Ddi2 expression profiling via β-galactosidase 
(encoded by lacZ in the Ddi2tm1b) activity screening with artificial substrate X-gal. Screening 
was performed on both whole-mount embryos and sagittal cryo-sections of embryos at 
different developmental stages. At stage E9.5, expression of Ddi2 occurs in rapidly 
developing body parts, such as forelimb, hindlimb and tail buds, heart, and maxillary and 
mandibular arches (see Figure 19B). Later, at stage E12.5, Ddi2 expression becomes 
ubiquitously spread all over the embryonal body, as shown in both whole-mount and paraffin 
section lacZ staining (see Figure 19C). Expression profile at later developmental stages is 
more specifically localized, e.g. sagittal section of head reveals expression in specific layer of 
cortex in forebrain and in trigeminal ganglion (E14.5, see Figure 19D, E17.5, see Figure 19F). 
Positive staining was as well observed in other ectodermal tissues, such as olfactory 
epithelium or skin (E14.5, Figure 19D) and in mesodermal tissues, such as smooth muscle of 
heart or cranium (E14.5, Figure 19D and E). In addition, positive Ddi2 expression in fetal 
liver in both E14.5 and E17.5 stages is localized in cells that might correspond to fetal 
macrophages differentiating into Kupffer cells, and with very low signal in hepatocytes 
themselves (see Figure 19E and 19F, respectively). Negative controls acquired for each of the 
hereby studied developmental stages did not reveal any false positive signal in the lacZ 
staining data (some of the negative control data is shown in Figure 19B, D and E). 
 
Figure 19: Expression profiling of Ddi2 during embryonal development. A) Estimation of Ddi2 
expression at stages E9.5, E10.5 and E11.5 of embryonal development using qRT-PCR. Transcript levels 
of H2afz were used for normalization. Error bars denote SD (n=6). B) Mapping of Ddi2 expression at stage 
E9.5 using lacZ reporter gene in Ddi2+/-. B) Ddi2 is expressed in developing parts of embryonal body at 
stage E9.5, such as limb buds, heart and mandibular and maxillary arches. C) Ddi2 expression is ubiquitious 
at E12.5. D) Sagittal sections show specific localization of Ddi2 expression at stages E14.5, in skin, brain 
(forebrain and trigeminal ganglion) and cranium. E) Smooth muscles of heart tissue and cells that most 
presumably correspond to Kupffer cells in liver at stage E14.5 also exhibit Ddi2 expression. F) Expression 
of Ddi2 at E17.5 in sagittal section of head (depicts localization in skin, trigeminal ganglion and olfactory 
epihelium) and liver. Abbreviations: C – cerebellum, F – forebrain  CMT – colliculus midbrain tectum, 
G - ganglion, H – heart, L – lung, OE – olfactory epithelium, P – pallium, S – skin, M – medulla, 
T - thalamus, TG – trigeminal ganglion, V – vertebra 
4.2.2.9 Activation of Nrf1 is diminished in both mouse model strains 
To verify whether mDdi2-Nrf1 interplay could be the reason of embryonal lethality, 
experiments of Nrf1 activation via proteotoxic stress were performed in MEFs isolated from 
E10.5 embryos of each genotype and strain. Primary fibroblasts were cultured to passage 3, 
when the experiments were performed after the cells acquired more than 85% confluence. 
Both Ddi2-/- and Ddi2exon6 -/- fibroblasts showed proliferation retardation in comparison to the 
cells isolated from wild-type and heterozygous embryos of both strains (data not shown). 
First, timeline setup and proteasome inhibitor screen was performed for refinement of 
experimental conditions (data not shown). The most representative results with the highest 
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response to proteasome inhibition in Nrf1 activation were acquired by treatment with 10 µM 
MG132 for 16 hours.  
In wild-type and heterozygous cells of both strains, the treatment with MG132 
resulted in overexpression (Nrf1 FL) and activation of Nrf1 (Nrf1 A) (see Figure 20A and B). 
In contrast, both Ddi2-/- and Ddi2exon6 -/- fibroblast cultures failed to produce an adequate 
response to proteasomal inhibition, by only accumulation of the full-length Nrf1 with missing 
activation of Nrf1 by mDdi2 cleavage (Figure 20A and B).  
A weak signal corresponding to mDdi2 full-length protein can be observed in the 
lysates of Ddi2exon6 -/- fibroblasts (see Figure 20B). We have previously observed this 
phenomenon in human DDI2 KO cell lines (HTC116) prepared in our laboratory. 
Additionally, smears around this area also occur in Ddi2-/- fibroblast lysates. This could be 
result of high total protein load onto the SDS-PAGE gel (see β-actin loading control in Figure 
20B) and therefore, we consider this to be a non-specificity of the antibody. 
 
Figure 20: MEF culture derived from Ddi2-deficient embryos exhibit impairment in “bounce back” 
effect of Nrf1 protein activation. MEFs were treated with 10 µM MG132 for 16 hours for activation of 
Nrf1 protein by Ddi2 cleavage. Ddi2-deficient cells derived from both Ddi2tm1b (A) and Ddi2protease defective 
(B) model strains fail to cleave Nrf1 sufficiently. 
Impairment in Nrf1 pathway activation in Ddi2-deficient model cells is one of the first 
evidence supporting the hypothesis of Ddi2-Nrf1 interplay and its essential function during 
embryonal development. Whether failure of Nrf1 activation might be the main cause of the 






4.2.2.10 My contribution to the project 
Since this thesis represents a part of a comprehensive study of our laboratory, results 
presented here were generated by several members of our laboratory and our collaborators 
from the CCP unit hosted by IMG CAS. My specific contribution to the project is enlisted 
below. 
1. Cloning, recombinant expression and purification of several protein constructs that 
were used for their characterization on molecular level. 
2. Solving of structure of yDdi1 UBL using NMR spectroscopy. 
3. Identification and characterization of binding properties of individual domains of 
human DDI2 protein using NMR spectrometry (titration experiments and binding site 
mapping). 
4. Selection of founder mouse and colony management of Ddi2protease defective mouse strain. 
5. Optimization of all protocols for protein purification, genotyping procedure, tissue 
lysis, cell lysis and Western blotting. 
6. Majority of chromosomal DNA isolations and genotype identification of mice or 
embryos. 
7. Harvest of majority of embryonal samples of Ddi2protease defective, their subsequent 
processing for mRNA isolation or protein expression analysis using Western blotting. 
8. Isolations and quality control of mRNA and reverse transcription. 
9. Processing of raw qPCR data with Vendula Novosadová (CCP). 
10. Harvest of all embryos for MEF isolation and realization of all related experiments. 
11. Majority of Western blotting analysis. 
12. Ddi1 expression studies using ISH were performed in collaboration with Michaela 
Procházková as further specified in chapter 3.4.5.16. 
13. Part of the lacZ staining experiment together with our collaborators from CCP. 
Complete Ddi2 expression analysis based on lacZ staining data. 
14. Design of most experimental procedures and data analysis related to both mouse 
strains. 







































































Maintenance of homeostasis is the key to cell survival and to the fulfillment of its 
function in the concept of whole organism. Homeostasis is acquired by highly regulated 
processes, such as protein quality control mechanisms or responses to manifold stress 
inducers (Galluzzi L., et al., 2018, Walter P. and Ron D., 2011). In addition to the function as 
proteins targeting towards degradation in the ubiquitin-proteasome system, several members 
of the Ddi1-like family of shuttling proteins have been recently identified as important actors 
in DNA damage repair and regulation of protein expression by activation of a specific 
transcription pathway in response to proteotoxic stress (Kaplun L., et al., 2005, Koizumi S., 
et al., 2016, Kottemann M. C., et al., 2018, Lehrbach N. J. and Ruvkun G., 2016). Despite 
these few recent findings, that suggest an essential function of Ddi1-like protein family in 
homeostasis maintenance, all its members have been understudies in general. This 
dissertation presents a broad study of several members of the Ddi1-like protein family, 
focusing both on their characterization on molecular level and their role in relevant biological 
systems, specifically in mouse knockout models.  
Ddi1-like protein family members have a unique domain architecture among other 
shuttling proteins of ubiquitin-proteasome system represented by Rad23 and Dsk2 (for 
domain architecture comparison see Figure 4 on page 48) (Bertolaet B. L., et al., 2001). Most 
of the non-mammalian Ddi1 orthologs harbor the conserved N-terminal UBL and the C-
terminal UBA domains that in general facilitate the primary role of shuttling proteins 
(Bertolaet B. L., et al., 2001, Elsasser S., et al., 2002). Recently, we structurally characterized 
and structurally characterized a novel helical domain of Ddi (HDD), which exhibits similarity 
to DNA-binding domains, in both yDdi1 and hDDI2 protein (Siva M., et al., 2016, Trempe 
J. F., et al., 2016). Analogous helical domains of Sti1-like family had been previously 
described for Rad23 and Dsk2 (Kaye F. J., et al., 2000, Kim B., et al., 2005, Lee J. H., et al., 
2005, Masutani C., et al., 1997). However, in addition to these regions, Ddi1-like proteins 
possess a central RVP domain, which gives them their uniqueness (Krylov D. M. and Koonin 
E. V., 2001, Sirkis R., et al., 2006). 
Primary sequences and hence the structure of individual domains of Ddi1-like protein 
family members are very well conserved from yeast to mammals (see the analysis of sequence 
identity and structural superimpositions in Figure 7 and Figure 8, respectively). It is therefore 
presumed that they might adopt similar binding properties and perform akin functions. 
The unique RVP domain of Ddi1-like proteins adopts a conserved structure, which 
highly resembles the structure of HIV-1 protease. It forms a homodimer of the full-length 
protein with catalytic aspartate positioned in the center of the substrate cavity protected with 
flaps (Sirkis R., et al., 2006, Siva M., et al., 2016, Trempe J. F., et al., 2016). The catalytic 
function of the RVP domain was first indirectly reported in complementation studies of 
yDdi1p knockout strain, where the inactive mutant was not able to rescue the observed 
secretion phenotype (White R. E., et al., 2011b). The hypothesis of proteolytic activity was 
recently supported by studies of both human DDI2 and C. elegans Ddi1 activity under 
proteotoxic stress. Human DDI2 and C. elegans Vsm-1 specifically cleaves its substrate, a 
transcription factor NRF1 (Skn1), which is thereby activated and translocated into nucleus to 
fulfill its function (Koizumi S., et al., 2016, Lehrbach N. J. and Ruvkun G., 2016). NRF3 was 
also identified as another specific substrate of hDDI2 (Chowdhury A., et al., 2017). Although 
the mechanism of cleavage has not yet been understood, the fact that DDI2 activates these 
two transcription factors and that DDI2 clearly plays an important role in DNA repair, puts 
DDI2 (specifically its protease domain) among clinically relevant targets. 
Based on sequence alignment of members of Ddi1-like family in Figure 7A and on 
our structure prediction analysis, the four helical bundle of HDD is present in all four mouse 
and human Ddi1-like proteins and in Ddi1 (Rngo) of D. melanogaster (this work, (Siva M., 
et al., 2016)). As mentioned previously, HDD is structurally similar to Sti1-like domains of 
the shuttling proteins that mediate protein-protein interactions (Kaye F. J., et al., 2000, 
Masutani C., et al., 1997, Trempe J. F., et al., 2016). Similar protein interface could thus be 
represented by HDD, or it could serve as interaction platform for substrate of the RVP domain 
and mediate transport of the substrate into the active site. HDD could also mediate interaction 
with DNA at site of DNA damage, based on resemblance of the N-terminal helical bundle of 
yDdi1 and DNA-binding domains of transcription factors, such as CUT domain of SATB or 
bacteriophage λ cII transcription activator (Trempe J. F., et al., 2016). Moreover, the two 
additional C-terminal helices of yeast HDD together with RVP are crucial for DNA damage 
response in yeast upon hydroxyurea treatment (for details see chapter 1.3.1) (laboratory of 
Dr. Grantz Šašková – unpublished data). We hypothesize that these two helices represent the 
substrate interaction site for the yDdi1p. The function of the four helical bundle of Ddi1-like 
proteins, which have lost the two adjacent C-terminal helices throughout evolution, remains 
to be clarified. 
The dimerization of the RVP and the position of the UBL and UBA domains at 
opposite ends offer two configurations of the full-length protein, a head-to-head or 
a head-to-tail homodimers. The fact that the UBL domain of yDdi1p binds ubiquitin allowed 
to propose a novel alternative shuttling mechanism, where both UBL and UBA would bind 
the polyubiquitin chain in a head-to-tail configuration. The putative dual functionality of the 
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hDDI1 and hDDI2 UBLs (both lacking UBA) would hence allow to bind both the 
polyubiquitin chain and the proteasome (Nowicka U., et al., 2015). This hypothesis was 
disapproved by results reported here, showing that despite the resembling fold, hDDI2 UBL 
and yDdi1 UBL differ in their surface properties: hDDI2 UBL does not possess the highly 
negatively charged β-sheet patch identified for yeast UBL, which interacts with the positively 
charged UBQ (Nowicka U., et al., 2015, Siva M., et al., 2016, Trempe J. F., et al., 2016). The 
low affinity of the hDDI2 UBL to ubiquitin was further confirmed in NMR titration 
experiments also in this work (see Figure 11). 
In connection to ubiquitin interactions, both yDdi1p and hDDI2 harbor a ubiquitin 
interacting region at their C-terminus, a UBA and a UIM, respectively (Nowicka U., et al., 
2015, Siva M., et al., 2016). As sequence alignment in Figure 7A shows, the UIM sequence 
is conserved as well in mDdi2 protein, however it is absent in both human and murine Ddi1 
homologs. We managed to characterize the very weak yet specific interaction between 
ubiquitin and the C-terminal UIM of hDDI2 in NMR titration experiments. In addition, we 
mapped the UIM interaction site onto the Ile44 patch of ubiquitin (see Figure 10). However, 
we were not able to pull down any of the di-ubiquitins chain types, which altogether defines 
the binding properties to be quite divergent from those previously described for the Ddi1p of 
S. cerevisiae (Siva M., et al., 2016). 
Regarding the overall structural properties of the full-length Ddi1 proteins, the human 
and yeast orthologs also exhibit different character. Our SAXS modeling data showed that 
yDdi1 with central protease dimer is flanked with rather flexible linkers to HDD and UBL 
domains. The data is supported by NMR experiment, where we did not observe any 
interaction between UBL and HDD-RVP constructs (Trempe J. F., et al., 2016). This is in 
agreement with Nowicka and colleagues, who reported that the individual UBL, RVP and 
UBA subunits of yDdi1p do not interact with each other according to NMR experiments 
(Nowicka U., et al., 2015). The SAXS modeling of the hDDI2 RVP-HDD dimer showed 
asymmetric distribution specific for elongated proteins. This is caused by the long linker 
between the RVP and HDD domains of hDDI2 (40 residues), which is not present in the yeast 
ortholog (this work, (Siva M., et al., 2016, Trempe J. F., et al., 2016)). On the contrary, based 
on the difference in the 2D HSQC spectra of sole UBL domain and the full-length hDDI2 
superimposition performed in our study (Figure 12A ), the UBL domain interacts with the 
body of the protein, which suggests that the hDDI2 ortholog forms rather a compact dimer 
than an extended protein (see chapter 4.1.3.2 and Figure 12). In addition, we observed that 
the UBL of hDDI2 does not interact with the C-terminal UIM motif and therefore it is unlikely 
that it would constitute a head-to-tail dimer. Altogether, we reason that while the HDD-RVP 
protein part is extended in the center of the dimer, both UBL and UIM sweep back towards 
the center of the protein. This, together with the low affinity of hDDI2 UBL towards ubiquitin 
(this work, (Siva M., et al., 2016)), is contradictory to the proposed model of the so-called 
“alternative shuttle” (Nowicka U., et al., 2015).  
Despite the study of Kottemann and colleagues, who observed association of hDDI2 
with proteasomal subunits in crosslinking/mass spectrometry experiments (Kottemann M. C., 
et al., 2018), direct interaction with any of the intrinsic ubiquitin receptors of the proteasome 
has not been shown either for human or mouse members of the Ddi1-like protein family. In 
fact, the multidomain architecture of Ddi1-like protein family members opens the discussion 
for their multifunctional potential. The diverse features and binding properties of their 
otherwise conserved domains suggest that the individual orthologs and mammalian homologs 
might have evolved different cellular roles, which remain to be further investigated. 
In order to study the role of both human homologs in biological systems, we chose 
mouse as a suitable, and experimentally feasible biological model organism, based on 
sequential and structural similarities between human and murine Ddi1-like family members 
(see Figure 7A and Figure 8 on pages 100 and 101, respectively).  
First, we focused on the understudied Ddi1 protein. Our colleagues from the 
laboratory of Dr. Ugo Mayor identified Ddi1 (Rngo) from D. melanogaster as a unique 
substrate of the E3 ubiquitin ligase Ube3a via unbiased ubiquitin proteomics approach 
(Franco M., et al., 2011, Ramirez J., et al., 2018). They also identified the human DDI1 
protein to be ubiquitinated by UBE3A in human SH-SY5Y neuroblastoma cells. 
Interestingly, this specific modification does not target the substrate (hDDI1) towards 
degradation in the proteasome and clearly has other signaling function (Ramirez J., et al., 
2018). UBE3A dysregulation is tied with a complex neurodevelopmental disorder called 
Angelman syndrome. How mutations in UBE3A gene influence the development of nervous 
system is not fully understood. It has been suggested that substrates of UBE3A could play 
specific and/or essential roles in brain development (Buiting K., et al., 2016, Sadikovic B., et 
al., 2014). Our Ddi1 expression profiling using ISH in developing brain of mouse embryos 
revealed specific expression localization of this gene throughout different stages of mouse 
brain development. The ventricular layer and cortical plate of isocortex and the ventricular 
layer of olfactory bulb exhibit specific expression of Ddi1 at stage E16.5 (see Figure 13H-J), 
when the expression significantly increases multiple-fold in comparison to adjacent 
developmental stages (Ramirez J., et al., 2018). Based on the similar expression profile of the 
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mouse and human Ddi1 proteins in adults, and the expression and specific ubiquitination of 
hDDI1 in human SH-SY5Y neuroblastoma cells, we suggest that hDDI1 could presumably 
be upregulated during development of human brain. In addition, several mutations of DDI1 
were recently identified and linked to a familial neurodegenerative disorder, which further 
supports possible function of DDI1 in neuronal tissue (Alexander J., et al., 2016). Therefore, 
it might represent one of the substrates of UBE3A with role in fetal brain that could be of 
importance in connection to Angelman syndrome and possibly other neuronal disorders and 
their clinical research.  
Next, we focused on deciphering the function of mammalian Ddi2 protein and 
generated two knockout mouse models. Human and mouse Ddi2 proteins share 96% 
sequence identity and highly conserved structural properties. As shown in Figure 7A on page 
100, mouse Ddi2 harbors the HDD domain that precedes the RVP and the C-terminal UIM 
described in hDDI2 protein (Siva M., et al., 2016).  
Two mouse model strains with alteration of Ddi2 gene were generated, a full knockout 
and a Ddi2 protease defective strain. Ddi2tm1b strain, which was generated by ESC 
manipulation and insertion of gene cassette encoding loxP sites intended for removal of 
critical exon 2 by Cre recombinase and a reporter-gene insert, represents the full knockout 
(Mansour S. L. et al., 1990). Ddi2 protease defective strain was generated in order to abolish 
the functions of the RVP domain – catalytic activity and dimerization of the full-length 
protein. Therefore, this second mouse model strain (C57Bl6/NCrl-Ddi2em1/Rase, here 
distinguished as Ddi2protease defective) was generated by TALEN-mediated excision of exon 6, 
which resulted in alteration of the RVP domain. The mDdi2PD protein is missing region of 
residues 254-296 that encodes catalytic aspartate and a part of the dimerization domain of the 
RVP. Expression of the altered mDdi2 protein variant was confirmed on mRNA level 
(sequencing of corresponding cDNA) and analysis of protein expression in embryo lysates 
using Western blotting. We were able to repeatedly observe small band with low signal at 44 
kDa, where the mDdi2PD variant is expected (see Figure 17D on page 116). Despite our effort, 
we failed to detect the protease defective variant in embryo or derived MEF lysates using 
mass spectrometry. 
Ddi2 gene belongs to the one third of mammalian genes that are essential for life, as 
both mouse models show embryonic lethality at mid-late gestation period (Dickinson M. E. 
et al., 2016). Strikingly, the homozygous individuals die at different developmental stages: 
while Ddi2-/- embryos die by E14.5 (mid-late gestation), Ddi2exon6 -/- embryos die earlier, by 
E12.5 (mid-gestation) (for comparison of survival of embryos of both strains see 
Kaplan-Meier curve in Figure 17C). In both models, the heterozygous embryos and adult 
mice do not exhibit any obvious phenotype, as revealed by our phenotyping study described 
in chapter 4.2.2.7, which suggests that the original allele might be able to entirely supplement 
the missing functional allele under non-challenging conditions. Despite no obvious 
phenotype, we have observed defects in conception after identification of vaginal plug in the 
heterozygous crossings of Ddi2tm1b strain mice.  
Ddi2-/- embryos show retardation at stage E12.5 when compared to their littermates, 
and die by E14.5. We have not yet entirely described the molecular and physiological reason 
of their death in utero at this specific stage. Due to fertility problems of the heterozygous adult 
mice, it is complicated to acquire sufficient number of embryonal samples. However, part of 
the harvested embryonal samples we have managed to acquire (see Figure 17A on page 116), 
is being processed for future studies, such as µCT scanning at the CCP embryology unit for 
detailed analysis of the retardation or qPCR analysis targeted on the influence of Ddi2 
ablation on Nrf1-driven pathways. In contrast, as Ddi2exon6 +/- adult mice exhibit normal rate 
in conception, we were able to harvest a significantly higher number of embryo samples and 
perform more experiments using this model. Ddi2exon6 -/- embryo retardation starts after E9.5, 
as it is already distinguishable at stage E10.5 and quite visible at E11.5 (see Figure 17F, page 
116). The embryos are smaller, they have lower number of somites at the same stage of 
harvest, lack mandibula and maxilla, the yolk sac is pale and exhibits less vascularization 
when compared to the littermates. The qPCR and lacZ staining experiments (see Figure 19 
on page 120) revealed quantitative and qualitative data on Ddi2 expression. The embryos at 
stage E9.5 exhibit two fold higher expression when compared to later developmental stages. 
This upregulation could be connected to the early onset of retardation in growth of the 
Ddi2exon6 -/- embryos compared to the Ddi2-/- embryos, possibly explained by a dominant 
negative effect of the mDdi2PD protein (will be further discussed below). They also shown 
defects in development of body parts with specific expression of Ddi2, based on our lacZ 
expression studies (see Figure 19B). The expression profile of Ddi2 in both stages E9.5 and 
E12.5 acquired by lacZ staining were consistent with our previously obtained data from Ddi2 
ISH studies on whole mount embryos (data not shown). Nevertheless, the reason of difference 
in stage of embryonic lethality of our two mouse model strains has to be further investigated. 
Next, we focused on the reason of embryonic death of our model mDdi2WT deficient 
mice. In general, high percentage of embryonically lethal knockout mouse strains exhibit 
defects in development of extraembryonic structures (yolk sac and placenta) in addition to 
the retardation of the embryo proper (Perez-Garcia V. et al., 2018). Yolk sac is essential for 
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nutrition supply during early embryo gestation prior to chorioallantoic attachment at E8.5 that 
thereafter provides nutrition for the rapidly growing embryo from the mother (Brett K. E. et 
al., 2014, Cross J. C. et al., 2003, Munro H. N. et al., 1983, Rossant J. and Cross J. C., 2001). 
Vasculogenesis first occurs in the yolk sac prior to vascular system development in the 
embryo proper (Boucher D. M. and Pedersen R. A., 1996). Furthermore, hematopoiesis 
during embryonal development starts in a primitive form already in the yolk sac. It is initiated 
with primitive erythroid progenitors in the first wave between E7.25 – E9.0, and in the second 
wave with definitive erythroid progenitors between E8.25 – E10.0 (Dieterlen-Lievre F., 1978, 
Lux C. T. et al., 2008, Palis J. and Yoder M. C., 2001, Wong P. M. et al., 1986, Yamane T., 
2018). At stages E10.0 – E11.0, the hematopoietic cells are transferred into fetal liver 
(Houssaint E., 1981, Zovein A. C. et al., 2010). Defects in placenta, representing the main 
nutrient supplier from E9.5 onward, are also closely linked to the embryo proper retardation. 
The primary placental phenotype shall be studied in the models that exhibit embryonic 
lethality, so that malnutrition as the primary cause of embryo proper retardation could be 
excluded. At the stage of formation of placenta-embryo connection at E8.5, the embryos are 
challenged by a major change in metabolism. Due to connection with maternal blood between 
maternal and fetal capillaries in placental labyrinth zone, the metabolism changes from 
glycolytic to oxidative (Bulusu V. et al., 2017, Shepard T. H. et al., 1997, Watson E. D. and 
Cross J. C., 2005). Here, at the mid-gestation stage, the primitive erythroid cells are essential 
for oxygen supply to peripheral tissue of the embryo proper (Yamane T., 2018). Interestingly, 
hypoxia is a very important modulator of vascularization in both extraembryonic and 
embryonic tissues (Dunwoodie S. L., 2009). All these above-mentioned developmental 
processes could be connected to the function of Ddi2 protein and are therefore further 
discussed below in comparison with our Ddi2-deficient mouse model strains.  
As shown in experiments on MEF cultures derived from our model Ddi2-/- and 
Ddi2exon6 -/- embryos, the activation of the transcription factor Nrf1 is diminished under 
proteotoxic stress (Figure 20 on page 121). We used proteasomal inhibition by MG132, as 
this experimental method has been previously established in several studies and the effect of 
Ddi2 functional deficiency can be easily visualized by Western blotting (studies from our 
laboratory, (Radhakrishnan S. K., et al., 2010, Sha Z. and Goldberg A. L., 2014, Xiang Y. et 
al., 2018). When we compared our mouse models with the model knockout mice of the Ddi2 
substrate Nrf1, the Ddi2-/- embryos exhibited lethality at similar developmental stage. 
Functional Nrf1 knockout embryos (bearing disruption of the CNC bZIP domain) die due to 
hematopoiesis failure in liver (Chan J. Y., et al., 1998) and quite interestingly, they do not 
show any obvious phenotype prior death except for growth retardation and anemia. As Ddi2-
/- embryos exhibit growth retardation, but not any specific developmental defects in individual 
body parts with specific Ddi2 expression (similarly to the Nrf1-/- embryos), the reason for their 
death in mid-late gestational stage could be as well caused by impaired processes in the yolk 
sac, for example the dismantled hematopoiesis due to failure of Nrf1 activation by Ddi2. This 
hypothesis is as well supported by our preliminary data from placental rescue of Ddi2tm1b 
model strain (Sox-2 Cre driver, data not shown), in which Ddi2-/- embryos die at stage E18.5 
– P0. This means, the lethality could be most likely induced by impairment of processes in 
placenta, in addition to the processes in the yolk sac and embryo proper. Similarly, the onset 
of retardation in the fetus and in the extraembryonic tissues (vascular network in the yolk sac 
and growth retardation of placenta) of Ddi2exon6 -/- embryo at stage E9.5 could be connected 
as well to erythropoiesis, but in earlier phase of the hematopoiesis pathway. Moreover, this 
profound lethal phenotype might be based on the attachment of embryo to the placenta after 
E8.5, when it is challenged with offset of oxidative processes (Bulusu V., et al., 2017, Shepard 
T. H., et al., 1997, Watson E. D. and Cross J. C., 2005). Note, that one of the main roles of 
Nrf1 has been described in response pathways to oxidative stress (see chapters 1.2.2 and 
1.3.2.1.1) (Chan J. Y., et al., 1998, Venugopal R. and Jaiswal A. K., 1998). The diminished 
vascularization observed in yolk sac of the Ddi2exon6 -/- embryos might be the result of inability 
of the Ddi2 protease to activate Nrf1 that leads to excessive production of ROS. The role of 
nitric oxide and elevation in ROS production was reported in several studies to modulate 
vasculogenesis in the yolk sac (Nath A. K. et al., 2004, Wang G. et al., 2016). In conclusion, 
both Ddi2 deficient and protease defective model strain mice show phenotype that might be 
linked with its function in Nrf1 activation, while the Ddi2exon6 -/- embryos exhibit profound 
sensitivity to developmental challenges as they die at earlier gestation stages. Furthermore, 
the loss of activation of the transcription factor Nrf3, another Ddi2 substrate that exhibits high 
expression levels in placenta, may second the loss of function in Nrf1 activation pathway and 
therefore contribute to the observed phenotype. This needs to be further verified (Chenais B., 
et al., 2005, Chowdhury A., et al., 2017). In addition, the embryonic lethality of our model 
strains could be linked to the involvement of hDDI2 in DNA repair processes. Previous 
studies of genes functionally related to mDdi2, such as DVC-1 (murine ortholog of 
metalloprotease Wss1) and Rad23B, exhibit pre-implantation lethality and offset of lethality 
during embryonal development at E13.5 with only 10% survival of Rad23B-/- mice up to 
adulthood (Maskey R. S. et al., 2014, Ng J. M. et al., 2002).  
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We considered the observation, that heterozygous adult mice of both strains do not 
show any abnormal phenotype, very interesting and wanted to reveal, whether these animals 
would respond to stressing conditions. Based on previous study of Lee and colleagues on 
Nrf1+/- mice, the author Monika Sivá in collaboration with the CCP hosted by IMG CAS 
performed a full phenotyping screening of Ddi2exon6 +/- aged males that were challenged with 
administration of proteasomal inhibitor bortezomib (data not shown). These animals did not 
show any obvious phenotype and in contrast to Nrf1+/- mice, which exhibited enhanced 
sensitivity to ER stress and steatosis upon inhibition of proteasome (Lee C. S., et al., 2013). 
Ddi2exon6 +/- mice did not evolve any pathologic condition in the liver that could be detected 
in biochemistry test from murine blood or in histopathology of the livers (laboratory of Dr. 
Grantz Šašková – unpublished data). These findings additionally support the full 
complementation of Ddi2 function in the heterozygous mice by the Ddi2WT allele. However, 
based on the same study of Lee and colleagues and the lethal phenotype of our mouse model 
strains, we generated a liver-specific Ddi2 knockout mouse strain. Based on our preliminary 
data (data not shown), the animals seem to be prone to elevated triglyceride content under 
non-challenged conditions (laboratory of Dr. Grantz Šašková – unpublished data). These 
findings of similarity between the knockout model strain mice link abolishment of Ddi2 
function with the function of Nrf1 and suggest the need of further studying and understanding 
of the interplay of these two essential genes.  
In order to decipher the differential lethality between the two model strains and 
validate proper folding of the altered protein, we performed characterization of the mDdi2PD 
protein. To do so, we first isolated the mRNA of both alleles of Ddi2protease defective strain, the 
WT and the ∆254-296, prepared corresponding cDNA and cloned the protein coding 
sequences into bacterial expression vectors. Both mDdi2WT and mDdi2PD protein variants 
were recombinantly expressed and subjected to several studies. 1D NMR spectra showed 
proper folding in the secondary structures of both protein variants (Figure 18A, page 117), 
however, we were not able to estimate the melting temperature of mDdi2PD using differential 
scanning fluorimetry, as the protein did not undergo any denaturing processes that would 
allow binding of the Sypro® Orange fluorescent dye into revealed hydrophobic regions upon 
denaturation (see Figure 18B, page 117). Both protein variants were also characterized using 
a semi-analytic chromatography and dynamic light scattering (data not shown), which 
revealed increased molecular mass of the recombinantly expressed mDdi2PD protein when 
compared to mDdi2WT. It seems, mDdi2PD forms low mass aggregates right after translation 
in bacterial cells during its recombinant expression. We wanted to verify, whether human 
cells could cope with expression of the altered mDdi2PD protein variant and therefore we 
performed transient expression studies of both mDdi2WT and mDdi2PD with analysis of 
protein expression in harvested cells at several time points after transfection (see Figure 18C, 
page 117). This experiment revealed higher expression of the wild-type protein variant and 
only weak signal for the protease defective variant, even at 48 hours after transfection. Our 
observations led us to assume that aggregation of the protein via unstructured part of RVP 
domain in regions that originally surround the exon 6 encoded sequence results in rapid 
mDdi2PD protein degradation by one of the response mechanisms to misfolding stress right 
after translation, therefore the low signal for this protein variant in Figure 18C. 
When comparing the lethality stages of the two mouse model strains, we hypothesize 
that one of the explanations could be partial complementation of the function of mDdi2 by its 
homolog mDdi1. It has been previously reported in two different studies in human cell lines 
that hDDI1 might act complementary to its homolog hDDI2. Kottemann and colleagues 
identified both hDDI1 and hDDI2 as shuttling proteins of UPS responsible for stalled fork 
restart via removal of RTF2 and another study showed impairment of NRF1 activation in 
hDDI1 knockout cells (Kottemann M. C., et al., 2018, Xiang Y., et al., 2018). While Ddi2-/- 
mice could benefit from the complementation of the activity by mDdi1, the existence of 
mDdi2PD protein in the Ddi2exon6 -/- individuals could abolish the shuttling factor function of 
mDdi1 by occupying the interaction site (such as the one on proteasome receptors), which 
could provide explanation for the earlier lethality observed in this model. The interaction of 
mDdi2PD protein with proteasome could be facilitated with its extended N-terminal and 
C-terminal domains, in spite of formation of aggregates by the misfolded core region of the 
protein. In fact, preventing of interaction of any molecules with proteasomal receptors would 
most probably lead to disruption of homeostasis, cellular apoptosis and result in organism 
death, in a dominant negative effect.  
In addition to the above-mentioned full knockout and liver-specific knockout mouse 
models, there is a number of options for studying the role of Ddi2 in a variety of tissues in 
adult mice, as was described for its substrates, for example neuronal tissue or osteoblasts (Kim 
J., et al., 2010, Kobayashi A., et al., 2011, Lee C. S., et al., 2011). Moreover, the discovery 
of Crispr/Cas9 system opened a pandora box with plentiful possibilities in studying the 
function of genes in diverse cell culture lines (Jinek M. et al., 2012). Here, we focused on 
human DDI2 and its up-to-date identified roles. It is clearly one of mammalian essential 
genes, involved in DNA repair response and most presumably in a variety of important 
cellular processes via its substrates Nrf1 and Nrf3. Indeed, the linkage of hDDI2 protein to 
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other pathways besides the recently described response to proteotoxic stress shall be further 
studied.  
The members of Ddi1-like protein family are proteins with remarkable evolutionary 
conservation and based on findings of our own and others, a presumably broad spectrum of 
functions. Even though a few biological functions have been described for the 
hereby-characterized members of the Ddi1-like protein family, their full potential and 
importance in the context of homeostasis maintenance of individual cells as well as on the 





























































































































1. Ddi1-like proteins relevant for NMR studies were cloned, recombinantly expressed 
and purified in sufficient yields and purity for their further biophysical characterization. 
2. Solution structure of the UBL domain of Ddi1p from S. cerevisiae was acquired 
using NMR spectroscopy and adopts a conserved ubiquitin fold. 
3. Based on NMR titration studies, we characterized the binding properties of the 
UBL domain and the UIM of hDDI2, which differ from those of domains of yDdi1p. Both 
the UBL domain and UIM of human DDI2 specifically bind ubiquitin, however with very 
weak affinity as opposed to the yeast ortholog. The hDDI2 UBL does not bind the C-terminal 
UIM region, hence the protein does not adopt a head-to-tail conformation in the homodimer. 
4. The in situ hybridization studies revealed specific expression of Ddi1 in mouse 
developing brain, which together with other findings lead to hypothesis of possible relevance 
of DDI1 to neurodevelopmental diseases. 
5. Two mouse model strains were produced in order to study the biological role of 
Ddi2. The full knockout model was generated by ESC manipulation and insertion of a lacZ 
reporter gene instead of the critical exon of Ddi2. The second model with ablated function of 
the protease domain of Ddi2 was prepared by TALEN-mediated excision of exon 6. 
6. Both mouse strains exhibit embryonal lethality of the homozygous mice in mid-late 
gestation period, while adult heterozygous animals did not reveal any obvious abnormality in 
phenotyping studies. 
7. Defect in the RVP domain of Ddi2 results in dominant negative effect and 
homozygous embryos exhibit earlier lethality (by E12.5) then the full knockout embryos (by 
E14.5). 
8. The protease defective Ddi2 variant (mDdi2PD) was reverse transcribed from 
isolated embryonal mRNA and cloned into bacterial expression vectors. Characterization of 
both recombinantly expressed mDdi2WT and mDdi2PD proteins revealed aggregate formation 
in the case of the mDdi2PD. 
9. Expression profiling of Ddi2 that was performed using qPCR and lacZ staining, 
revealed difference among critical embryonal stage relevant for our model strains and 
localization of the expression in ectodermal and mesodermal tissues.  
10. The morphologic phenotype was described for both strains as well as their 
inability in activation of Nrf1 transcription factor. 
11. Application of proteotoxic stress onto primary MEF cultures isolated from 
embryos of our model strains reveals evidence of the ablation of the Nrf1 activation pathway, 
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Abstract 
Angelman syndrome is a complex neurodevelopmental disorder caused by the lack of function in 
the brain of a single gene, UBE3A. The E3 ligase coded by this gene is known to build K48-linked 
ubiquitin chains, a modification historically considered to target substrates for degradation by the 
proteasome. However, a change in protein abundance is not proof that a candidate UBE3A 
substrate is indeed ubiquitinated by UBE3A. We have here used an unbiased ubiquitin proteomics 
approach, the bioUb strategy, to identify 79 proteins that appear more ubiquitinated in the 
Drosophila photoreceptor cells when Ube3a is over-expressed. We found a significantly high 
number of those proteins to be proteasomal subunits or proteasome-interacting proteins, 
suggesting a wide proteasomal perturbation in the brain of Angelman patients. We focused on 
validating the ubiquitination by Ube3a of Rngo, a proteasomal component conserved from yeast 
(Ddi1) to humans (DDI1 and DDI2), but yet scarcely characterized. Ube3a-mediated Rngo 
ubiquitination in fly neurons was confirmed by immunoblotting. Using human neuroblastoma SH-
SY5Y cells in culture, we also observed that human DDI1 is ubiquitinated by UBE3A, without 
being targeted for degradation. The novel observation that DDI1 is expressed in the developing 
mice brain, with a significant peak at E16.5, strongly suggests that DDI1 has biological functions 
not yet described that could be of relevance for Angelman syndrome clinical research. 
Introduction 
Angelman syndrome (AS) is a rare neurodevelopmental disorder (OMIM #105830), with an 
estimated incidence of 1/15 000 births, characterized by a severe developmental delay, language 
impairment, ataxic movements, epilepsy, sleep disturbances and episodes of frequent laughter (1). 
In contrast to other complex syndromes that are caused by large genetic duplications/deletions, 
the underlying cause for AS is the loss of maternal expression in neurons of the brain of one single 
enzyme, UBE3A (2,3), a HECT-type ubiquitin E3 ligase (4–6). Although the deficiency of this 
paternally imprinted gene (7) is commonly originated by maternally inherited deletions on the 
15q11-q13 chromosomal region (8), the syndrome is also caused by mutations affecting 
exclusively the UBE3A gene (9). Some of these UBE3A mutants lack the ubiquitin-ligase activity 
when tested in vitro (10,11), indicating that AS is caused by the lack of the ubiquitin ligase activity 
of UBE3A in neurons. Ubiquitinated substrates of UBE3A are therefore likely to be the effecting 
pathways of the resulting brain connectivity and/or function alterations. Interestingly, excess 
ligase activity of UBE3A has also been associated with autism spectrum disorders (12–14). 
Ubiquitin E3 ligase enzymes catalyze the covalent attachment of ubiquitin to the lysine residues 
on target proteins. According to in vitro studies, UBE3A catalyzes the preferential attachment of 
K48-linked poly-ubiquitin chains (15), presumably targeting its substrates for proteasomal 
degradation. Based on this premise, several UBE3A putative substrates (AIB1, Bak, Blk, Mcm7, 
Pbl) whose levels changed in the presence/absence of this enzyme were reported (16–20). 
Nevertheless, ubiquitination of those proteins by UBE3A has not yet been described. Similarly, 
the ubiquitination of other proposed neuronal UBE3A substrates was only validated in vitro (Arc, 
Na+/K+ ATPase, p27, Ring1B, Adrm1, Rpt5) or using non-denaturing immunoprecipitation 
approaches (Annexin A1, HHR23A, PSMD2, Ephexin5, p53) (21–29). We developed an 
ubiquitination assay for neuronal cell culture using a highly denaturing protocol, and showed that 
proteasome regulating proteins Rpn10 and Uch-L5 are ubiquitinated by Ube3a (30), both being 
reported to be essential for mammalian brain development (31,32). Recently, evidence is 
accumulating in regards to UBE3A regulating proteasomal activity (28–30,33), suggesting that 
UBE3A might indirectly be affecting the regulation of many other proteins targeted to the 
proteasome by other E3 ligases. 
Interaction between an ubiquitin ligase and its substrates is transient and hard to capture in vivo. 
Additionally, the low stoichiometry at which ubiquitin modified proteins are found within the cell 
hinders the identification of ubiquitination substrates in vivo. Antibodies that specifically 
recognize the ubiquitin diGlycine (diGly) signature have been employed to isolate, and 
subsequently identify putative ubiquitination sites by mass spectrometry (MS) (34–39). Such 
methodology has also been recently used in a screen for putative UBE3A substrates in HEK293 
cells (29). However, this approach requires digestion of proteins by trypsin prior to their isolation, 
preventing any orthogonal validation, which is essential, as the diGly signature is also a remnant 
of other ubiquitin-like (UBL) modifications, such as Nedd8 or ISG15 (35), and can even be an 
experimental artefact under certain conditions (40). We have developed in our lab two 
methodologies that have proven to be suitable for the in vivo analysis of ubiquitinated proteins 
(41). The bioUb strategy, based on the in vivo biotinylation of ubiquitin (42), has recently been 
used in combination with quantitative shotgun proteomics to identify substrates of the E3 ligase 
Parkin involved in Parkinson’s disease (43). The second strategy favours the isolation of GFP-
tagged proteins under denaturing conditions, and was first used to screen for Drosophila Ube3a 
substrates (30). 
In the present study, we have combined the bioUb strategy with the over-expression of Ube3a to 
identify 79 putative neuronal Ube3a substrates. Amongst those, we noted the presence of 13 
proteasome subunits or proteasome interacting proteins. We validated that Ube3a ubiquitinates 
the proteasomal ubiquitin receptor Rings lost (Rngo) in Drosophila photoreceptor neurons in vivo. 
Furthermore, we have confirmed that ubiquitination of DNA damage-inducible protein 1 
homologue 1 (DDI1), the human orthologue of Rngo, is enhanced upon UBE3A over-expression 
in neuroblastoma cells, without being targeted for degradation. The observation that Ddi1 is 
highly expressed in the developing mice brain suggests that this protein has a yet uncharacterized 
biological function in neuronal development. 
Results 
Unbiased identification of Ube3a substrates in Drosophila neurons in vivo 
In order to identify by MS analysis the proteins whose ubiquitination depends on Ube3a, we used 
the following fly lines: BirA, bioUb, bio15B and bioA3. bioUb flies express the (bioUb)6-BirA 
precursor (Fig. 1A) in the Drosophila photoreceptor neurons under the control of the eye-specific 
GMR-GAL4 driver, which has been shown to be the most suitable neuronal(-like) driver for 
identifying low abundance proteins, and for optimizing reproducibility across samples (44). BirA 
control flies express just the bacterial biotinylating enzyme BirA (44). bioA3 flies are bioUb flies 
over-expressing the Ube3a E3 ligase (Fig. 1B), as confirmed by immunoblotting (Fig. 1C). On 
the other hand, bio15B flies are bioUb flies carrying a loss of function Ube3a deletion (Ube3a15B 
allele) in heterozygosis. Homozygous mutant Ube3a15B flies lack any detectable Ube3a protein 
(Supplementary Material, Fig. S1A), but flies carrying this allele could not be expanded in 
homozygosis. The Ube3a15B heterozygous bio15B flies used for this study only show a partial 
reduction of Ube3a protein levels (Fig. 1C). Free BirA, indicating appropriate processing of the 
(bioUb)6-BirA precursor, was observed for all three genotypes (Fig. 1D); no undigested forms of 
the precursor were found above the expected molecular size of BirA (35 kDa). Biotin 
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immunoblotting confirmed biotinylation and incorporation into conjugates of the GMR-GAL4-
driven ectopic biotin-tagged ubiquitin in all bioUb, bioA3 and bio15B flies (Fig. 1E). Expression of 
the bioUb construct in those three fly lines did not significantly alter total ubiquitin levels, when 
compared to the BirA control (Supplementary Material, Fig. S1B).  
Comparison of the ubiquitinated proteome of bioA3 flies and bioUb flies should allow the 
identification of proteins whose ubiquitination is enhanced by Ube3a. Conversely, we would 
expect to have a reduction on the ubiquitination of Ube3a substrates on bio15B flies in respect to 
bioUb flies (Fig. 2A). Biotinylated ubiquitin conjugates formed within the fly photoreceptor 
neurons were isolated using neutravidin beads, those pulldowns being performed on three 
biological replicates for each of the three conditions. Despite collecting whole heads, the isolated 
material is expected to originate just from the GMR-GAL4 expressing cells. Similar amounts of 
ubiquitinated proteins were eluted from the three genotypes (Fig. 2B and Supplementary Material, 
Fig. S2A and B). After fractionation by SDS-PAGE, each gel lane, corresponding to one sample, 
was cut into several slices as indicated in Supplementary Material, Fig. S2B). Protein loads from 
each individual gel slice were in-gel digested with trypsin and subsequently analysed by LC-
MS/MS. 
Similar number of ubiquitinated proteins and a high correlation of the label-free quantification 
(LFQ) intensity values were detected, both between replicas and across the different genotypes 
(Supplementary Material, Fig. S3A and B). Random LFQ values from a distribution meant to 
simulate expression below the detection limit (45) were imputed to those proteins for which 
LFQ values were not reported by the MaxQuant software on that given experiment 
(Supplementary Material, Fig. S3C). The experimental design was successful as evidenced from 
the LFQ intensity values obtained for Ube3a, which appeared highly enriched in the bioA3 
sample, and significantly reduced in the bio15B sample (Fig. 2C). Western blot analysis 
confirmed those results and revealed that Ube3a is mostly isolated in an unmodified form 
(Fig. 2D), as reported previously (44). 
We compared the LFQ intensities of ubiquitinated proteins on the bioA3 sample with the 
corresponding bioUb values and plotted their fold-changes (X-axis) and significance P-values (Y-
axis) as a Vulcano plot (Fig. 3). As expected, most of the proteins detected in this study displayed 
a ratio close to one, including endogenously biotinylated proteins acetyl-CoA carboxylase (ACC), 
pyruvate carboxylase (PCB) and CG2118 (46) (shown with filled squares in Fig. 3), indicating 
that the pull-down process was equally efficient in the different samples. From the 751 protein 
groups identified across all genotypes, 79 were significantly (P < 0.05) enriched at least 2-fold in 
the bioA3 sample relative to the bioUb control, and can therefore be defined as putative Ube3a 
substrates (Supplementary Material, Table S1). In order to focus on the highest confidence Ube3a 
substrates, the 79 proteins regulated by Ube3a were analysed at the peptide level to comply with 
the following requirements: (1) Average ratio between common peptides identified in both 
conditions should be at least two after the subtraction of the standard error of the mean (S.E.M.); 
and (2) individual peptide intensities should globally follow the same tendency as the protein LFQ 
intensity and show in average a 2-fold enrichment. Out of the 79 proteins identified as enriched 
at the protein level, 39 candidate Ube3a substrates (labelled with filled circles in Fig. 3) appeared 
homogenously enriched also at the peptide level (Supplementary Material, Fig. S3D), most of 
them having human orthologues (Table 1). Among those 39 high confidence candidate Ube3a 
substrates, eight proteins regulate protein degradation through the ubiquitin-proteasome system, 
including proteasomal subunits Prosα1, Prosα3, Rpt2, Rpt4, Rpn3 and Rpn8, and the proteasomal 
shuttling proteins Rngo and Rpn10, the latest being previously identified as target of Ube3a in 
neuronal cell culture (30). Besides, two proteins related to autophagy, Atg8a and Ref(2)P (47), 
and three chaperone proteins, CCT3, CCT7 and CCT8 (48), were also found as high confidence 
substrates of Ube3a. In addition, proteasomal subunits Prosα4, Prosα7, Rpn2, proteasome 
activator REG and the proteasome-associated deubiquitinating (DUB) enzyme Uch-L5 were 
significantly enriched according to LFQ values, but did not pass the requirements at peptide level.  
On the other hand, a total of 55 proteins also appeared to be less ubiquitinated in bioA3 sample due 
to the over-expression of Ube3a (Supplementary Material, Table S1), displaying a 2-fold 
significant reduction in their abundance compared to bioUb (bioA3/bioUb < 0.5; P < 0.05). Following 
the same peptide analysis described before (Supplementary Material, Fig. S3E), we concluded 
that 14 proteins are clearly less ubiquitinated when Ube3a is over-expressed, as compared to the 
control sample (labelled with empty circles in Fig. 3). Interestingly, we reliably identified 
calcium/calmodulin-dependent protein kinase II (CaMKII)—which in Drosophila is coded by a 
single gene—as being less ubiquitinated upon over-expression of Ube3a. 
We also compared the LFQ intensities of the bio15B sample with the bioUb values; but, using the 
same criteria as above, Ube3a itself did not appear significantly enriched with high confidence in 
the bioUb sample relative to the bio15B ubiquitinated material. However, three proteins (Rdhb, 
Map2015 and Axo) appeared significantly less ubiquitinated in the bio15B sample, barely above 
the defined thresholds (data not shown). 
Ubiquitin LFQ values and ubiquitin chain linkages indicate proteasomal perturbation upon 
Ube3a over-expression 
Based on the experimental design, we expected ubiquitin levels to be unaltered by Ube3a over-
expression. Furthermore, no significant differences were observed on the hard-to-quantify smears 
of the silver stained gels (Fig. 2B), as well as ubiquitin (Supplementary Material, Fig. S1B) and 
biotin (Supplementary Material, Fig. S2A) blots. However, based on LFQ values, ubiquitin levels 
were quantified to have a significant increase of 1.66-fold in the bioA3 flies, relative to the bioUb 
sample (Supplementary Material, Table S1), this is, a >60% increase of ubiquitin was detected on 
the collected ubiquitinated material of bioA3 flies. In order to elucidate the type of ubiquitin chains 
enriched upon over-expression of Ube3a, we compared the intensity of all detected diGly-
containing peptides across the samples. Digestion of a complex mixture of ubiquitinated proteins 
is expected to result in a complex mixture of ubiquitin chain linkages. Even though the isolated 
ubiquitinated material is composed of substrates of hundreds of ligases, this analysis indicated 
that K48 and K63 linkages were significantly more abundant on the bioA3 sample, while K33 
linkages were reduced (Supplementary Material, Fig. S3F). The 60% increase on ubiquitin levels 
together with the significant changes in chain linkages suggests a global perturbation of the 
ubiquitin proteasome system upon Ube3a over-expression. 
Rngo is ubiquitinated by Ube3a in vivo in Drosophila neurons 
Amongst the highest confidence candidates as Ube3a substrates (Table 1), eight of the identified 
proteins are proteasome integral or regulatory subunits. We decided to focus on Rngo, a predicted 
proteasomal shuttling factor for which working antibodies were available (49), and which was 
already observed in our first neuronal ubiquitome studies (42). According to the label-free 
quantitative MS-based analysis performed, Rngo is 5-fold more enriched in Ube3a over-
expressing flies in respect to control flies. In agreement with that, western blot analysis showed 
that ubiquitination of Rngo is enhanced when Ube3a is over-expressed and reduced in its absence 
(Fig. 4A), making Rngo the first Ube3a substrate validated in any type of neuron in vivo. 
Interestingly, Rngo total levels were not altered, suggesting that it is not being targeted for 
degradation. As a control, the same membrane was used to detect the presence of Fax, a protein 
that we found by MS to be less ubiquitinated upon Ube3a over-expression (Fig. 3). Indeed, Fax 
displayed the opposite trend, and its ubiquitination was dramatically reduced by the over-
expression of Ube3a (Fig. 4A), indicating that the increase ubiquitination seen for Rngo is specific 
to the protein and not to a more efficient general isolation of proteins in the bioA3 sample. We also 
analysed by western blot the ubiquitination of another proposed UBE3A substrate (27), the 
Na+/K+-ATPase α-subunit (Atpα), but as with the MS analysis (Fig. 3), western blot did not show 
any enhancement by Ube3a over-expression on its ubiquitination (Fig. 4B).  
Ddi1 and Ddi2 are expressed throughout development in the mouse brain 
Mammalians have two protein homologues to Drosophila Rngo: DNA damage-inducible protein 
1 homologue 1 (DDI1) and homologue 2 (DDI2). Partial expression data for DDI2 are available 
at the Human Protein Atlas (www.proteinatlas.org; date last accessed March 19, 2018), but 
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information about mammalian DDI1 is very scarce. We tried to assess the expression of DDI1 
using commercially available antibodies, but, since DDI1 and DDI2 proteins have very high 
amino acid sequence identity (72%), all the commercially available antibodies recognize DDI2 
protein, or do simply not work (data not shown). We therefore tested whether mouse Ddi1 and 
Ddi2 are expressed in the brain. Analysis of Ddi1 gene expression in mice brain at different ages 
performed by qRT-PCR revealed a drastic and significant increase of Ddi1 mRNA levels at 
embryonic stage E16.5 (Fig. 5A). The Ddi1 mRNA expression peak was rapidly reduced from 
E17.5, returning to basal levels at E19.5-P1, remaining relatively stable during all the tested adult 
time points. In contrast, Ddi2 mRNA levels, which were also detectable in the mice brain, only 
fluctuated slightly during development (Fig. 5B).  
Additionally, we analysed the expression profile of Ddi1 in the developing brain by performing 
RNA in-situ hybridization experiments in CD-1 mouse embryos at four different stages of 
development—E9.5, E10.5, E14.5 and E16.5. As shown in Figure 6, Ddi1 is expressed in all parts 
of developing brain (telencephalon, diencephalon, mesencephalon and rhombencephalon) at the 
two younger developmental stages. Similar Ddi1 expression pattern was observed for these two 
stages in both whole mount samples (Fig. 6A and C) and sagittal paraffin sections (Fig. 6B and 
D). At the stage E14.5, the expression is located in neurons of mesencephalic and telencephalic 
structures, with signal accumulation in upper hill (colliculus tectum) and ventricular zone of 
pallium (Fig. 6E–G). At further developmental stage E16.5, which shows highest mRNA level 
expression according to our qRT-PCR screen, Ddi1 is expressed in particular telencephalon parts, 
mainly the ventricular layer and cortical plate of isocortex and the ventricular layer of olfactory 
bulb (Fig. 6H and I). This could represent the dividing neuroblasts and their migration toward the 
superficial layer of isocortex. The positive staining of neuronal cells in the isocortex (Fig. 6J) is 
clear evidence of Ddi1 expression in neuronal tissue, however, up to date no single report has 
described the role DDI1 could exert in the brain. 
Human DDI1 is ubiquitinated by UBE3A, but is not targeted for degradation 
Once identified and confirmed that Ube3a ubiquitinates Rngo in flies, we aimed to test whether 
its homologs DDI1 and DDI2 are substrates of human UBE3A. For that purpose, we employed 
an in cellulo ubiquitination assay (30,50) in SH-SY5Y neuroblastoma cells. Wild-type UBE3A 
(UBE3AWT) induced the ubiquitination of DDI1-GFP in SH-SY5Y cells (Fig. 7 and 
Supplementary Material, Fig. S5A), but did not seem to increase the ubiquitination status of 
DDI2-GFP (Supplementary Material, Fig. S5B). We also confirmed the specificity of UBE3A-
dependent DDI1 ubiquitination by proving that Parkin, the E3 ligase involved in Parkinson’s 
disease, could not mediate ubiquitination of DDI1 (Supplementary Material, Fig. S5B). 
Altogether, the data presented here demonstrates for the first time that Rngo human homologue 
DDI1 is a UBE3A substrate. Despite earlier reports suggested that UBE3A generates degradation-
leading K48 ubiquitin linkages in vitro (15), at least in SH-SY5Y neuroblastoma cells, UBE3A-
mediated ubiquitination of human DDI1 does not lead to its degradation, as indicated by the 
intensity of the DDI1-GFP bands, which is independent of the activity of UBE3A (Fig. 7).  
Discussion 
Our unbiased proteomic analysis for the identification of differentially ubiquitinated proteins in 
Drosophila photoreceptor neurons upon Ube3a over-expression has resulted in a list of 79 putative 
Ube3a substrates, out of which proteasomal proteins appear very highly enriched. To our 
knowledge, this is the first time a list of candidate Ube3a substrates, whose ubiquitinated fraction 
is enhanced upon Ube3a over-expression, is reported in neurons in vivo. Several of the putative 
Ube3a substrates identified (Arc1, Chc, Gclc, GlyRS, Path, Tig and SesB) play a role either in 
axon and dendrite morphogenesis (51–54) or synaptic transmission (55–57). Interestingly, upon 
Ube3a over-expression we also found a significant reduction of the ubiquitination of CaMKII, a 
key kinase known in humans to regulate neurotransmitter synthesis and release, modulation of ion 
channel activity, neurite extension, synaptic plasticity, learning and memory (58). Reduced 
activity and protein levels of CaMKII at the postsynaptic density have been described in a mouse 
model of AS (59). It still remains to be explained how a reduction of UBE3A levels enhances the 
ubiquitination and/or degradation of CaMKII. 
Analysis of the putative Ube3a substrates by g:Profiler analysis of GO terms and KEGG pathways 
indicate a highly significant enrichment of the proteasome (data not shown). Furthermore, 
comparison of the data obtained in this work to the dataset of Parkin substrates (43), further 
confirms a deregulation of the proteasome upon Ube3a over-expression. Indeed, UBE3A is 
known to be a proteasome-associated protein (28,60), as well as being capable of ubiquitinating 
several proteasomal subunits in cell culture (28–30). However, it is controversial whether UBE3A 
inhibits (28) or stimulates (33) the proteolytic activity of the proteasome. Ube3a over-expression 
results in an increase in total ubiquitin levels, while over-expression of Parkin did not. Having 
identified several proteasomal subunits as ubiquitinated by Ube3a, the simplest explanation is that 
Ube3a-driven proteasomal deregulation results in the accumulation of substrates ubiquitinated by 
Ube3a or other E3 ligases. This would also explain the reduction observed here in the 
ubiquitination of many other proteins. It is known that the specific deregulation of the proteasome 
by over-expressing a dominant negative Rpn10 subunit reduces the ubiquitination levels of Fax 
and other mono-ubiquitinated proteins (44). Deubiquitination of mono-ubiquitinated proteins is 
also seen when inhibiting the proteasome pharmacologically (35), and is explained by a reduction 
of the free ubiquitin available pool concomitant to the accumulation of proteasome targeted poly-
ubiquitinated proteins (36,61–63). The decrease on Fax ubiquitination upon Ube3a over-
expression, detected here by both MS (Fig. 3) and immunoblotting (Fig. 4A), could therefore be 
caused by an Ube3a-induced proteasomal inhibition. Significant changes in global ubiquitin chain 
linkages (Supplementary Material, Fig. S3F) are also in line with this interpretation. 
In this work, we have validated by western blot that Rngo is a direct Ube3a substrate in 
photoreceptor neurons. Rngo contains both an UBL and an Ubiquitin-binding domain (UBD), a 
hallmark of proteasomal shuttles (49), but can also bind directly another proteasomal shuttle 
protein, Rpn10 (49). The ubiquitination of Rpn10 is also increased in Ube3a over-expressing flies 
(Fig. 3), and was already identified as an Ube3a substrate in Drosophila cells, as well as being 
shown to interact genetically with Ube3a in neurons in vivo (30). Ubiquitination of such 
proteasomal regulators by Ube3a can be predicted to severely interfere with proteasomal function. 
Considering that the proteasome regulates dendritic development (32), long-term potentiation 
(64), long-term depression (65), synaptic plasticity (66), synaptic strengthening (67), memory 
consolidation (68), circadian rhythms (69) and many other aspects of neuronal function, an 
UBE3A-dependent proteasomal regulation could easily explain how a single E3 ligase mutation 
can cause a disorder as complex as AS. And indeed, it should be noted that UBE3A has been 
shown to regulate most aspects of neuronal function listed above (70–74). Non-degradative 
ubiquitination of proteasomal receptors could alter their function to a similar extent as their 
degradation, since the activity of those receptors is dependent on their UBDs. An ubiquitinated 
ubiquitin-binding subunit is likely to prioritirily bind its own ubiquitin moieties, therefore 
blocking its normal function. Our prediction would be that—based on the increased ubiquitination 
of those subunits upon UBE3A over-expression—proteasome activity should be increased in the 
brain of AS patients, on which UBE3A levels are reduced. 
Interestingly, Rngo is also the Drosophila homologue of yeast Ddi1/Vsm1, a protein that binds to 
several Snc-interacting t-SNAREs (75), negatively regulates exocytosis (76) and also regulates 
protein secretion (77). Similarly, the C. elegans homologue DDI-1/VSM-1 has also been proposed 
to regulate synaptic function, with vsm-1 mutants displaying a significant increase in synaptic 
density along the dorsal nerve cord (78). Thus, Rngo/DDI1 may have an additional role in synaptic 
transmission by controlling SNARE mediated exocytosis. In fact, over-expression of Ube3a, but 
not its ligase dead form, has been reported to alter neurotransmission at the neuromuscular 
junction in Drosophila (79). 
Two mammalian Rngo homologues have been described, DDI1 and DDI2, but neither of those 
proteins have to date been functionally characterized. We have found that both are expressed in 
the developing brain (Figs 5 and 6). Structurally, both proteins contain the characteristic 
Retroviral Protease-like domain that was recently reported to cleave/activate the Nrf1 
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transcription factor under proteasome inhibition (80,81). Further, they both contain an additional 
helical HDD domain (82,83) and an N-terminal UBL domain, but lack the well-defined Ubiquitin-
associated (UBA) domain. Although, a weak Ubiquitin-binding motif (UIM) is present at the C-
terminus of DDI2 (82), no such a motif can be found in DDI1. It is thus feasible that the DDI1 
UBL domain, which in yeast Ddi1 is capable of binding ubiquitin (84), could substitute the role 
of the UBA domain, a mechanisms that would be facilitated by DDI1’s homodimeric 
conformation. 
Having confirmed the ubiquitination of Rngo in photoreceptor neurons by the Drosophila Ube3a 
and the expression of its mammalian homologues in the brain, we then tested whether any of 
Rngo’s human orthologues are ubiquitinated by UBE3A. We confirmed DDI1 to be an 
ubiquitination substrate of UBE3A in SH-SY5Y neuroblastoma cells. Different controls indicated 
that ubiquitination of DDI1 by UBE3A is specific, but does not lead to a reduction of DDI1 protein 
levels. It is not the first time that regulation of protein activity, even with formation of K48-linked 
chains, has been reported to be proteolysis independent (85). A UBD found in Met4 was proposed 
to cap its own K48-linked ubiquitin chain, inactivating the protein and protecting it from 
degradation (86), and something similar could be happening with Rngo/DDI1. Further work is 
required to elucidate what the functional role of DDI1 ubiquitination might be and whether the 
presence of UBD/UIM/UBA/UBL in ubiquitination substrates might interfere into the canonical 
role of K48 ubiquitin-linked chains. 
Up to now, no candidate ubiquitination substrates of UBE3A had been directly validated in 
neurons in vivo. We had earlier identified a proteasomal shuttling factor, Rpn10, to be regulated 
by Ube3a in Drosophila cells (30), which we now confirmed in vivo by MS. Further, we have 
validated that in Drosophila photoreceptor neurons Ube3a ubiquitinates another proteasomal 
shuttling factor, Rngo, becoming the first Ube3a substrate to be identified and validated in vivo in 
neurons within a whole organism. More importantly, UBE3A regulates the orthologue DDI1 
protein in human neuroblastoma cells. Since UBE3A ubiquitination appears to be regulating 
several proteasomal-associated subunits, as already indicated by ourselves and others (29,30,33), 
it would not be surprising to see that a highly significant number of proteins regulated downstream 
the proteasome will display significant changes on their abundance upon UBE3A mutation or 
over-expression. It is now a challenge to elucidate which Ube3a substrates are direct, in addition 
to the proteasomal proteins themselves. 
DDI1 gene has been reported to be affected in siblings of a familial neurodegenerative disorder 
characterized clinically as a variant of Alzheimer’s disease (87). Having now described for the 
first time the temporal and spatial expression of Ddi1 in the mouse brain, we next need to perform 
a functional characterization to uncover the neuronal role of DDI1, as this might as well bring 
light to our understanding of how AS is regulated. Based on studies in yeast and C. elegans, it is 
likely that DDI1 is involved in both regulation of synapses and proteasomal function (75–78,84). 
Given the complexity of neuronal function, and previous work aiming to identify the mechanisms 
regulated by UBE3A, it is likely that both processes are actually misregulated during the genesis 
of AS. Finally, if we take into account that Ube3a regulates the proteasome, and that UBE3A 
expression declines with age (88), it would not be surprising that this E3 ligase has a further role 
in proteostasis not yet characterized. 
Materials and Methods 
Drosophila stocks and sample collection 
We have used in this work the BirA, bioUb, bioA3 and bio15B flies, all of which express their 
corresponding constructs in the Drosophila photoreceptor neurons under the control of the GMR-
GAL4 driver. BirA and bioUb flies, expressing respectively the BirA enzyme alone and the 
(bioUb)6-BirA precursor, have been described previously (44). Their genotypes are respectively 
GMR-GAL4/CyO; UAS-BirA/TM6 and GMR-GAL4, UAS-(bioUb)6-BirA/CyO. Ube3a gain of 
function (UAS-Ube3aA3) and loss of function (Ube3a15B) flies (89) were a gift from Professor 
Janice Fisher. Both UAS-Ube3aA3 and Ube3a15B fly lines were independently mated to GMR-
GAL4, UAS-(bioUb)6-BirA/CyO; TM2/TM6 flies to generate GMR-GAL4, UAS-(
bioUb)6-BirA/CyO; 
UAS-Ube3aA3/TM6 and GMR-GAL4, UAS-(bioUb)6-BirA/CyO; Ube3a
15B/TM6 lines. The 
Drosophila Ube3a mutants (Ube3a15B) had been reported to be viable and fertile in homozygosis 
(89). When combined with bioUb flies, it was, however, required to grow them in heterozygosis, 
as null Ube3a flies were viable but not fertile at 25°C (J. Ramirez and U. Mayor, unpublished 
data). GMR-GAL4 (BL 1104) and OregonR (BL 2376) flies were provided by the Bloomington 
Drosophila Stock Center (Bloomington, IN, USA). The bioUb abbreviation is used throughout the 
text to refer to the GMR-GAL4, UAS-(bioUb)6-BirA/CyO flies, and the bioA3 and bio15B (for 
Ube3aA3 and Ube3a15B alleles) to refer to GMR-GAL4, UAS-(bioUb)6-BirA/CyO; UAS-
Ube3aA3/TM6 and GMR-GAL4, UAS-(bioUb)6-BirA/CyO; Ube3a
15B/TM6 flies, respectively. 
Flies were grown at 25°C in 12 h light-dark cycles in standard Drosophila medium (0.9% agar, 
7.5% dextrose, 6% corn flour, 8.5% yeast, 2.5% Nipagin, 0.4% propionic, 0.02% benzalkonium 
chloride in distilled H2O). Mixed-sex flies of 2–5 days old were flash-frozen in liquid nitrogen 
and shaken while still frozen to sever the heads. Frozen fly heads were then separated from the 
remaining body parts using a pair of sieves with a nominal cut-off of 710 and 425 µm, and then 
stored at −80°C. Head collections were typically performed in the morning. 
Plasmids 
Commercial pEGFP-N1 vector (Clontech) was used to generate DDI1-GFP and DDI2-GFP 
vectors (see Cloning procedures section). FLAG-UBE3A-pCMV (UBE3AWT) and FLAG-
UBE3ALD-pCMV (UBE3ALD) plasmids, expressing N-terminally FLAG-tagged versions of the 
wild type and catalytically inactive human UBE3A protein (90), were a gift from Dr Vjekoslav 
Tomaić. FLAG-tagged ubiquitin (30) in pCDNA3.1 vector (FLAG-Ub) was generously provided 
by Dr Jose Antonio Rodriguez Pérez (University of the Basque Country-UPV/EHU, Spain). 
Untagged human Parkin plasmid has been described previously (43). Empty pCDNA3.1 vector 
(Invitrogen) was used as control. 
Cloning procedures 
DDI2-pEGFP-N1 (DDI2-GFP) plasmid was generated by amplifying DDI2 gene (Uniprot 
Q5TDH0) from DDI2-pET16b plasmid (82) with DDI2-Fw (5′-
AAGGTACCATGCTGCTCACCGTG-3′) and DDI2-Rv (5′-
AAGGATCCCCTGGCTTCTGACGCTCTGC-3′) primers and inserted between KpnI and BamHI 
restriction sites of pEGFP-N1 vector (Clontech). Gene for human DDI1 protein (Uniprot 
Q8WTU0) was synthesized by GenScript and further amplified using the DDI1-Fw (5′-
TATAGGTACCATGCTGATCACCGTG-3′) and DDI1-Rv (5′-
TATAACCGGTATGCTCTTTTCGTCC-3′) primers and inserted between the Acc65I and AgeI 
sites of the DDI2-pEGFP-N1 vector, after the DDI2 gene had been removed using the same 
restriction enzymes. All PCR reactions were carried out with Phusion High-Fidelity DNA 
polymerase (Thermo Scientific). PCR product gel extractions and plasmid purifications were 
performed with the QIAGEN Gel Extraction Kit and QIAGEN plasmid mini and midi kits, 
respectively. Correct sequence for all plasmids was confirmed by sequencing either by the GATC 
Biotech Company (Köln, Germany) or the SGIKER Unit of Sequencing and Genotyping at the 
University of the Basque Country (Leioa, Spain). 
Western blotting and silver staining 
Both 4–12% Bolt Bis–Tris Plus pre-cast gels (Invitrogen) and 4–12% NuPAGE Bis–Tris gels 
(Invitrogen) were used for SDS-PAGE, then proteins were transferred to PVDF membranes using 
the iBlot system (Invitrogen). Following primary and secondary antibody incubation, membranes 
were developed with an ECL kit (Biorad Clarity). Dual-colour westerns were prepared by 
assigning independent colour channels to two independent westerns developed in the same 
membrane. The amount of material loaded for western blot analysis varied according to the tissue 
and the antibody employed. In the case of material obtained from fly biotin pulldowns, between 
0.001% and 0.2% of the input samples and 5–10% of the elution samples were loaded. However, 
when material purified from cells was used, between 10–20% of inputs and 10–40% of the elution 
samples were loaded. 
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The following primary antibodies were used: goat anti-biotin-horseradish peroxidase (HRP)-
conjugated antibody (Cell Signalling; catalogue number 7075) at 1: 1000; chicken polyclonal anti-
BirA antibody (Sigma; catalogue number GW20013F) at 1: 1000; mouse monoclonal anti-GFP 
antibody (Roche Applied Science; catalogue number 11814460001) at 1: 1000; mouse 
monoclonal anti-FLAG M2-HRP conjugated antibody (Sigma; catalogue number A8592) at 1: 
1000; mouse monoclonal anti-Syx1A antibody (Developmental Studies of Hybridoma Bank; 
DSHB; catalogue number 8C3) at 1: 100; rabbit polyclonal anti-Fax antibody, a gift from Eric 
Liebl (Deninson University, OH, USA) at 1: 1000; mouse monoclonal anti-Atpα antibody 
(DSHB; catalogue number α5) at 1: 50; rabbit polyclonal anti-Ube3a antibody (91) for the 
detection of Drosophila Ube3a protein at 1: 1000; rabbit polyclonal anti-Rngo antibody (49) at 1: 
500; rabbit polyclonal anti-ubiquitin antibody (Sigma; catalogue number U5379) at 1: 100; mouse 
monoclonal anti-UBE3A (clone E6AP-300) antibody (Sigma; catalogue number E8655) for the 
detection of human UBE3A protein at 1: 1000. The following secondary antibodies were used: 
goat anti-mouse-HRP-labelled antibody (Thermo Scientific; catalogue number 62-6520) at 1: 
4000; goat anti-rabbit-HRP labelled antibody (Cell Signalling; catalogue number 7074) at 1: 4000 
and donkey anti-chicken-HRP labelled antibody (Jackson ImmunoResearch; catalogue number 
703-035-155) at 1: 2000. 
About 10% of the neat elution samples were used for silver staining analysis. Gels were fixed for 
1 h at room temperature with 40% methanol and 10% acetic acid containing solution and then 
were stained using the SilverQuest kit from Invitrogen according to manufacturer’s instructions. 
Biotin pulldown 
Biotin pulldowns (42) from Drosophila heads were performed as described previously (43,44,92). 
About 500 mg of 2–5 days old fly heads of each genotype were homogenized in 2.9 mL of Lysis 
buffer (8 M urea and 1% SDS in PBS) supplemented with 50 mM N-ethylmaleimide (Sigma) and 
a complete protease inhibitor cocktail (Roche Applied Science). Lysates were centrifuged for 5 
min at 16000g at 4°C and supernatant applied to a PD10 desalting column (GE Healthcare) 
previously equilibrated with 25 ml of binding buffer (3 M urea, 1 M NaCl, 0.25% SDS and 50 
mM N-ethylmaleimide). Eluates, except 50 µl that were kept for monitoring the inputs, were then 
incubated with 250 µl of NeutrAvidin agarose beads suspension (Thermo Scientific). Unbound 
material (flow through) was separated by spinning the beads at 230g for 2 min. Beads were then 
subjected to stringent washes with six different washing buffers (WB): twice with WB1 (8 M 
urea, 0.25% SDS), thrice with WB2 (6 M guanidine-HCl), once with WB3 (6.4 M urea, 1 M NaCl, 
0.2% SDS), thrice with WB4 (4 M urea, 1 M NaCl, 10% isopropanol, 10% ethanol, 0.2% SDS), 
once with WB1, once with WB5 (8 M urea, 1% SDS) and thrice with WB6 (2% SDS). All buffers 
were prepared in PBS. Beads were then heated at 95°C for 5 min in 125 µl of elution buffer (250 
mM Tris–HCl pH 7.5, 40% glycerol, 4% SDS, 0.2% BPB, 100 mM DTT) and centrifuged for 2 
min at 16 000g in a Vivaclear Mini 0.8 µm PES micro-centrifuge filter unit (Sartorius) to recover 
the eluted proteins. Finally, eluates were concentrated in Vivaspin 500 centrifugal filter units 
(Sartorius). 
Cell culture and transfection 
Human neuroblastoma SH-SY5Y cells were cultured under standard conditions (37°C, 5% CO2) 
in Dulbecco’s modified Eagle medium/nutrient mixture F-12 (DMEM/F-12) with GlutaMAX 
(Thermo Scientific), supplemented with 10% fetal bovine serum (Thermo Scientific), 100 U/ml 
of penicillin (Invitrogen) and 100 µg of streptomycin (Invitrogen). SH-SY5Y cells (3 × 105 
cells) were seeded in six well-plates for transfection experiments. Overnight incubation under 
serum starvation was routinely performed prior to transfections. The following day OptiMEM 
serum-free medium (Thermo Scientific) was replaced by fresh DMEM/F-12 and cells were co-
transfected with 1 μg of FLAG-Ub and 1 μg of DDI1-GFP, or DDI2-GFP, for 72 h using 
Lipofectamine 3000 transfection reagent (Invitrogen) according to manufacturer’s instructions. 
About 1 µg of either pcDNA3.1 (control), UBE3AWT, UBE3ALD or Parkin plasmids were 
additionally added to the transfection mixture to check the effect of UBE3A in DDI1 and DDI2 
ubiquitination. Cells were washed twice in PBS and stored at −20°C until required. 
GFP beads pull-down assay 
Transfected SH-SY5Y cells were lysed with 500 μl of lysis buffer (50 mM Tris–HCl pH 7.5, 
150 mM NaCl, 1 mM EDTA, 0.5% Triton, 1× protease inhibitor cocktail from Roche Applied 
Science and 50 mM N-ethylmaleimide from Sigma) and centrifuged at 14 000g for 10 min. 
Supernatants were mixed with 25 μl of GFP-Trap-A agarose beads suspension (Chromotek 
GmbH), which had been previously washed twice with a Dilution buffer (10 mM Tris–HCl pH 
7.5, 150 mM NaCl, 0.5 mM EDTA, 1× protease inhibitor cocktail, 50 mM N-ethylmaleimde). 
The mixture was then incubated at room temperature for 150 min with gentle rolling and 
centrifuged for 2700g for 2 min to separate the beads from the unbound material. GFP beads 
were subsequently washed once with the dilution buffer, thrice with washing buffer WB5 (8 M 
urea, 1% SDS in PBS) and once with 1% SDS in PBS. Bound GFP-tagged proteins were eluted 
in 25 µl of elution buffer (250 mM Tris–HCl pH 7.5, 40% glycerol, 4% SDS, 0.2% BPB, 100 
mM DTT) by heating at 95°C for 10 min. 
In-gel trypsin digestion and peptide extraction 
Eluates from biotin pull-down assays were resolved by SDS-PAGE using 4–12% Bolt Bis–-Tris 
Plus pre-cast gels (Invitrogen) and visualized with Colloidal Blue following manufacturer’s 
instructions (Invitrogen). When processing biotin pull-down samples, each gel lane was cut into 
seven slices (see Supplementary Material, Fig. S2B). Based on earlier experiments and the BirA 
control, we excluded the intense bands corresponding to avidin monomers, dimers and an 
endogenously biotinylated protein from further analysis. The remaining four slices were 
subjected to in-gel digestion as described previously (93). Briefly, proteins were reduced and 
alkylated by incubating with DTT and chloroacetamide, respectively. Protein digestion was 
performed by saturation of the gel pieces with trypsin and overnight incubation at 37°C. 
Resulting peptides were extracted from the gel, dried down in a vacuum centrifuge and stored at 
−20°C. Peptide mixture was resuspended in 0.1% formic acid previous to the LC-MS/MS 
analysis. 
LC-MS/MS analysis 
Mass spectrometric analyses were performed on an EASY-nLC 1000 liquid chromatography 
system interfaced with a Q Exactive mass spectrometer (Thermo Scientific) via a nanospray flex 
ion source. Peptides were loaded onto an Acclaim PepMap100 pre-column (75 µm × 2 cm, 
Thermo Scientific) connected to an Acclaim PepMap RSLC (50 µm ×x 15 cm, Thermo 
Scientific) analytical column. Peptides were eluted from the column using a linear gradient of 2 
to 40% acetonitrile in 0.1% formic acid at a flow rate of 300 nL min−1 over 45 min. The mass 
spectrometer was operated in positive ion mode. Full MS scans were acquired from m/z 300 to 
1850 with a resolution of 70 000 at m/z 200. The 10 most intense ions were fragmented by 
higher energy C-trap dissociation with normalized collision energy of 28 and MS/MS spectra 
were recorded with a resolution of 17 500 at m/z 200. The maximum ion injection time was 120 
ms for both survey and MS/MS scans, whereas AGC target values of 3 × 106 and 5 × 105 were 
used for survey and MS/MS scans, respectively. In order to avoid repeat sequencing of peptides, 
dynamic exclusion was applied for 45 s. Singly charged ions or ions with unassigned charge 
state were also excluded from MS/MS. Data were acquired using Xcalibur software (Thermo 
Scientific). 
Data processing and bioinformatics analysis 
Acquired raw data files were processed with the MaxQuant (94) software (version 1.5.3.17) using 
the internal search engine Andromeda (95) and searched against the UniProt database restricted 
to Drosophila melanogaster entries (release 2015_11; 43712 entries). Spectra originated from the 
different slices corresponding to the same biological sample were combined. 
Carbamidomethylation (C) was set as fixed modification whereas Met oxidation, protein N-
terminal acetylation and Lys GlyGly (not C-term) were defined as variable modifications. Mass 
tolerance was set to 8 and 20 ppm at the MS and MS/MS level, respectively. Enzyme specificity 
was set to trypsin, allowing for cleavage N-terminal to Pro and between Asp and Pro with a 
maximum of two missed cleavages. Match between runs option was enabled with 1.5 min match 
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time window and 20 min alignment window to match identification across samples. The minimum 
peptide length was set to seven amino acids. The false discovery rate for peptides and proteins 
was set to 1%. Normalized spectral protein label-free quantification (LFQ) intensities were 
calculated using the MaxLFQ algorithm. 
Data analysis and statistical tests 
MaxQuant output data was analysed with the Perseus module (version 1.5.6.0) (45). Initially, 
proteins only identified by site, contaminants, reverse hits and proteins with no unique peptides 
and/or no intensity were removed. Missing LFQ intensity values were replaced with values from 
a normal distribution (width 0.3 and down shift 1.8), meant to simulate expression below the 
detection limit (45). To determine statistically significant changes in protein abundance, as well 
as in ubiquitin diGly peptides, two-tailed Student’s t-test was used. 
In the analysis of the biotin pulldowns, two comparisons were carried out: bioA3 versus bioUb (i.e. 
Ube3a gain of function versus control) and bio15B versus bioUb (i.e. Ube3a loss of function versus 
control). Proteins displaying a LFQ fold change bigger than 2 with a P-value smaller than 0.05 
were selected for further analysis. The selected proteins were further filtered based on the intensity 
pattern observed for their peptides. Statistical significance in western blotting semi-quantification 
was evaluated using an analysis of variance (ANOVA) complemented by Tukey’s honest 
significance difference test (Tukey’s HSD) performed in GraphPad PRISM software. 
RNA extraction, reverse transcription and real-time qPCR 
Total RNA was isolated from 30 mg of brain from embryos, young and adult wild-type mice from 
different ages. RNA was extracted and further purified by using the RNeasy Mini Kit (QIAGEN) 
according to the manufacturer’s protocol. Contaminating genomic DNA was removed by 
treatment with deoxyribonuclease I (QIAGEN), and cDNAs were synthesized from 1 μg RNA 
using the AffinityScript Multi Temperature cDNA Synthesis Kit (Agilent Technologies). 
Quantitative RT-PCR was performed on cDNA in the presence of Power SYBR Green PCR 
Master Mix (Applied Biosystems) containing preset concentrations of deoxynucleotide 
triphosphates and with specific primers, using the ABI Prism 7900 sequence Detection System 
(Applied Biosystems). PCR parameters were 50°C for 2 min, 95°C for 10 min, 40 cycles at 95°C 
for 15 s and 60°C for 1 min. The purity of the PCR products was assessed by dissociation curves. 
The amount of target cDNA was calculated by the comparative threshold (Ct) method and 
expressed by the 2-ΔΔCt method according to Applied Biosystems’ instructions, using 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as an internal control. Expression of 
GAPDH mRNA was not affected by age, and the ratio of ΔCt value did not vary with the amount 
of cDNA. Each primer set was used at its optimal concentration (300 nM) with maximal efficacy. 
It was verified that one single specific product was amplified as shown by analysis of its melting 
temperature value. 
Primers GAPDH—Forward: 5′-ACCACAGTCCATGCCATCAC-3′ 
Reverse: 5′-TCCACCACCCTGTTGCTGTA-3′ 
Primers DDI1—Forward: 5′-TCACTGTGTATTGTGTGCGTAG-3′ 
Reverse: 5′-AGCTGTTCCATGTAAACGATCTG-3′ 
Primers DDI2—Forward: 5′-CCTCTCCGAGGTGACCTTTTC-3′ 
Reverse: 5′-GGCCTTTCTGCATAGACAATCT-3′ 
RNA in situ hybridization 
CD-1 mice were mated overnight, and the presence of a vaginal plug indicated embryonic day (E) 
0.5. Unsexed embryos at E9.5 and E10.5 (the age 9.5 and 10.5 days post coitum) were fixed in 
4% PFA and used for in situ hybridization, both in whole mount and in paraffin sections. Heads 
of 14.5 and 16.5 days post coitum old CD-1 embryos were fixed in 4% PFA and further processed 
for paraffin sections. Embryo samples for whole mount ISH were frozen in methanol at −20°C 
prior tissue hydration, proteinase K treatment, acetylation and the prehybridization and 
hybridization procedures. The embryos and heads used for sectioning were dehydrated, embedded 
in paraffin, cut to 7 µm sections and rehydrated prior further treatment. The experimental 
procedures were performed according to standard protocols (96). 
Murine Ddi1 coding sequence (NM_027942.1) was synthesized by GenScript and cloned into 
pGEM-T® easy plasmid. Linearized plasmid was purified with PCR Purification Kit (QIAGEN) 
and used for generation of digoxigenin labelled riboprobes with digoxigenin RNA labelling kit 
(Roche Applied Science) by in vitro transcription according to the provided manual. Probes were 
further cleaned by RNeasy Mini kit (QIAGEN) following RNA clean-up manual. Hybridization 
was performed overnight at 70°C with all probes for both whole mount and sectioned embryo 
samples. The DIG labelled probes were detected with anti-DIG antibody conjugated with alkaline 
phosphatase and BM purple AP substrate precipitating solution (Roche Applied Science) was 
used for signal development. All samples were postfixed in 4% PFA and the slides were mounted 
in Aquatex. Images were taken using Zeiss ApoTome microscope. 
Cell staining and microscopy 
SH-SY5Y cells in Supplementary Material, Fig S5C were transfected using Lipofectamine 3000 
transfection reagent (Invitrogen) and grown over a coverslip glass. After 48 h, cells were washed 
twice with 2× PBS, fixed in 4% PFA for 20 min at room temperature, washed with PBST (0.1% 
Triton X-100 in 1× PBS) for three times and nuclei were stained with NucBlue Fixed Cell Stain 
Readyprobes reagent (Invitrogen). After staining, cells were washed with 1× PBS three times, the 
cover slips were mounted into slides with ProLong Diamond antifade reagent (Invitrogen), and 
samples were analysed in an inverted microscope ECLIPSE TS2-FL (Nikon). 
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Figure 1: Drosophila Ube3a mutant and over-expressing flies expressing the biotin-tagged ubiquitin. (A) Schematic representation 
of the (bioUb)6-BirA construct, which is expressed as a poly-ubiquitin chain fused to BirA. This precursor polypeptide is digested by 
endogenous DUBs, so the ubiquitin moieties and the BirA enzyme are released. Each ubiquitin bears a 16 amino-acid long 
biotinylatable motif at their N-terminal part (bio) that is recognized by BirA. The sequence for biotinylation added to each ubiquitin 
is shown underlined, followed by the five amino-acid linker (italicized). The lysine where the biotin is attached is highlighted in bold. 
(B) Schematic representation of the domain structure of Drosophila Ube3a. Only two domains have been characterized for Ube3a so 
far: the AZUL domain (Amino-terminal Zn-finger of Ube3a E3 Ligase), which is thought to play a role in substrate recognition, and 
the HECT domain (Homologous to the E6-AP Carboxyl Terminus) that provides the E2-binding platform and a catalytic cysteine 
residue (C941) to which ubiquitin associates via a thioester linkage. Flies over-express Ube3a without any tag and under the control 
of a UAS sequence. (C) Anti-Ube3a immunoblot on head extracts. The specific band for Ube3a is indicated with an arrow. Unspecific 
bands are indicated with arrowheads. (D) Anti-BirA immunoblot on head extracts. Appropriate processing of the (bioUb)6-BirA 
precursor was observed for all three genotypes (bioUb, bioA3 and bio15B). Flies over-expressing just BirA were used as control. (E) 






















Figure 2: Isolation of candidate Ube3a substrates in Drosophila neurons. (A) Workflow for the identification of Drosophila Ube3a 
substrates. Flies over-expressing the (bioUb)6-BirA precursor in the photoreceptor cells under the control of the GMR-GAL4 driver 
(bioUb) were compared with heterozygous Ube3a mutant (bio15B) or with Ube3a gain of function flies (bioA3) in order to identify 
proteins whose ubiquitination increases in a Ube3a dose-dependent manner. Fly heads of each of the genotype were subjected to biotin 
pulldown and MS analysis. Proteins whose ubiquitination is regulated by Ube3a should be found in more abundance in bioA3 flies, as 
compared with bioUb and bio15B controls. (B). Silver staining of the eluted material from biotin pulldowns. Only endogenously 
biotinylated proteins are detected on the BirA control sample. (C) LFQ intensities of Ube3a obtained from MS analysis of eluted 
samples. One asterisk indicates P-value < to 0.05; three, P < to 0.0001. (D). Western blot to Ube3a indicates that it is mostly purified 
in its unmodified form (arrow), which is bound to the avidin beads due to ubiquitin bound to its active-site cysteine. This ubiquitin is 
removed from the active site by DTT-treatment of the samples on the elution step. A small fraction of Ube3a was also found conjugated 


















Figure 3: Identification of candidate Ube3a substrates in Drosophila neurons. Comparison of the abundance, determined by their LFQ 
intensities, of the ubiquitinated proteins identified by MS upon Ube3a over-expression relative to bioUb flies. The Vulcano plot displays 
the LFQ bioA3/bioUb ratios in log2 scale (X-axis) and the t-test P-values in −log10 scale (Y-axis), determining the statistical significance 
(P < 0.05, horizontal grey lane) of the fold changes, for each protein. Labelled filled circles represent high confidence proteins found 
more ubiquitinated in the bioA3 sample than in the bioUb sample. Labelled empty circles are those found less ubiquitinated in bioA3 
sample. Endogenously ubiquitinated proteins (ACC, CG2118 and PCB) are shown with filled squares, and ubiquitin with an empty 
square. The earlier reported putative Ube3a candidate Atpα, is shown with a triangle. bioUb: GMR-GAL4, UAS-(bioUb)6-BirA/CyO; 

























Figure 4: Rngo is ubiquitinated by Ube3a in Drosophila photoreceptor neurons. (A) Immunoblot with anti Rngo-antibody confirmed 
the increase ubiquitination detected by MS in bioA3 flies as compared with bioUb flies, and more significantly to bio15B flies. This same 
membrane was reprobed with anti-Fax. Levels of ubiquitinated Fax were found reduced in bioA3 flies, which corroborated the MS 
results and confirmed that the increase ubiquitination seen for Rngo is specific to the protein and not to a more efficient general 
isolation of proteins in the bioA3 sample. Putative mono-, tri- and tetra-ubiquitinated forms are indicated with asterisks and unmodified 
or cysteine-ubiquitinated forms are indicated with an arrow. Equal levels of Avidin bands, which are non-specifically detected by 
Rngo antibody, are also shown. (B) Atpα is not a substrate of Ube3a in Drosophila photoreceptor cells. Western blot performed with 
anti-Atpα showed that its ubiquitination is not regulated by Ube3a, as levels of mono-ubiquitinated Atpα are similar, or even lower in 



















Figure 5: Ddi1 and Ddi2 gene expression temporal profiles in the mouse brain. Changes in expression of Ddi1 (A) and Ddi2 (B) 
mRNA levels in brains of C57BL/6J mice during aging. RNA was isolated from the brains of E13.5 to 9-month-old mice and subjected 
to qRT-PCR. A significant increase of Ddi1 mRNA level was observed at embryonic stage E16.5. Ddi1 and Ddi2 mRNA levels were 
determined and adjusted by the signal intensity of GAPDH, and the average results (n = 3) were calculated and expressed with respect 






















Figure 6: Spatial profile of Ddi1 gene expression in the mouse brain. Ddi1 is expressed in central nervous system during embryonic 
development according to RNA in-situ hybridization study on CD-1 mouse embryos. (A) and (B) Expression profile of Ddi1 in whole 
mount and paraffin sections of E9.5 embryo, respectively. (C) and (D) Ddi1 expression mapping in whole mount and paraffin section 
of E10.5 embryos. (E) Sagittal section of E14.5 embryonic brain with clearly located expression of Ddi1 in colliculus midbrain tectum 
and pallial part of telencephalon. (F) Detail of pallium: Ddi1 is expressed in isocortex and olfactory bulb. (G) Midbrain and hindbrain 
tissue shows expression of Ddi1 in culliculus tectum. (H) and (I) Ddi1 is specifically expressed in isocortex and ventricular layer of 
olfactory bulb of E16.5 mouse brain. (J) High resolution detail of the scan shown in (I). Red stars highlight tubular structures—
probably capillaries of the central nervous system. Abbreviations: T, telencephalon; D, diencephalon; M, mesencephalon; R, 
rhombencephalon; C, cerebellum; CMT, colliculus midbrain tectum; TL, thalamus; P, pallium; SP, subpallium; HT, hypothalamus; 
















Figure 7: Human DDI1 is ubiquitinated by UBE3A in SH-SY5Y cells. (A) DDI1-GFP showed a significant increase in its 
ubiquitinated fraction in the presence of wild type UBE3A (UBE3AWT), as illustrated by western blot to FLAG-tagged ubiquitin, 
compared with control (pCDNA3.1) or to ligase dead UBE3A (UBE3ALD). The non-modified form of DDI1 was detected with anti-
GFP antibody (green). The bottom panel shows levels of human UBE3A protein in the whole cell extract before the isolation of the 
GFP-tagged proteins. (B) Quantification of the ubiquitination of DDI1 was performed by calculating the FLAG: GFP ratio in panel A 
with Image-J. Statistical significance differences [***, P < 0.001 (mean ± S.E.M., n = 5)] were observed for the UBE3AWT sample 

















Table 1: High confidence proteins whose ubiquitination is dependent on Ube3a over-expression 
 
Proteins whose abundance in the pulldowns is significantly altered by Ube3a, both at protein and at peptide level, are shown. The 
complete data set is available as Supplementary Material, Table S1. Proteasomal proteins are highlighted in bold. Cellular localization 
(CC) of the human proteins are indicated by graytones (dark grey rounded rectangle: nuclear; light grey cell: cytoplasmic; black 
surrounding square: plasma membrane). If a more specific localization within each compartment has been reported, it is further 
indicated with text (CT, cytoskeleton; E, endosome; ER, endoplasmic reticulum; P, peroxisomes; S, secreted; V, vesicles). 
a) Given according to Flybase nomenclature. 
b) Orthologues with the best Flybase score are provided. 
c) Given according to HUGO Gene Nomenclature Committee. 
d) Given according to Human Protein Atlas (www.proteinatlas.org) and Uniprot (www.uniprot.org). 
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